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Chapter 1
Introduction

Introduction
In the late 1960s, Professor Edwards and Doctor Steptoe started 
collaboration and developed In Vitro Fertilisation (IVF). They made the 
breakthroughs in IVF that have revolutionised the lives of infertile couples 
worldwide, that started with the birth of the first IVF-baby Louise Brown 
on July 25, 1978.1 For the development of IVF, Professor Edwards won the 
Nobel Prize in 2010.
The prevalence of infertility worldwide is estimated to be 9% and 
approximately 50% demand for medical services.2 Male factors account for 
approximately half of the cases.3 However, IVF could not help the infertile 
couples with severe male factor. The introduction of intracytoplasmic 
sperm injection (ICSI) in 1992 enabled the management of severe male 
factor infertility with high success rates.4 ICSI involves the injection 
of a preselected spermatozoon into a mature oocyte after ovarian 
hyperstimulation and oocyte retrieval. For men with azoospermia, ICSI 
with sperm retrieved at the level of the epididymis or testis is the sole 
possibility to father their own genetic progeny.
The use of IVF has increased, and its effectiveness has grown over time, 
especially with the introduction of embryo cryopreservation5 and ICSI. To 
date, in Europe more than 350.000 IVF/ICSI cycles are started annually, 
corresponding to 850 cycles per million inhabitants.6 The proportion of 
ICSI versus standard IVF procedures increased from 39.6% in 1997 to 
66.5% in 2006.7 A similar trend has been observed in the USA with a 
percentage from 11.0% in 1995 to 57.5% in 2004.8 There is a more 
liberal use of ICSI in couples with unexplained infertility, light to moderate 
impairments of semen quality and in patients with various mixed causes of 
infertility or few oocytes. So in many countries there may be an overuse of 
ICSI, compared to IVF, without good medical evidence that it is beneficial 
neither for the patients or society.7
In 2006 the clinical pregnancy rate per transfer was 32.4% for IVF and 
33.0% for ICSI. It can be estimated that 1.0% to 4.1% of the overall 
number of live births are the result of IVF or ICSI.6 These numbers 
indicate that artificial reproductive techniques (ART), and especially ICSI, 
are available and practiced successfully on a large scale. Along with the 
success story, less attention is paid to safety and the potential risks and 
complications of this treatment.39
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In ICSI the risks are theoretically increased for several reasons.10 Firstly, 
the risks of the female gamete: injection of the oocyte might cause 
damage to the ooplasm or meiotic spindle apparatus; foreign substances 
or contaminants might be injected in the oocyte; and moreover an 
anomalous female gamete, that otherwise would be bypassed by 
natural selection, might be fertilized. Secondly, the risks of the male 
gamete: sperm carrying DNA anomalies, i.e. breaks and aneuploidy,1112 
Y-chromosome deletions,13 or structural defects, might be injected. When 
sperm is surgically retrieved from the epididymis or from the testis, there 
are additional risks, like ageing after a prolonged stay in the epididymis 
(in case of obstruction) and incomplete maturation.14
Because of all these theoretical risks, there are concerns about the possible 
adverse effects on birth defects and on the health and development of 
children, especially when non-ejaculated sperm is used.
Beside possible effect of ICSI treatment for the children, there are 
possible short-term complications for woman after assisted reproductive 
technology. The prevalence of these complications is approximately 
2%, ovarian hyperstimulation syndrome is responsible for half of all 
complications.15 Furthermore, the high incidence of multiple pregnancies 
increases the complication risks, but also singleton pregnancies have a 
higher complication risk such as pre-eclampsia.1617
ICSI with non-ejaculated sperm
Azoospermia is present in approximately 5% of all investigated infertile 
couples3 and is found in 10% of male infertility cases.18 Azoospermia can 
be divided into two groups: obstructive azoospermia (OA) with a normal 
spermatogenesis and non-obstructive azoospermia (NOA) as the result 
of a testicular failure. Since the introduction of ICSI, it is possible for 
these couples to father their own progeny by using sperm retrieved 
by percutaneous epididymal sperm aspiration (PESA), microsurgical 
epididymal sperm aspiration (MESA) or testicular sperm extraction (TESE). 
PESA and MESA are eligible in cases of obstructive azoospermia (OA) 
with an assumed normal spermatogenesis. In cases of non-obstructive 
azoospermia (NOA), as the result of a testicular failure or in cases of 
unsuccessful PESA or MESA, TESE is indicated.
Risks and complications
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From 1994, ICSI in the Netherlands was carried out either with ejaculated 
semen or with non-ejaculated semen. However, a few years later concerns 
arose in the Dutch society about the health of the children born after 
ICSI with non-ejaculated sperm, referring to unknown risks of using aged 
(epididymal) or immature (testicular) sperm cells. This led to a national 
moratorium for the application of ICSI with non-ejaculated sperm in 
1996. With support from the Dutch government, studies were set up to 
obtain more information about these risks. Preclinical studies showed that 
motile epididymal sperm cells did not show increased DNA abnormalities 
as measured by TUNEL and CMA3 assays.19 20 Furthermore, studies in 
other countries showed no increase in the number of congenital defects 
in children born after ICSI in combination with MESA, PESA and TESE 
compared to ICSI with ejaculated sperm.21 22 23 Therefore, the Dutch 
government agreed in 2001 with the start of a new prospective and 
multicentre clinical study to confirm whether sperm retrieved by PESA or 
MESA in case of an obstructive azoospermia can be used safely for ICSI. 
From June 2007, ICSI with sperm retrieved by TESE followed, on the 
same condition.
ICSI children
Worldwide there are around 2,5 million children conceived after an ICSI 
treatment (ICMART, personal communication). The proportion from non­
ejaculated sperm is not known, but it should be quite low, certainly less 
than 5 % worldwide. The proportion of ICSI versus standard IVF procedures 
and the clinical pregnancy rate per transfer is still growing, so the amount 
of ICSI children will also grow in the coming years. Together with this 
ongoing progress, it is important to follow these children on karyotyping, 
congenital malformations, health, growth, development and fertility. 
These items and the knowledge of an increased risk of Y-chromosome 
deletions and of cystic fibrosis, are important for counselling the future 
parents. Y-chromosome deletions, mainly in the AZFc region, are found 
in approximately 10% of azoospermic men and 6% of men with severe 
oligozoospermia.24 This Y-chromosome deletion will be transmitted to the 
male offspring. One of the causes of azoospermia is congenital bilateral 
absence of the vas deferens (CBAVD), these men carry mutations in the 
cystic fibrosis transmembrane regulator (CFTR) gene.25 Their offspring 
has an increased risk of cystic fibrosis, so genetic testing of the partner 
and counselling of the couple is recommended.
13
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A significantly higher rate of de novo chromosomal anomalies such as sex 
chromosome aneuploidies and structural chromosome anomalies, notably 
reciprocal translocations, has been observed in ICSI-mediated offspring.26 
This has led to a situation in which we do not know to what extent ART 
procedures increase the genetic load and how this could be reflected in 
the expressed congenital malformations.
Large follow-up studies have revealed a small though statistically 
significant increase in the incidence of certain birth defects in IVF and 
ICSI children compared to naturally conceived infants.27 28 This increase 
of birth defects in singletons born after ART might be related with the 
hormonal treatment for infertility or the procedure itself (oocyte retrieval, 
culture medium, embryo transfer), but the underlying cause of infertility 
or its determinants might play a role as well.29 Another effect may be a 
lower birth weight of the IVF and ICSI singletons than children conceived 
spontaneously, even after correction for gestational age, gender and 
maternal factors.30 31 In addition increased rates of small-for-gestational 
age (SGA) have been reported for IVF and ICSI singleton pregnancies.32 33 
The mechanism behind this difference in birth weight is unknown, but 
beside the explanations mentioned before, the pre-existing condition of 
the mother or double-embryo transfer might play a role.34 35 Whether the 
effect is restricted to birth weight or reflects a general delay in growth or 
influences the health and/or development of the children is not yet known.
Although in the literature increased rates were found of abnormal karyotypes 
and major malformations of the ICSI-children, it should be considered that 
most study groups were small and heterogenic with numerous potential 
biases. Standardized methodology for follow-up studies after ART are 
necessary with well-defined groups, such as ICSI with ejaculated sperm, 
ICSI with epididymal sperm and ICSI with testicular sperm.
Aim and outline of the thesis
The main aim of the thesis was to follow the children conceived after 
ICSI with ejaculated and especially with non-ejaculated sperm. A 
questionnaire was developed with questions about parental, pregnancy 
and child factors, including gestational age, pregnancy complications, 
mode of delivery, weight at birth and several measure points in the first 
four years, presence or absence of malformations and neonatal problems.
14
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These questionnaires were sent to the parents of IVF and ICSI children at 
one year and four years of age. All children were born after a treatment in 
the Radboud University Nijmegen Medical Centre. The same questionnaires 
were sent to the parents of children born after an ICSI treatment with 
epididymal sperm, carried out in six centres in The Netherlands. These 
centres were all dealing with the protocol approved by the Dutch Central 
Committee on Research involving Human Subjects (CCMO, The Hague, 
The Netherlands).
This thesis is divided in two parts, with an intermezzo between. The first 
part concerns about the follow-up after ICSI with ejaculated sperm with 
a literature search and analyses of the results of the questionnaires. The 
intermezzo deals with the first clinical results of ICSI with epididymal 
sperm in The Netherlands. After these results the study continued with 
the follow-up after ICSI with non-ejaculated sperm, starting with an 
explorative study on DNA-arrays, a systematic review about karyotyping, 
congenital malformations and development of the children and the 
analyses of the results of the questionnaires of the study groups. In detail, 
the main questions of this thesis are:
• Follow-up after ICSI w ith ejaculated sperm
1. What are the theoretical risks and complications of ICSI for women, 
men and children? (Chapter 2)
2. Is there an association of decreased ovarian reserve in woman 
with pre-eclampsia? (Chapter 3)
3. What is the weight at birth and the longitudinal growth in the early 
childhood of IVF and ICSI children? (Chapter 4)
• Intermezzo
4. What are the first clinical results of ICSI with epididymal sperm 
after restarting this treatment under conditions in the Netherlands? 
(Chapter 5 and 6)
15
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5. Are there differences between the incidence of de novo genomic 
copy number changes in a group of ICSI children and a control 
group of naturally conceived children? (Chapter 7)
6. What is already published about karyotypes of fetuses, congenital 
anomalies and follow-up of the children born after ICSI with 
epididymal or testicular sperm? (Chapter 8)
7. Are there differences in the results of the follow-up of children 
born after ICSI with epididymal sperm compared with children 
conceived after IVF and ICSI with ejaculated sperm? Additionally, 
are there differences at two years of age in development of 
children born after ICSI with epididymal sperm in comparison with 
the Dutch reference group? (Chapter 9)
8. What are the overall results and conclusions of all presented 
studies? A general discussion. (Chapter 10)
• Follow-up after ICSI with non-ejaculated sperm
16
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Risks and complications of ICSI
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Risks and complications of ICSI
The incidence of couples seeking fertility treatment in the western world 
is estimated to be 15%/ and male factors account for about half of the 
cases.2 Since the birth of Louise Brown in 1978, in vitro fertilization (IVF) 
has become a widely used treatment for infertile couples. The introduction 
of intracytoplasmic sperm injection (ICSI) in 1992 revolutionized the 
management of severe male-factor infertility, with high success rates.3 
ICSI involves injecting a preselected spermatozoon into a mature oocyte 
(Fig. 1) after ovarian superovulation and oocyte retrieval. For men with 
azoospermia, ICSI with sperm retrieved at the level of the epididymis or 
testis is the sole possibility to father their own genetic progeny.
In Europe, >250 000 IVF/ICSI cycles are started annually, which accounts 
for 500-1500 cycles per million inhabitants per year.4 The numbers of 
reported cycles continued to increase in the last few years, with an 
increase of 37% from 1997 to 2000.
The mean (range) proportion of ICSI in different countries is 44 (24- 
68)%. In the European countries in 2000, the clinical pregnancy rate per 
transfer was 28.4% for IVF and 28.7% for ICSI. It can be estimated that 
«3% of the overall number of live births are the result of IVF or ICSI.5 
These figures indicate that artificial reproductive techniques (ARTs) are
Introduction
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practiced successfully on a large scale. Along with the success story, less 
attention is paid to safety and the potential risks for the offspring, and to 
the consequences of the high rate of multiple pregnancies.6
Theoretical risks of ICSI
Natural conception is associated with failures in all stages, ranging from 
fertilization through birth defects to developmental abnormalities and 
infertility in the offspring. In ICSI the risks are theoretically increased for 
several reasons.7 Firstly, there are risks to the female gamete: injection 
of the oocyte might cause damage to the ooplasm or meiotic spindle 
apparatus; foreign substances or contaminants might be injected in the 
oocyte; and moreover an anomalous female gamete, that otherwise would 
be bypassed by natural selection, might be fertilized. Secondly, there are 
risks to the male gamete: sperm carrying DNA anomalies, i.e. breaks and 
aneuploidy,89 Y-chromosome deletions,10 or structural defects, might be 
injected. Most infertile men with congenital bilateral absence of the vas 
deferens (CBAVD) carry mutations in the cystic fibrosis transmembrane 
regulator (CFTR) gene;11 their offspring have an increased risk of cystic 
fibrosis, so genetic testing of the partner and counseling of the couple is 
recommended. When sperm is surgically retrieved from the epididymis or 
from the testis, there are additional risks, e.g. incomplete maturation and 
ageing after a prolonged stay in the epididymis (in case of obstruction).12
Finally, the process of genomic imprinting might be incompletely installed 
during gametogenesis, or maintained during embryonic development.13 
Mouse developmental genetic research and the genetics of some rare 
developmental disturbances in humans, such as Angelman syndrome, 
Prader Willy and Beckwith-Wiedemann syndrome, clearly show that 
some chromosome regions derived from oocytes rather than sperm 
are different for a subset of «50 genes. Depending on the gene, during 
prenatal life or into adulthood, there is monoallelic expression of either 
the male-derived allele or the female-derived allele. When mouse 
zygotes are reconstructed to contain genetic material from the father 
only, the balance during early embryogenesis between the embryo proper 
and the embryonic part of the placenta shifts towards the latter. These 
observations agree with the developing insight that genomic imprinting 
is specifically important for placental functioning. Similarly, during mouse 
in vitro development before implantation, the pattern of imprinting can 
be upset by the type of medium used and most easily for the placenta.14
26
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Of most human imprinting defects that are associated with ART, involving 
IVF and ICSI, there was hypomethylation on the genomic areas concerned 
for the maternal allele.
Together with observations in farm animals, this led to the suspicion that in 
vitro embryo culture conditions are responsible. Consequently, imprinting 
disorders might result indirectly from ICSI and are probably unrelated to 
sperm differentiation.
Multiple pregnancies
The major concern of ICSI is the high rate of multiple pregnancies (26%), 
because two or more embryos are transferred per cycle. The result is that 
40% of ICSI-derived offspring are a part of multiple pregnancy.4 In natural 
conception a twin is the result of the fertilization of two separate oocytes 
(1.2% of pregnancies) or a single fertilized oocyte that subsequently 
divides into two identical structures (0.4% of pregnancies).15 Although, 
singleton pregnancies after ICSI have a worse perinatal outcome than 
unassisted singleton pregnancies, twin pregnancies after ICSI have a better 
outcome than after natural conception.16 Perinatal and maternal mortality 
and morbidity are increased, because of the higher rate of prematurity 
(<37 weeks of gestation), low birth weights (<2.5 kg) and maternal 
complications (pre-eclampsia, anaemia, postpartum haemorrhage).
Children born after multiple gestation may suffer long-term consequences 
of perinatal complications, including cerebral palsy and learning disabilities. 
Furthermore, parents of multiple births experience more stress, and 
siblings of multiple births are more likely to have behavioural problems.17
Until recently, physicians and patients underestimated the negative 
consequences of multiple pregnancies.15 Currently however, elective 
single embryo transfer (eSET), with the aim of reducing the number of 
multiple pregnancies while maintaining an acceptable pregnancy rate, 
is practiced in increasingly many institutions.18 In the eSET scenario, a 
multiple pregnancy is regarded as a complication.19
27
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The percentage of abortion after ICSI is 17.6%, which is similar to the rates 
after IVF, irrespective of the cause of male infertility and the origin of the 
sperm.20 Moreover, it is similar to the overall risk of spontaneous abortion 
after naturally conceived pregnancies, which is 14-21%. This proportion 
depends on the woman's age and previous history of spontaneous 
abortion.21 However, the percentage of aneuploidy in ICSI conceptus is 
significantly higher,22 possibly due to abnormalities in the sperm of patients 
with ICSI.8 23 Lower fertilization and implantation rates are reported when 
testicular sperm of men with unobstructive azoospermia is injected.24 
These data suggest that the theoretical risk in ICSI is partly expressed in 
reproductive failure in the preclinical stage of pregnancy before implantation, 
i.e. during fertilization and early embryo development.25 There was a 
significantly higher rate of de novo chromosomal anomalies (1.6 vs 0.5% 
in the normal population, on amniocentesis for a mean maternal age of 
33.5 years) in ICSI offspring, relating mainly to more sex chromosomal 
anomalies and partly to more autosomal structural anomalies.26 
This finding was related to sperm concentration and motility, and not 
morphology. The significantly higher rate of observed inherited anomalies 
(1.4 vs 0.3-0.4% in prenatal tests in the general population) was related 
to a higher rate of constitutional chromosomal anomalies, mainly in the 
fathers.27
Birth defects
After the introduction of ICSI in 1992, several researchers expressed 
concerns about the possible adverse effects on birth defects, and on the 
health and development of children, especially when unejaculated sperm 
is used. Some critics even suggested that ICSI might have a negative 
impact on the genetic composition of the human race.28 In the Netherlands 
this has led to a moratorium on the application of ICSI in azoospermic 
men using unejaculated sperm. That reasoning appears to be valid from 
the viewpoint that ICSI bypasses the effective biological mechanisms of 
sperm selection, and has not been preceded by research. Consequently, 
the human experience with ICSI is only the experimental record.29
In particular, the risk of boys born to couples with male factor 
subfertility has attracted attention, because for many patients 
with male factor subfertility, a genetic cause can be suspected.
Early pregnancy
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These include Y-chromosomal microdeletions, X-chromosomal and 
autosomal aberrations (i.e. Robertsonian translocations), syndromal 
disorders featuring infertility (i.e. Kallmann's syndrome) and ultrastructural 
sperm defects with a genetic origin.30 Theoretically, with ICSI these defects 
can be transmitted to the next male generation.
Furthermore, there is some evidence that the risk of congenital 
malformations is increased,31,32,33 especially after ICSI with surgically 
retrieved sperm in unobstructive azoospermia.25 34 The results of these 
studies are of interest because the chance of chromosomal aberrations and 
genetic abnormalities is higher in men with unobstructive azoospermia. 
Unfortunately, too few infants have been investigated to draw valid 
conclusions.
The major malformation rate (those causing functional impairment or 
requiring surgical correction) varies in different studies, at 0.7-9.1% 
for ICSI patients and 0.5-7.2% for naturally conceived children.35 36 
However, the case for a causal relationship between ICSI and adverse 
effects on the offspring is difficult to make, because in most studies 
maternal characteristics (e.g. age and parity), comorbidity, life-style 
(smoking, drinking, drugs), and that ICSI children are more often born 
prematurely with a low birth weight, are confounding factors. Moreover, 
the low incidence of malformations demands large-scale studies. 
In recent large Swedish studies, hypospadias was found more often 
in a cohort of ICSI male infants.37 The investigators associated this 
malformation with paternal subfertility. However, there was also a greater 
incidence of hypospadias in a cohort of IVF boys, and it was related to 
maternal progesterone administration.38
Imprinting diseases like Beckwith-Wiedemann syndrome and Angelman 
syndrome are very rare, but for the first syndrome, ART (irrespective of 
the fertilization technique) increases the relative risk by a factor of «6.39 
Large-scale and long-term follow-up studies are necessary to confirm 
an association between imprinting disorders and ART. Further laboratory 
research is required to understand the pathogenesis of this association.
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Infant development
Since the late 1990s only a few studies have been published on the 
development of children conceived by ICSI. Most of these studies compared 
the development of such children and control children during the first 2 
years of life, using either the Bayley scales of Infant Development or 
comparable scales. In 1998, an Australian study40 found lower scores in 
the Bayley mental scale for the ICSI offspring at 1 year than for the IVF and 
natural-conception controls. These differences were statistically significant 
for boys but not for girls. However, other studies could not corroborate 
these data. Bonduelle et al.41 reported a prospective study with a follow- 
up of 2 years; the overall Bayley mental development scores were similar 
in the ICSI and IVF offspring and naturally conceived children. Sutcliffe 
et al.42 found no difference in neurodevelopment using the Griffiths scales 
of mental development at up to 15 months old in ICSI-conceived children 
compared with their naturally conceived peers. A pilot study in Belgium 
showed that the ICSI-conceived children had a similar psychomotor and 
intellectual development as the IVF- and naturally conceived children at 
the age of 5 years.43
Risks of ICSI for women
Short-term medical complications of inducing ovulation or retrieving 
oocytes for IVF are rare. Ovarian hyperstimulation syndrome (1.8%), 
intra peritoneal bleeding (0.2%), pelvic infections (0.4%) and adnexal 
torsion (0.13%) have been reported.44 Another short-term effect of IVF or 
ICSI treatment is the emotional impact. After an unsuccessful treatment 
cycle, couples score higher on depression scales and many women have 
a clinically relevant form of depression.45
Hormonal and reproductive factors are involved in the causes of breast 
cancer and cancers of the female genital tract. Therefore, the long-term 
effect of fertility drugs on the risk of these cancers has been investigated. 
Many studies have not been able to reach firm conclusions because of low 
statistical power, lack of control for important confounders (e.g. causes 
of subfertility and parity) and short duration of follow-up. In a large-scale 
cohort study in the Netherlands, after a follow-up of 5-8 years, there 
was no increased risk of breast and ovarian cancer in women who had 
undergone IVF compared with subfertile women who had received no IVF.
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For endometrial cancer there was a greater risk in those exposed to 
IVF and in the unexposed group of women with subfertility caused by 
hormonal disorders.46 The ESHRE consensus group concluded that there is 
currently no evidence that ART has any effect on the incidence of genital 
or breast cancer.4
Risks of ICSI for men
Surgical sperm retrieval by percutaneous epididymal sperm aspiration 
or testicular sperm extraction in case of obstructive or unobstructive 
azoospermia is a procedure with only minor complications; pain, bleeding, 
bruising and scarring are the most common.47 There might be a risk of a 
decrease in serum testosterone levels after testicular sperm extraction, 
especially in cases of small testicular volume and hypogonadism, such 
as patients with nonmosaic Klinefelter syndrome.48 After an unsuccessful 
treatment cycle, couples score higher on depression scales.45 A greater 
subjective responsibility for the infertility, impact of childlessness on daily 
life and treatment-related stresses (particularly for sperm aspiration/ 
extraction methods) is described for men after an ICSI treatment. The men 
only reported marginally higher depression scores than their controls.49
Conclusions
The theoretical risks of ICSI may result in fertilization failure, abortion, 
birth defects, genetic abnormalities, developmental abnormalities and 
infertility in the offspring. According to the current state of knowledge, 
it appears that the incidence of chromosomal abnormalities, including de 
novo abnormalities, is higher after ICSI than in the general population. This 
might be a result of the infertility per se rather than the ICSI technique. 
The incidence of congenital malformations might be slightly higher after 
ICSI, but more large prospective studies, with naturally conceived children 
as controls, are needed to address this question definitively.
Special attention is needed for children born after ICSI using epididymal 
or testicular sperm obtained from men with obstructive or unobstructive 
azoospermia. Concerns about the use of immature testicular spermatozoa 
from men with testicular failure require further study. One of the ESHRE 
consensus recommendations is to offer chromosomal analysis in cases of 
unobstructive azoospermia and oligozoospermia with <5 x 106 sperm/mL, 
and offer microdeletion testing in men with unobstructive azoospermia and
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oligozoospermia of <1 x 106 sperm/mL. CFTR gene analysis must be offered 
in cases of CBAVD. If the genetic abnormality is confirmed, counseling of 
the couple by a trained genetics specialist must be involved.4 Another 
recommendation is to offer midtrimester ultrasonographic screening for 
congenital malformations, and amniocentesis may be considered.
The conclusion that children conceived by ICSI have similar psychomotor 
and intellectual development at the age of 5 years as have those conceived 
by IVF or spontaneously need to be confirmed by multicentre studies.
The increased risk of congenital malformations seems also to be related 
to preterm and multiple births, so a twin pregnancy is regarded as a 
complication. The ESHRE consensus meeting agreed that the essential 
aim of IVF and ICSI is the birth of one healthy child, so elective single­
embryo transfer is proposed in a first IVF/ICSI cycle in women aged <36 
years if at least one good quality embryo is available.
The question of possible risks of infertility in the offspring, especially boys, 
is still unanswered, because the oldest children are only 12 years old. It 
is very difficult to follow these children to their fertile age, because of 
privacy and the possible stigmatization of these children.
Before starting ICSI treatment it is important to counsel all patients, 
verbally and by standard patient information material. They must be 
informed that not everything is known about the health and development 
of children in their puberty and beyond, and about their fertility.
Finally it is important to have good registries in all countries, including all data 
on maternal and fetal morbidity and mortality, congenital malformations 
(with a uniform nomenclature), ART and non-ART procedures.
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Abstract
BACKGROUND: Pre-eclampsia affects 2-10% of all pregnancies and is a 
major cause of maternal and fetal morbidity and mortality. As compared 
with the general population, IVF pregnancies are associated with a 2.7- 
fold risk of preeclampsia. An advanced age and associated subfertility in 
the IVF group reflects a general decrease in ovarian reserve, which itself 
has been linked to cardiovascular disease. We tested the hypothesis that 
decreased ovarian reserve is associated with pre-eclampsia as a vascular 
complication in IVF/ICSI pregnancies.
METHODS: In this retrospective case-control study, 41 cases with a 
history of pre-eclampsia were compared to 82 matched controls without 
hypertension or (pre)eclampsia. All pregnancies were established after IVF 
or ICSI. Several indicators of ovarian reserve such as variables related to 
basal ovarian function and response to hyperstimulation were compared 
in both the groups by multivariate analysis. The condition of the neonates 
was evaluated as well.
RESULTS: A higher amount of total administered FSH and FSH per day, 
together with a lower number of obtained oocytes during IVF treatment, 
were associated with an increased risk to pre-eclampsia in a subsequent 
pregnancy. The administered FSH per follicle and per obtained oocyte 
showed even stronger relationships, the latter having the best predictive 
value. Neonatal outcome was comparable between the groups.
CONCLUSION: Diminished responsiveness of the ovaries to FSH stimulation 
in an IVF cycle, reflecting decreased ovarian reserve, is associated with 
an increased risk of developing pre-eclampsia in a subsequent pregnancy.
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Pre-eclampsia is a major cause of maternal and fetal morbidity and 
mortality worldwide. The severity of the disease ranges from a mild 
disorder with transient hypertension and proteinuria in the later part of 
pregnancy to a life-threatening disease with seizures and severe fetal 
distress.1 Overall, pre-eclampsia affects 2-10% of all pregnancies and 
accounts for as much as 15-20% of maternal mortality in developed 
countries.2 Identifying pregnancies at risk for pre-eclampsia is of great 
value, because close monitoring is helpful in preventing some adverse 
events.3 Numerous studies have tried to identify risk factors or have 
searched for screening tests to diagnose the disease at an early preclinical 
stage.4 However, to date, this pursuit has not resulted in any suitable test 
for routine use in clinical practice.5
As compared with the general population, IVF pregnancies are associated 
with a 2.7-fold risk of pre-eclampsia6 and a two-fold increased incidence 
of small for gestational age.7 Several reasons have been brought up 
to explain this phenomenon, such as multiple gestation and advanced 
age at first ongoing pregnancy.8 However, these cannot fully clarify the 
observed association. The advanced age and associated subfertility in this 
group also reflect a general decrease in ovarian reserve, which itself has 
been linked with cardiovascular risk as well.910 Consequently, indicators 
of decreased ovarian reserve, such as elevated basal FSH levels or a 
diminished response to stimulation by exogenous FSH,11 may point out 
those women at risk for development of vascular complications in their 
subsequent pregnancies.
In this study, we hypothesize that decreased ovarian reserve in women 
is associated with pre-eclampsia as a vascular complication in pregnancy. 
To this end, we conducted a retrospective case-control study amongst 
IVF and ICSI pregnancies. Cases that developed pre-eclampsia were 
compared to matched controls without hypertension or (pre)eclampsia 
in pregnancy. Ovarian reserve was assessed by basal levels of FSH and 
estradiol (E2) and by the response to hyperstimulation with exogenous 
FSH during IVF/ICSI treatment. These characteristics and subsequent 
pregnancy outcome variables were compared between the study groups.
Introduction
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Patients
In this retrospective case-control study, data were obtained from two 
databases: (I) objective information on fertility treatment and pregnancy 
outcome and (II) self-reported data on demographic features and 
pregnancy complications based on an earlier performed questionnaire 
study. Verification of reported complications during pregnancy and 
examination of other data were performed by studying the individual 
medical record.
A total of 1130 women who were successfully treated by IVF or ICSI 
in the Radboud University Nijmegen Medical Centre between October 
1994 and April 2004 were enrolled in this study. Pregnancies established 
after transfer of frozen embryos and pregnancies that did not result in 
a live birth were not included. Of these 1130 eligible women, 201 were 
excluded because of insufficient data in the database of the questionnaire 
study (Figure 1). Of the remaining 929, 41 (4.4%) women reported 
pre-eclampsia during pregnancy, which was confirmed by checking the 
individual medical records. These women served as cases. For each case, 
two control women were selected out of a group of 526 women without 
any reported vascular complication in pregnancy (Figure 1). These 82 
controls were matched according to the type of fertility treatment and 
several characteristics known to influence the risk of pre-eclampsia in 
pregnancy:4 the number of fetuses, parity, maternal age at the time of 
delivery, pre-pregnant BMI (kg/m2), race and smoking. Smoking was 
evaluated as three subgroups, referred to 'no smoking', 'smoking but not 
during pregnancy' and 'smoking also during pregnancy'. In case of more 
patients matching with the same treatment, the number of fetuses, parity 
and smoking group, the four patients with the best match for age at the 
time of delivery were checked for the two best matches for BMI. Because 
the indication for assisted reproduction treatment (ART) and the duration 
of subfertility might also have an effect on the development of pre­
eclampsia,12 we studied these variables as well, the latter being defined 
as the time evolved between the reported date of child wish and the date 
of ovum pick up minus 14 days.
Materials and methods
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IVF and ICSI treatment
Baseline FSH (IU/l) and baseline E2 (pmol/l) were measured on day 3 
(±1) of a menstrual cycle before fertility treatment.
All IVF and ICSI cycles were performed according to a standardized ovarian 
stimulation protocol with pituitary down-regulation with a GnRH-agonist 
(leuproreline or triptoreline) followed by daily injections with urinary HMG 
or recombinant FSH (rFSH). At the moment of down-regulation, checked 
by ultrasound, daily injections with 150 units of FSH were started. Women 
older than 38 years, those who had a baseline FSH above 10 IU/l or had 
a poor response (less than four follicles with a diameter >15 mm) in a 
treatment cycle before, started with a higher daily dose up to 300 units
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of FSH. Women known to have polycystic ovary syndrome (PCOS), or 
with overstimulation in a previous cycle, started with a lower dose of 
FSH. The total amount of administered FSH was defined as the product 
of the dose of administered FSH per day and the total number of days 
of administration. An injection of 10000 units of hCG was given 36 h 
before oocyte retrieval. The luteal phase was supported by injections of 
hCG or vaginally administered progesterone. The maximal achieved E2 
concentration represented the highest level of E2 measured during FSH 
stimulation in the cycle leading to conception and was determined by 
measuring the serum E2 concentration on the day of hCG-injection, 2 
days before oocyte retrieval. Maximal endometrial thickness (mm) was 
the greatest thickness of the triple-layer intracavitary-lined endometrium 
reached during stimulation. The number of follicles with a diameter >9 
mm was determined on the day of hCG injection. The fertility laboratory 
determined the number of obtained oocytes and the number of embryos 
usable for transfer. An embryo usable for transfer was defined as an 
embryo with two pronuclei on day 1 and which had reached the 2- to 
8-cell stage on day 3.
From these data, the administered FSH units per follicle and per obtained 
oocyte were calculated, defined as the total amount of administered FSH 
divided by the number of follicles and the number of obtained oocytes, 
respectively. The number of the treatment cycles in which the women 
conceived was examined as well.
Pregnancy course and outcome
Pre-eclampsia was defined according to the criteria of the Report of the 
National High Blood Pressure Education Program Working Group on High 
Blood Pressure in Pregnancy,2 which included gestational hypertension 
(repeated blood pressure measurements of >140 mm Hg systolic or 
>90 mm Hg diastolic) and proteinuria (urine protein creatinine ratio 
of >0.3g/10 mmol or dipstick test >1+ for protein) after 20 weeks of 
gestation. Gestational age at delivery was defined as the difference 
between the date of oocyte retrieval and the date of delivery with 14 
days added. Birthweight was measured, and for determination of the 
birthweight centile, we used the Dutch national reference curve, which 
adjusts for parity, gestation and sex of the infant.13 Apgar score and sex 
of the children were evaluated as well.
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Statistics
Statistical analysis was carried out using the Statistics Package for Social 
Sciences (SPSS) 12.0.1 for Windows. Variables, detailed as median and 
range or as percentage, were evaluated non-parametrically by using 
Mann-Whitney U-test and Fisher's exact test, where appropriate. We 
considered a difference statistically significant when P < 0.05. If applicable, 
correlations were evaluated by Spearman's Rho correlation analysis. 
To identify actual independent factors, we performed a multivariate 
backward stepwise logistic regression analysis that included as covariates 
those variables that were found to be correlated with the study variables. 
Receiver operation characteristic (ROC) curves were constructed from the 
possible predictors to explore their predictive values. We calculated the 
Mantel-Haenszel common odds ratios and 95% CI at the threshold points 
that yielded to a reasonable value in sensitivity and specificity.
Results
The demographic characteristics of the women with preeclampsia 
and the control group are summarized in Table I. Both the 
subgroups were comparable with respect to duration of subfertility, 
indication for IVF or ICSI and all matching criteria, such as 
maternal age at delivery, pre-pregnant BMI, maternal smoking 
status, parity, number of fetuses and type of fertility treatment. 
There were no pregnancies with more than two fetuses in the study 
population, and in case of multiparity, it was always a pregnancy of the 
second child of the woman. All women were Caucasians. In the both 
groups, the median treatment number of the conception cycle was 2 
[range: 1-6].
Leuproreline versus triptoreline, urinary HMG versus rFSH and the used 
medication during the luteal phase were comparable between the group 
of women with pre-eclampsia and the control group.
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Table I Demographic characteristics of the study groups
Pre-eclampsia 
(n = 41)
Controls 
(n = B2)
P-value
Maternal age at delivery (years) BB.S [2S.B-40.9] BB.S [2S.S-B 9.B] 0.7S0
Pre-pregnant body m ass index 
(kg/m 2) 22.9 [1B.B-B1.S] 22.S [17.B-B2.B] 0.40B
Maternal smoking
No smoking (% ) 75.S B1.7 0.479
Sm oking but not during 
pregnancy (% ) 9.B 7.B 0.7B0
Sm oking also during pregnancy 
(% )
14.S 11.0 0.5S9
Nulliparous (% ) B7.B B7.B 1.000
Singleton pregnancies (% ) 5B.7 5B.7 1.000
Assisted reproductive 
technologies
IV F (% ) 41.5 41.5 1.000
IC S I (% ) 5B.5 5B.5 1.000
Duration of subfertility (years) 4.2 [1.2-11.7] B.9 [0.7-14.B] 0.95B
Indication for assisted 
reproductive technologies
Tubal factor (% ) 7.B 9.B 0.750
Endometriosis (% ) 9.B 9.B 1.000
Male subfertility (% ) 5B.5 S1.0 0.B4S
Unexplained subfertility (% ) 19.5 17.1 0.B05
Cervical hostility (% ) 4.9 2.4 0.S00
Data are expressed as median [range] or percentage.
P-value is calculated non-param etrically (Mann-Whitney U-test or Fisher's Exact Test).
Data of the baseline, stimulation and response variables are summarized 
in Table II. There was no difference in baseline FSH and E2 levels between 
the two groups. As compared with the controls, more pre-eclamptic women 
received an increased daily dose of FSH (Figure 2), although the median 
in both the groups was the same. There were 19 (47.5%) women in the 
pre-eclamptic group, who received >150 units of FSH daily as compared 
with 22 (26.8%) women in the control group (P = 0.027). The first group 
also received a higher total dose of FSH. A lower number of oocytes was 
obtained in this group. After assessment of multivariate backward stepwise 
logistic regression analysis on the baseline, stimulation and response
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variables, two independent variables—the total dose of administered 
FSH and the number of obtained oocytes—remained. Consequently, the 
calculated administered FSH per obtained oocyte was higher in the pre­
eclamptic group as compared with the controls. Considering the effect of 
age on the incidence of pre-eclampsia, as well as an observed correlation 
between age and dose of administered FSH, we performed a multivariate 
analysis including maternal age as covariate as well. Moreover, another 
multivariate analysis was carried out to examine the possible influence of 
the used FSH and GnRH-agonists and the medication for luteal support. 
The results showed that maternal age, as well as the medication used in 
cycle control and for support in the luteal phase, had not influenced the 
results (data not shown).
Table II Baseline, stimulation and response variables of the study groups
Pre-eclampsia 
(n = 41)
Controls 
(n = 82)
P-value
Baseline
FSH (IU/l) 5.7 [2 .9-11.7] 6.3 [2.8-13.0] 0.304
Estradiol (pmol/l) 110 [66-250] 135 [38-240] 0.462
Stimulation
Administered FSH in dose/day 
(U/d) 150 [75-375] 150 [75-300] 0.033
Days of administration 11 [8-15] 10 [7-16] 0.381
Total administered FSH (U) 1800 [900-4125] 1650 [750-4200] 0.027
Response
Maximal estradiol (pmol/l) 7200 [440-15000] 7000 [1100-14000] 0.931
Maximal endometrial 
thickness (mm) 11.5 [5.0-18.2] 12.0 [7.3-18.5] 0.329
Number of follicles (>9m m ) 12 [4-33] 14 [4-28] 0.069
Number of obtained oocytes 8 [2-20] 11 [4-24] 0.029
Number of usable embryo's 5 [2-17] 6 [1-18] 0.101
Indexes
Administered FSH/follicle (U) 159 [38-660] 128 [45-500] 0.016
Administered FSH/obtained 
oocyte (U) 240 [50-1300] 163 [63-540] 0.004
Data are expressed as median [range].
P-value is calculated non-parametrically (Mann-Whitney U-test).
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Figure 2 Box plot of administered FSH in dose per day
With respect to responsiveness, there were no differences in the maximally 
reached E2 levels, endometrial thickness, number of follicles with a 
diameter >9 mm and usable embryos. Yet, in line with our findings in FSH 
per obtained oocyte, the FSH administered per follicle was also higher in 
the pre-eclamptic subgroup as compared with controls.
The results of the univariate analysis of predictive variables at given 
threshold points as assessed after ROC construction are summarized in 
Table III. At these threshold points, the administered FSH per obtained 
oocyte had the best, yet the modest, predictive power. The ROC curve of 
this variable is shown in Figure 3.
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Table III Univariate analysis of variables associated with the occurrence of 
pre-eclampsia
Sensitivity Specificity AUC OR 9 5 % C I
Administered FSH in dose/day 
(>17 5  U/d) 46.2 72.8 0.610 2.355 1.075-5.161
Total administered FSH 
(>15 50  U) 73.2 47.6 0.622 2.474 1.094-5.591
Number of obtained oocytes 
(< 1 0 )
62.2 58.5 0.620 2.323 1.081-4.991
Administered FSH/follicle 
(> 1 5 4  U) 53.7 70.7 0.633 2.798 1.287-6.083
Administered FSH/obtained 
oocyte (> 1 9 6  U) 61.0 67.1 0.659 3.183 1.461-6.932
AUC = area under the curve, OR = Mantel-Haenszel common odds ratio, 
C I = confidential interval.
3
Figure 3 Receiver operation characteristic (RO C) curve of
administered FSH per obtained oocyte related to the 
development of preeclampsia
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The pregnancy outcomes of the study groups are summarized in Table 
IV. For singleton as well as for twin pregnancies, the gestational age at 
delivery and birthweight of all children were lower in the pre-eclamptic 
subgroup. Between the two subgroups, there were no differences in 
observed sex, birthweight centile and umbilical arterial pH at birth and 
Apgar score after 5 min.
Table IV Pregnancy outcome of the study groups
Pre-eclampsia 
(n = 41)
Controls 
(n = 82)
P-value
Singleton pregnancies
Gestation at delivery (weeks) 37.9 [30.6-40.6] 40.3 [36.7-42.3] < 0.001
Birth weight (gram s) 2935 [1130-4250] 3265 [2465-4680] 0.018
Birth weight centile 54 [8-99] 52.5 [1-99] 0.703
Umbilical arterial pH at birth 7.28 [7.13-7.36] 7.25 [7.00-7.38] 0.667
Apgar score 5 minutes 9 [4-10] 10 [7-10] 0.318
Twin pregnancies
Gestation at delivery (weeks) 35.7 [31.0-39.6] 38.0 [33.0-40.4] 0.001
Birth weight (gram s)
First child 2280 [1392-2990] 2762.5 [2005-3525] 0.001
Second child 2245 [1138-3270] 2722.5 [1800-3660] 0.003
Birth weight centile
First child 22 [7-93] 41.5 [1-95] 0.360
Second child 22 [2-72] 31.5 [1-88] 0.186
Umbilical arterial pH at birth
First child 7.26 [7.20-7.39] 7.26 [7.04-7.39] 0.642
Second child 7.25 [7.13-7.34] 7.25 [7.04-7.33] 0.330
Apgar score 5 minutes
First child 10 [8-10] 10 [6-10] 0.885
Second child 9 [4-10] 9 [4-10] 0.670
Data are expressed as median [range] or percentage.
P-value is calculated non-param etrically (Mann-Whitney U-test or Fisher's Exact Test).
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Pre-eclampsia affects 2-10% of all pregnancies and relates to substantial 
maternal and fetal morbidity and mortality.14 Women conceiving through 
treatment by ART seem to more likely develop pre-eclampsia.615 In our 
study, we explored a possible association between ovarian reserves, 
as measured by basal ovarian function and response capacity to FSH 
stimulation on one hand and the development of pre-eclampsia as 
pregnancy-related vascular complication on the other. We observed that a 
decreased responsiveness of the ovaries to FSH stimulation, as indicated 
by the need for a higher amount of total administered FSH and FSH 
per day and a lower number of obtained oocytes during an IVF or ICSI 
cycle, was associated with an increased risk to develop pre-eclampsia in 
a subsequent pregnancy. The administered FSH per follicle and FSH per 
obtained oocyte showed an even stronger relation, with the latter being 
the most powerful predictor of all variables studied.
Patients with PCOS have a higher risk of pre-eclampsia.16 Because PCOS 
patients generally have a high ovarian response to FSH,17 these women 
may be overrepresented in the group with low FSH dosages per obtained 
oocyte. This may have biased our results. However, the number of patients 
with PCOS in our group was too small to draw conclusions on this possible 
bias.
In our study, basal ovarian function, as assessed by baseline FSH and 
E2 concentrations, did not relate to the development of pre-eclampsia. 
Although basal FSH is a frequently used marker for ovarian reserve, 
its value in clinical practice is argued.18 The response of the ovaries 
to hyperstimulation might be superior in reflecting ovarian reserve as 
compared with basal functions.19 This seems to be in line with our findings 
with respect to the relation with pre-eclampsia.
To our knowledge, this is the first study examining a relation between 
ovarian reserve and vascular complications in pregnancy. Although we 
found no similar studies to compare our results with, several authors 
have examined the response to hyperstimulation in ART in relation with 
treatment success. An association between diminished responsiveness 
of the ovaries and decreased pregnancy rates has been found.20 There 
is also a higher chance of pregnancy loss found as correlation with 
diminished ovarian reserve.21 This high loss rate was likely to be because
Discussion
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of fetal aneuploidy, which was higher among women with elevated FSH 
concentrations,22 but there are also other possible factors affecting the 
chance of an ongoing pregnancy in patients with diminished ovarian 
reserve.
Pregnancies after oocyte donation are associated with an increased risk 
of pregnancy-induced hypertension compared with pregnancies after IVF 
with own oocytes.23 On the one hand, this may be viewed upon as an 
immunological imbalance between 'graft' and 'host'. On the other hand, 
the ovarian failure may also indicate a generalized ageing of the system, 
including vascular system, ultimately leading to the vascular disease of 
pre-eclampsia. This latter explanation is supported by the observation that 
patients with primary ovarian failure are at a higher risk for preeclampsia 
after oocyte donation.24
An association between decreased ovarian reserve and an increased risk 
of pre-eclampsia may have implications for several reserve like those 
with a family history of a premature menopause, or having a history 
of chemotherapy, radiotherapy, pelvic surgery or infection,25 might 
be counselled for closer monitoring during pregnancy. Women without 
these risk factors but showing a low response to hyperstimulation could 
also be considered to be at increased risk for developing pre-eclampsia 
if pregnancy should occur. Unfortunately, at the chosen threshold point 
in the ROC curve, our most powerful variable showed only a modest 
discriminative power, which makes it hardly suitable for routine use in 
clinical practice. More research on these and other potential predictors is 
needed.
Because maternal vascular complications in pregnancy relate to neonatal 
morbidity as well,1 we studied several variables associated with the 
condition of the newborn. Apgar score and umbilical arterial pH at birth 
did not differ between both the study groups. In accordance to other 
studies, we observed a shorter gestation at delivery in the preeclamptic 
subgroup, which was expected, considering the tendency to induce labor 
artificially in case of pre-eclampsia. Although these children had a lower 
birthweight, after adjustment for gestational age, parity and sex, the 
outcome between both the groups were comparable. This is in contrast 
with the findings of several other studies that state that birthweight even 
after adjustment for gestational age is lower in children born to mothers 
with pre-eclampsia.26 Possibly we did not observe this in our study because
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The selection of cases in this study was based on reported complications 
during pregnancy, and although these were all verified in both cases and 
controls, the reported incidence of pre-eclampsia was low as compared 
with that of the general population, especially because pre-eclampsia 
is stated to occur more frequently in pregnancies resulting from ART.6 
Probably there were women who were not aware of their clinical condition 
before delivery, in that case we did not select them through their self­
report. In addition, the low BMI amongst our studied population may 
also have affected the incidence of pre-eclampsia. This figure may have 
been biased by our local selection protocol before IVF, which excludes 
women when having a BMI above 32 kg/m2, because obesity is associated 
with lower changes for live birth after IVF and ICSI,27 increased rates of 
miscarriage, gestational diabetes, hypertension and mechanical problems 
during delivery.28 Despite the considerable number of women who initially 
enrolled in this study, the low number reporting pre-eclampsia resulted 
in a small case group that led to a modest power. Considering this, and 
because the used case-control design has the tendency to overestimate 
found relations, a larger prospective study is needed to verify our results.
In conclusion, diminished responsiveness of the ovaries to FSH stimulation 
in an IVF cycle, which reflects a decreased ovarian reserve, is associated 
with an increased risk of developing pre-eclampsia in a subsequent 
pregnancy. We speculate that reduced ovarian responsiveness also reflects 
diminished vascular reserve capacity, the latter giving rise to pregnancy- 
associated vascular complications.
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Abstract
Birth weight and longitudinal growth in the first 4 years of life of term 
singletons conceived with the use of IVF and intracytoplasmic sperm 
injection (ICSI) were compared with those of naturally conceived singletons. 
Although IVF and ICSI singletons had a statistically significantly lower 
birth weight than naturally conceived singletons, the average individual 
weight curves showed that this difference was lost before the age of 4 
years in all subgroups: IVF, ICSI, boys, and girls.
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Weight of IVF and ICSI singletons
Singletons conceived through IVF and intracytoplasmic sperm injection 
(ICSI) have a lower birth weight than children conceived spontaneously, 
even after correction for gestational age, sex, and maternal factors.1 
Whether the effect is limited to birth weight or reflects a general delay in 
growth is not yet known. Reduced birth weight and delayed growth are 
not without health consequences.2 Epidemiologic studies have established 
associations between intrauterine and extrauterine growth restriction and 
the risk of development of health problems in later life, for example, 
cardiovascular disease.3 Only a few studies have investigated postnatal 
growth of IVF children and ICSI children as,45 but a longitudinal growth 
pattern with at least four measurements of the children has never been 
published before.
The objective of our study was to compare birth weight and longitudinal 
growth in the first 4 years of life of IVF and ICSI term singletons with 
those of term singletons of a national reference group. In addition we 
investigated whether there are differences within these groups for 
treatment (IVF, ICSI) and sex (male, female).
The study included 347 IVF and 330 ICSI (with ejaculated sperm) term 
singletons (gestational age of >37 weeks) conceived at the Radboud 
University Nijmegen Medical Center and born between June 1995 and 
December 2003. Information on fertility treatment and pregnancy outcome 
was retrieved from medical records. In addition, questionnaires were sent 
to the parents of all children at the first and fourth birthday to obtain data 
on parental, pregnancy, and child factors. These questionnaires included 
questions about weight at 1, 3, 4, 12, and 18 months and 2, 3, and 
4 years of age. These points of measurement are part of the protocol 
of the regular periodic health examinations by general practitioners at 
municipal infant welfare centers in the Netherlands. The weight data are 
documented on a card that the parents take home. The parents were 
asked to use these weight data to fill in the questionnaire.
The reference group included a total of 5,059 term singletons, from a 
large population-based cross-sectional growth study in the Netherlands of 
children between 0 and 5 years measured in 1996 and 1997.6 Measurements 
of weight after birth were performed by a general practitioner during 
the regular periodic health examinations at the municipal infant welfare 
centers, at the same intervals as in our study population. Statistically 
significant differences
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(P < 0.01 using the Fisher's exact test) between the IVF and ICSI groups 
and references were seen in smoking behavior during pregnancy and in 
birth order. More IVF and ICSI mothers did not smoke during pregnancy 
(IVF 89.3%, ICSI 88.2%, and the references 76.7%). Moreover, there 
were more firstborns in the IVF and ICSI groups (respectively 67% and 
77.0%) compared with the reference group (45.1%).
A linear regression model was developed to estimate the average weight 
curves in the two sex categories of the reference group, separately. 
The dependent variable was the logarithmic transformed weight. The 
independent continuous variable was the logarithmic transformed age 
(days after birth).
The mean birth weights were calculated from the observed data, and 
the weights from 1 month to 4 years were calculated by using the linear 
mixed model. We found that the differences between the IVF and ICSI 
group were never statistically significant, and therefore the results of the 
IVF and ICSI combined groups also are presented.
Table I shows the mean birth weights and ratios of the different subgroups 
and their associated references. We found that there was a statistically 
significant difference (the value 1 is not included into the 95% CI of the 
mean ratios) between the study groups and their associated reference 
groups at birth but no longer at the age of 4 years. We also calculated the 
intersection of the growth curves of the study groups and their associated 
reference group. Specifically the point of intersection of the study group 
of IVF boys and the associated reference group occurred before 4 years.
Our study showed that term IVF and ICSI singletons had a significantly 
lower birth weight than children from a national reference group. This 
difference in birth weight between IVF and ICSI singletons and reference 
singletons is in accordance with findings of others.7 The mechanism behind 
this difference in birth weight is unknown, but several explanations have 
been given, such as a late effect of the hormonal ovary stimulation, the 
IVF-ICSI procedure itself (oocyte retrieval, culture medium, ET), the 
preexisting condition of the mother, factors related to subfertility, or double 
ET.8,9 It was not possible in our study to verify all these explanations. For 
instance, information on the preexisting condition of the mother or the 
number of early vanishing twins was lacking. However, because there 
were no differences between the IVF and ICSI groups, it is not plausible
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Table I Weight, ratio to the reference group, and time of intersection with 95% confidence interval at birth and at 4 years by 
gestational age, sex, and type of conception
Birth weight Weight at 4 years Time of intersection a
Gender Type of conception n
Mean in grams 
(95% CI)
Ratio 
(95% CI)
Mean in grams 
(95% Cl)
Ratio 
(95% Cl)
Year 
(95% Cl)
Boys
IVF 169 3407 (3332-3483) 0.97 (0 .95-1 .00) 16875 (16576-17179) 1.00 (0 .98-1 .02) 3.5 (0 .1 -84 .9 )
ICSI 150 3404 (3323-3487) 0.97 (0 .95-1 .00) 16524 (16184-16870) 0.98 (0 .96-1 .00) > 4
IVF/ICSI 319 3406 (3351-3461) 0.97 (0 .96-0 .99) 16711 (16486-16939) 0.99 (0 .98-1 .01) > 4
natural 2519 3500 (3480-3520) 1.00 (ref) 16863 (16743-16984) 1.00 (re f) NA
Girls
IVF 178 3301 (3234-3369) 0.98 (0 .96-1 .01) 15964 (15644-16291) 0.99 (0 .97-1 .01) > 4
ICSI 180 3264 (3181-3350) 0.97 (0 .95-0 .99) 15950 (15614-16292) 0.99 (0 .97-1 .01) > 4
IVF-ICSI 358 3282 (3229-3337) 0.98 (0 .96-0 .99) 15962 (15730-16197) 0.99 (0 .97-1 .00) > 4
natural 2521 3356 (3337-3374) 1.00 (ref) 16184 (16065-16304) 1.00 (re f) NA
Note: Cl = confidence interval; NA = not applicable; Ref = reference group.
a Point of crossing of the weight curves of IVF and/or ICSI group and the associated reference group.
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that the factors related to subfertility or the ICSI procedure itself are 
of a great influence. In most cases the indication for ICSI was a male 
factor and the women had no other fertility problems themselves. Other 
influences on the birth weight that may play a role are maternal age, 
parity, and smoking behavior during pregnancy.1011 The first two factors 
could have contributed to the lower birth weight in our study group. 
Parity was significantly lower in the study group. The age of the mothers 
of the reference group at time of birth was not available. However, the 
mean age at delivery in the Netherlands in 1990 was 29.2 years and in 
2004 was 31.0 years (http://www.cbs.nl). This is substantially lower than 
in the study group and is in agreement with previous data.12 Because 
significantly more IVF and ICSI mothers did not smoke during pregnancy, 
the weight difference between IVF and ICSI children and the reference 
group could have been more pronounced if the smoking behavior had 
been equal in both groups.13
Previous studies reported on postnatal growth of IVF children1415 and 
other studies about ICSI children as well.45 Although almost all studies are 
reassuring, they have some limitations such as having not differentiated 
for gestational age, having performed only one single weight measurement 
at 5 years of age, or having included only IVF children. However, our 
study differentiated for gestational age, had at least four measurements, 
and included IVF and ICSI children. Our study shows that the weight 
difference at birth is lost in both IVF and ICSI children before the age of 
4 years.
Ludwig et al.16 reported in a review an increase in childhood illnesses, 
in chronic diseases, and in the use of health care in IVF children, which 
may be related to the lower birth weight and higher frequency of preterm 
birth. Children with a low birth weight have a risk for development of 
health problems in later life, for example, cardiovascular disease.3 For 
these reasons it is important to know the weight curves of the IVF and 
ICSI children with a gestational age of<37 weeks as well. In our study, 
because these groups were too small to describe for a reliable conclusion, 
we recommend future studies for preterm IVF and ICSI infants with a long 
follow-up time.
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Children with diagnosed growth disorders and those receiving medication 
known to interfere with growth were excluded from the reference group, 
but these children were not identified in the study group. It was not 
possible to exclude the IVF and ICSI children from the reference group, 
because the type of conception was not known. However, the proportion 
of IVF children in this reference group will be very low. In 1996, one out 
of 77 Dutch children was born after an IVF or ICSI treatment.17 Close to 
25% of these children are from a twin pregnancy and 5.8% to 15% of the 
singletons were born before 37 weeks of gestational age;18 therefore, the 
number of IVF and ICSI term singletons in the reference group is <1%.
We compared longitudinal data of IVF and ICSI children with cross-sectional 
data of a reference group. This approach has disadvantages although it 
gave us the opportunity to have a large population-based control group. 
In future studies control groups with longitudinal data are to be preferred, 
with all confounding factors taken into account. The large sample size 
(especially the reference group), high response rate, and relatively long 
follow-up with at least four measurements are the strengths of our study. 
The scheme with frequent measurements of weight made it possible to 
assess a detailed longitudinal pattern of growth in both IVF and ICSI 
children.
We conclude that IVF and ICSI singletons with a gestational age of >37 
weeks have a significantly lower birth weight than natural conceived 
singletons. It is reassuring that the longitudinal growth of the IVF and 
ICSI children is comparable with the growth of natural conceived children 
and that the difference of birth weight is lost before the age of 4 years.
Acknow ledgm ents
The authors thank Mr. Wim Lemmens for his assistance in the statistical 
analysis and Ms. Pippa Staps for updating the databases.
63
Chapter 4
References
1. McDonald SD, Murphy K, Beyene J, Ohlsson A (2005) Perinatal outcomes of singleton 
pregnancies achieved by in vitro fertilization: a systematic review and meta-analysis. J 
Obstet Gynaecol Can 27,449-59.
2. Huxley RR, Shiell AW, Law CM (2000) The role of size at birth and postnatal catch-up 
growth in determining systolic blood pressure: a systematic review of the literature. J 
Hypertens 18,815-31.
3. Barker DJ (2004) The developmental origins of wellbeing. Philos Trans R Soc Lond B Biol 
Sci 359,1359-66.
4. Bonduelle M, Wennerholm UB, Loft A, Tarlatzis BC, Peters C, Henriet S, et al. (2005) A 
multicentre cohort study of the physical health of 5-year-old children conceived after 
intracytoplasmic sperm injection, in vitro fertilization and natural conception. Hum 
Reprod 20,413-9.
5. Knoester M, Helmerhorst FM, Vandenbroucke JP, van der Westerlaken LA, Walther FJ, 
Veen S, et al. Perinatal outcome, health, growth, and medical care utilization of 5- to 
8-year-old intracytoplasmic sperm injection singletons. Fertil Steril 2008;89:1133-46.
6. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, et 
al. (2000) Continuing positive secular growth change in The Netherlands1955-1997. 
Pediatr Res 47,316-23.
7. Koudstaal J, Van Dop PA, Hogerzeil HV, Kremer JA, Naaktgeboren N, Van Os HC, et al. 
(1999) [Pregnancy course and outcome in 2956 pregnancies after in-vitro fertilization 
in Netherlands]. Ned Tijdschr Geneeskd 143,2375-80
8. Pinborg A, Lidegaard O, Freiesleben NC, Andersen AN (2007) Vanishing twins: a 
predictor of small-for-gestational age in IVF singletons. Hum Reprod 22,2707-14.
9. Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcos LS (2002) Low and very low 
birth weight in infants conceived with use of assisted reproductive technology. N Engl J 
Med 346,731-7.
10. Hindmarsh PC, Geary MP, Rodeck CH, Kingdom JC, Cole TJ (2008) Factors predicting 
ante and postnatal growth. Pediatr Res 63,99-102.
11. Olivennes F, Fanchin R, Ledee N, Righini C, Kadoch IJ, Frydman R (2002) Perinatal 
outcome and developmental studies on children born after IVF. Hum Reprod Update 
8,117-28.
12. Kallen B, Finnstrom O, Nygren KG, Otterblad Olausson P (2005) In vitro fertilization in 
Sweden: maternal characteristics. Acta Obstet Gynecol Scand 84,1185-91.
13. Pringle PJ, Geary MP, Rodeck CH, Kingdom JC, Kayamba-Kay's S, Hindmarsh PC (2005) 
The influence of cigarette smoking on antenatal growth, birth size, and the insulin-like 
growth factor axis. J Clin Endocrinol Metab 90,2556-62.
14. Ceelen M, van Weissenbruch MM, Prein J, Smit JJ, Vermeiden JP, Spreeuwenberg M, 
et al. (2009) Growth during infancy and early childhood in relation to blood pressure 
and body fat measures at age 8-18 years of IVF children and spontaneously conceived 
controls born to subfertile parents. Hum Reprod 24,2788-95.
64
Weight of IVF and ICSI singletons
15. Koivurova S, Hartikainen AL, Sovio U, Gissler M, Hemminki E, Jarvelin MR (2003) 
Growth, psychomotor development and morbidity up to 3 years of age in children born 
after IVF. Hum Reprod 18,2328-36.
16. Ludwig AK, Sutcliffe AG, Diedrich K, Ludwig M (2006) Post-neonatal health and 
development of children born after assisted reproduction: a systematic review of 
controlled studies. Eur J Obstet Gynecol Reprod Biol 127,3-25.
17. Kremer JA, Bots RS, Cohlen B, Crooij M, van Dop PA, Jansen CA, et al. (2008) Ten years 
of results of in-vitro fertilisation in the Netherlands 1996- 2005. Ned Tijdschr Geneeskd 
152,146-52.
18. Helmerhorst FM, Perquin DA, Donker D, Keirse MJ (2004) Perinatal outcome of singletons 
and twins after assisted conception: a systematic review of controlled studies. BMJ
65

Intermezzo
5
6

Chapter 5
5
Obstructive azoospermia in men who 
wish to father children; diagnostics 
and surgical sperm retrieval
Nederlands Tijdschrift voor Geneeskunde 2003 Dec 27;147(52):2583-7 
(translated by Michaela van Montfoort-Kreuzer)
Deric K.E. van der Schoot1 
Liliana Ramos2 
Gwendolyn H.Woldringh2 
Didi D.M. Braat2 
Jan A.M. Kremer2 
Alex M.M. Wetzels2 
Erc J.H. Meuleman1
1 Department of Urology, Radboud University Nijmegen Medical Centre
2 Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre
Chapter 5
Abstract
OBJECTIVE: To evaluate diagnostic procedures and surgical sperm 
retrieval in men with suspected obstructive azoospermia who wish to 
father children.
DESIGN: Descriptive, retrospective.
METHOD: During the period 1 April 1999-31 December 2001 93 men 
suspected of having obstructive azoospermia underwent surgical sperm 
retrieval by means of percutaneous epididymal sperm aspiration (PESA). 
In each patient a testicular biopsy was performed to determine the 
Johnsen score (a score > 8 is equivalent to a normal spermatogenesis). 
Cryopreservation was performed whenever possible. The findings in both 
percutaneous and surgical sperm retrieval were compared.
RESULTS: In 76 patients (82%) epididymal motile sperm were obtained 
using PESA. Their Johnsen score on the testis biopsy was 9.1 (range: 7.4­
10). In 73 of the patients the Johnsen score was > 8. In the 17 patients 
(18%) in whom no sperm were found with PESA, the median Johnsen 
score was 5.8 (range: 2-9.8). Epididymal sperm were not found in patients 
with a testicular volume < 15 ml. In all 28 patients who had undergone 
a vasectomy in the past, motile sperm were found along with a Johnsen 
score > 8. In 23 of the 24 patients with congenital bilateral absence of the 
vas deferens (CABVD) the Johnsen score was > 8. Cryopreservation was 
possible in 45 (59%) of all patients and in 5 (35%) of the 13 patients with 
an unknown cause for the obstructive azoospermia.
CONCLUSION: In men with suspected obstructive azoospermia in whom 
sperm were found using PESA, a diagnostic testis biopsy provided no 
additional relevant information about the spermatogenesis. There was 
always a good spermatogenesis after vasectomy. CBAVD patients probably 
had at least some focal areas in the testes with normal spermatogenesis. 
Sperm retrieval and cryopreservation could be carried out less frequently 
in the case of obstructions with an unknown cause.
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Until recently, it was not possible for men with azoospermia to have offspring 
that was genetically their own. The introduction of intracytoplasmatic 
sperm injection (ICSI) created the option of producing offspring by means 
of surgically retrieved sperm. On 1 January 2001 the moratorium on ICSI 
with surgically retrieved (non-ejaculated) sperm was abolished. Treatment 
of men suffering from histological proved obstructive azoospermia, with 
epididymally retrieved sperm was permitted, according to the protocol 
approved by the Central Commission for Human-Centered Research 
(CCMO).1
The prevalence of azoospermia in the Netherlands is an estimated 600 to 
800 cases a year. Approximately two thirds of these cases are caused by 
defects in spermatogenesis, and about one third of the cases are caused 
either by a functional obstruction or by a mechanical obstruction in the 
genital tract. The obstructive cases are in men who have azoospermia 
after vasectomy or (re)vasovasostomy, and men with congenital bilateral 
absence of the ductus deferens (CBAVD); the latter is diagnosed with 1% 
to 2% of subfertile men.23 Furthermore, there is a small number of men 
who have an irreparable obstruction caused by a variety of causes, such 
as trauma (either or not iatrogenic), infections, a median prostate cyst, or 
an unknown cause that cannot be found.
So, there are a number of men of whom it is certain that they have 
an obstruction, for instance those who have had an unsuccessful 
vasovasostomy. Moreover, there are a number of men in whose cases 
it is unknown whether or not their azoospermia is obstructive. For the 
latter, it is important to determine by precise non-invasive diagnostic 
techniques whether they have either an obstruction or a defect in their 
spermatogenesis.
In this article we will describe what implications the conditions, mentioned 
in the protocol, have had for the procedures for the selection of patients 
and for sperm retrieval. This description will be based on the results of the 
first 93 men who were examined.
Introduction
71
Chapter 5
In a retrospective study the results of percutaneous epididymal sperm 
aspiration (PESA) and testis biopsies were analysed.
Patients
During the period from 1 April 1999 through 31 December 2001, 93 men 
with supposed obstructive azoospermia had their sperm retrieved surgically 
by means of PESA at our hospital. Their average age was 39 years. They 
all had a testis biopsy taken at the same time for an examination of their 
spermatogenesis. Before 2001 this was done as part of the diagnostic 
effort. Whenever possible, cryopreservation of the sperm was carried out 
for future ICSI treatment.
Obstructive azoospermia became the supposed diagnosis as a result 
of anamnesis, physical examination and hormone examination (when 
the follicle-stimulating hormone (FSH) turned out to be below 11 U/l). 
Semen analysis was carried out at least twice, with a period of at least 
three months between the two analyses. After all, azoospermia may be 
temporary, for instance as a result of a severe influenza. In the anamnesis 
the researchers paid attention primarily to the patients' medical history 
(such as genital infections, vasectomy, maldescensus testis, orchitis, or 
torsio testis). During the physical examination, the volume of the testes 
was examined because it usually corresponds to the number of sperm 
cells in the ejaculate. Furthermore, it was examined whether the patient 
had an epididymis and a ductus deferens, and whether the epididymis 
was stowed. Scrotal sonography was not carried out routinely. All of the 
CBAVD patients were subjected to a genetic examination (Table I).4
Johnsen score
In order to make the diagnosis "obstructive azoospermia" appear more 
likely, a testis biopt with the size of a rice grain was taken for the 
determination of the Johnsen score as a measurement of spermatogenesis. 
The Johnsen score is acquired by giving the tubuli seminiferi a score 
related to the percentage of either the presence or the absence of the 
main cell types in spermatogenesis in the order of their maturation.5 So, 
the presence of spermatozoa is given the score of 10 to 8; the presence 
of spermatides (but no further) is given a score of 7.9 to 6; the presence 
of spermatocytes is given a score of 5.9 to 4; and the presence of only 
spermatogonia is given a score of 3; a score of 2 is assigned to the
Patients and methods
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Table I Diagnostics in the case of azoospermia
Anamnesis: case history
Physical examination: testis-volume, presence of ductus deferens, stowage of 
epididymis
Semen analysis: at least twice
Hormonal examination: value of follicle-stimulating hormone (FSH)
Scrotal sonography
Transrectal prostate sonography: on indication
Genetical examination: in case of congenital bilateral agenesis of the ductus deferens
Sertoli-cell-only syndrome, and a score of 1 is given to the absence of 
stem cells. The definition of normal spermatogenesis is a Johnsen score 
of 8 or more. The Johnsen score correlates strongly with the quality of 
spermatogenesis.5 Essentially, a single one-sided biopt from the largest 
testis is sufficient. It must be kept in mind that spermatogenesis is not 
distributed equally between the two testes, and that this distribution is 
even more unequal in case of a spermatogenetic disorder. Consequently, 
even with a testis biopsy obstructive azoospermia cannot be diagnosed 
with certainty.
PESA
At present, in those cases of obstructive azoospermia in which no 
reconstruction is considered, PESA is the simplest method of sperm 
retrieval. In case of an obstruction, enough sperm cells are usually found 
in the epididymis; the percentage of vital (motile) sperm cells usually 
decreases from proximal (caput) to distal (cauda), depending on the level 
of obstruction. This is contrary to non-obstructive azoospermia, in which 
case most motile sperm cells can be found in the distal epididymis.
PESA is carried out as a policlinical operation under local anaesthesia by 
means of a funiculus block. A (wing-) needle of 17 to 21 gauge is stuck 
into the epididymis and is withdrawn while sucking in a vacuum (see 
the figure). The needle is fastened with a small tube to a 5 ml syringe 
containing 1 ml of NaCl. After that, the small tube is purged into a syringe 
with a flushing medium (a salt solution to which plasma proteins were 
added). Its contents are immediately assessed under a microscope by
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a laboratory staff member, to assess the presence and the motility of 
sperm cells. This procedure may be repeated a number of times in each 
session. In practice, however, it turns out that, if the needle is positioned 
correctly, the first procedure yields the best output, and that subsequently 
the output decreases rapidly. The advice is to begin at the side of the 
largest testis. In case of an insufficient output, the other epididymis may 
be punctured.
Cryopreservation
In case of a good output, cryopreservation is applied. After concentrating 
the various aspirations, the sperm cells are mixed with a cryoprotective 
medium and are frozen in liquid nitrogen in portions of 500 |jl each 
(-1960 C). If possible, a straw is defrosted immediately after freezing in 
order to judge the motility of the sperm cell. Thanks to cryopreservation, 
if there is a good output, the patient in question does not need any 
sperm aspiration any more during subsequent ICSI attempts. Because 
cryopreservation can be successfully carried out with only some of the 
patients, the PESA procedure must be repeated with some patients at the 
moment of the woman's ovum retrieval. This requires good logistics from 
the departments of Gynaecology and Urology.
Statistics
For statistical evaluation the X2 test was used, calculated with the Statistical 
Package for the Social Sciences (SPSS, version 10.1).
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PESA combined with a testis biopsy was tolerated well by all of the 93 
patients. Only one patient had a complication. He developed a hydrocele 
a few weeks after the operation. This was corrected in an operation.
In case of PESA, epididymal motile sperm was extracted from 76 patients 
(82%). 73 of these patients had a Johnsen score >8 and three had a 
score of 7.4. The median score was 9.1 (the extremes were 7.4 - 10). 
With 17 patients (18%) no epididymal sperm was found. Their median 
Johnsen score was 5.8 (extremes: 2 - 9.8). One patient had a Johnsen 
score of 9.8. In the case of positive sperm retrieval by means of PESA, the 
average Johnsen score was statistically significantly higher than in those 
cases when no sperm could be retrieved (P < 0.001).
The average volume of the testis from which the biopt was taken, was 20 
ml. In case of a testis volume < 15 ml, no epididymal sperm was found 
(n = 4). In Table II the results are presented per cause of obstructive 
azoospermia. There were no statistical significant differences in FSH value 
or in testis volume. With all of the 28 patients with a vasectomy and a 
failed vasovasostomy, epididymal sperm and a Johnsen score > 8 were 
found. Of the 24 patients with CBAVD, 23 patients had a Johnsen score > 
8, and one patient had a score of 7.4; the average Johnsen score in this 
group was 9.0.
Cryopreservation was successful (meaning that after defrosting, motile 
sperm cells were found) with 45 (59%) of the epididymal punctures. In 
advance there were no indications identifying a certain group with whom 
no cryopreservation would be possible. The group of patients with whom 
cryopreservation most rarely could be carried out were those who had an 
unexplained obstruction (5/13; 35%). In this group, epididymal sperm 
retrieved by means of PESA was found with 13 patients (46%), and the 
average Johnsen score was 7.2.
Results
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Table II Diagnostical results for 93 men with obstructive azoospermia, arranged 
according to causes of azoospermia
Cause Number Mean values Number (%)
FSH (U/l) testis-
volume
(ml)
Johnsen
scorea
epididymal
spermb
cryo-
preservation
successful
CBAVD 24 5.7 19 9.0 23 (96) 13 (59)
vasectomie 28 6.5 21 9.0 28 (100) 17 (61)
trauma or 
injury 13 4.7 20 9.1 13 (100) 10 (77)
unknown 26 6.2 20 7.2 13 (46) 5 (35)
Totally 93 5.8 20 8.5 77 (83) 45 (59)
CBAVD = congenital bilateral agenesis of the ductus deferens 
a score of testisbiopsy: score of > 8 is equivalent to a normal sprematogenesis 
b retrieved by percutaneous epididymal sperm aspiration 
c after defrosting, motile sperm cells were found
Discussion
In this study there was a statistical significant connection between finding 
epididymal sperm with PESA and a normal spermatogenesis. In case of a 
supposed obstructive azoospermia, diagnostical PESA that preferably will 
be combined with cryopreservation suffices, a diagnostical testis biopsy is 
no longer necessary. Our results are confirmed by other research.6
The fact that epididymal sperm is also found with men with a Johnsen 
score < 8 may be explained by the fact that spermatogenesis is not divided 
equally among both testes. Locally there may be focal areas with normal 
spermatogenesis. In such cases a testis biopt may have been taken just 
beside such an area. The absence of epididymal sperm does not always 
indicate a spermatogenetic disorder, but may as well be based on an 
intratesticular obstruction. This was illustrated by one patient without any 
sperm by PESA with a Johnsen score of 9.8.
The characteristic features of obstructive azoospermia are a normal testis 
volume and normal FSH values. In a recent American study the FSH values 
(with a cut-off value of 7.6 U/l) and the size of the testis (with a cut-off value 
of 4.5 cm) had the highest prognostic value for the diagnosis of obstructive 
azoospermia.6 Moreover, inhibin B is mentioned as a good indicator for 
spermatogenesis.7 In our study, however, the latter was left aside.
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Ultrasound may make a limited contribution to the diagnosis of an 
obstruction, but it does contribute to tracing defects that are not found 
during an ordinary physical examination. From two studies in which 
altogether more than 9000 men participated,89 it appears that a tumour 
of the testis or a carcinoma in situ is diagnosed with 0.4 - 0.5% of the 
men. This is 20 to 50 times as often as with fertile men the same age. 
For this reason it is standard at a number of hospitals to do an ultrasound 
of the scrotum with each new subfertile man. A transrectal ultrasound of 
the prostate may also be carried out if there is an indication for doing so. 
If the semen volume and the pH of the semen are low, the azoospermia 
may be caused by a distal obstruction such as a median prostate cyst.10 
Such an obstructive median prostate cyst can be visualised by means of 
transrectal prostate ultrasound. Moreover, the presence or absence of the 
vesiculae seminales can be ascertained that way.
Genetic examination of patients who have obstructive azoospermia is 
carried out in case of a CBAVD. This defect can easily be detected by 
means of a physical examination. Research into mutations in the "cystic 
fibrosis transmembrane regulator" gene (CFTR) is carried out.4 Besides 
cystic fibrosis, this gene may also cause CBAVD. 85% of all men with 
CBAVD have one or two CFTR-gene mutations, whereas one in every 
thirty Dutch people is a carrier of one mutation. If the man has a CFTR- 
gene mutation, a genetical examination of the woman is carried out as 
well. If the woman also has a CFTR-gene mutation, then, depending on 
the mutation in question, there is a probability of 25% the child will have 
cystic fibrosis or a CBAVD. If both the man and the woman are carriers, 
the couple is sent to a clinical genetic consultant.
In the first surgical sperm retrievals with patients who had an obstructive 
azoospermia the sperm was retrieved from the epididymis1112 or from the 
testis.13 In these cases a high percentage of pregnancies was accomplished 
by means of ICSI. The methods of surgical sperm retrieval included 
microsurgery at the location of the epididymal ductuli (MESA) or an open 
testis biopsy with testicular sperm extraction (TESE). However, TESE 
may have a negative influence on the testis as a result of the formation 
of fibrosis.14 Later on, sperm was retrieved by means of less invasive 
methods, including PESA15,16 or testicular sperm aspiration (TESA).17,18,19 
The percentage of sperm that is still motile after cryopreservation varies 
from 0 to 25 of the original motile fraction. The duration of cryopreservation 
has no influence on these percentages.20
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All of our patients had normal spermatogenesis after vasectomy. After 
all, this concerned only men who had proved their fertility prior to their 
sterilisation, in many cases in a relationship with a different woman. 
Probably all of the CBAVD patients have at least some focal areas 
with normal spermatogenesis. In the cases of unexplained obstructive 
azoospermia, sperm was less frequently found by means of PESA, and 
cryopreservation turned out to be possible with only one third of the men.
In conclusion, a man in the Netherlands who has a wish to father children 
and who for clinical reasons is supposed to have obstructive azoospermia, 
who has an epididymis that can easily be felt, and who has normotrophic 
testicles may be referred to a centre for in-vitro fertilisation where ICSI is 
carried out in combination with PESA. For all other cases of azoospermia, 
no treatment with a man's owns sperm is possible in the Netherlands. 
In case of an unknown cause, there is a lower probability of retrieval 
of epididymal sperm than in those cases when the cause is known, but 
the difference between the two groups is statistically not relevant. This 
information is important for the counselling of couples that consider 
assisted reproduction.
Meanwhile, based on the first draft of this article, an amendment to the 
protocol approved by the CCMO was passed. This amendment states that 
testis biopsies must no longer be carried out if epididymal sperm was 
found by means of "diagnostical" PESA.
No conflict of interests was reported. No financial support was reported.
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Abstract
OBJECTIVE: To evaluate the results of intracytoplasmatic sperm injection 
(ICSI) with surgically retrieved epididymal sperm.
DESIGN: Prospective, descriptive.
METHODS: Patients with an obstructive azoospermia confirmed by 
cytological examination of a testis biopsy, and conforming to the regular 
IVF/ICSI criteria as laid down in 2001 at the University Medical Centre 
St Radboud Nijmegen, the Netherlands, were included for percutaneous 
epididymal sperm aspiration (PESA) and ICSI. The main outcome measure 
was the ongoing pregnancy rate per initiated cycle.
RESULTS: A total of 44 cycles were started in 31 couples. In 43 cases 
(98%) an ovum pick-up was performed and 41 (93%) embryo transfers 
were carried out. In 19 (43%) cases, treatment resulted in a positive 
pregnancy test and 15 (34%) ongoing pregnancies were recorded. In 
total, 17 healthy children were born (11 boys and 6 girls).
CONCLUSION: ICSI with surgically retrieved sperm was successfully used 
as a treatment for childlessness caused by obstructive azoospermia.
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Introduction
Intracytoplasmatic sperm injection (ICSI) with surgically retrieved sperm 
has been permitted again under certain conditions in the Netherlands 
since 1 January 2001. During the previous years, for Dutch couples, this 
treatment had only been possible abroad. Since 1994, in the Netherlands 
ICSI was carried out either with ejaculated sperm or with surgically 
retrieved sperm. In the latter case, the sperm was retrieved from the 
epididymis by means of microsurgical or percutaneous epididymal sperm 
aspiration (MESA or PESA, respectively), or from the testis by means of 
testicular sperm retrieval (TESE).
In 1996, the Dutch Association of Obstetrics and Gynaecology (NVOG, 
Nederlandse Vereniging voor Obstetrie en Gynaecologie) and the 
Association of Clinical Embryologists (KLEM, Vereniging van Klinisch 
Embryologen) established a moratorium on ICSI with surgically retrieved 
sperm because of the uncertainty about its consequences for posterity. 
It was unknown what the effect would be of the aging of the sperm cells 
that for a longer time had been stored up in the epididymis, or what effect 
immature sperm cells from the testis would have. In 1998 the moratorium 
was taken over in the Planning Decision Concerning In-Vitro Fertilisation.1
Until so far, it does not appear from any research in any other country 
that ICSI combined with MESA, PESA or TESE would result in a larger 
number of congenital defects in posterity.2 3 4 In studies carried out at 
our own IVF laboratory, motile epididymal sperm cells did not show any 
increased damage on the DNA either.56 As a consequence, the NVOG, 
the KLEM, the Dutch Urology Association (Nederlandse Vereniging voor 
Urologie), and the Minister of Health, Welfare and Sports proposed to 
repeal the moratorium under certain conditions. By 1 January 2001, the 
Minister ordered the removal of the moratorium and modified the planning 
decision in such a way that the use of surgically retrieved sperm cells from 
the epididymis (by means of MESA or PESA) was permitted in a protocol 
that was tested by the Central Commission for Human-Centered Research 
(Centrale Commissie Mensgebonden Onderzoek: CCMO).7
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The Radboud University Nijmegen Medical Centre is the first medical centre 
in the Netherlands that reintroduced ICSI with surgically retrieved sperm, 
in conformity with the protocol approved of by the CCMO. Criteria are 
described in the protocol, according to which only men with an obstructive 
azoospermia may be admitted to the treatment. Moreover, in this protocol 
the follow-up research into the physical and psychological condition of the 
children born after the treatment is described.
In the meantime, the MESA technique in Nijmegen was largely replaced 
by PESA, as the latter is an easier technique with a similar output and 
that may be carried out as a policlinical operation.8 In this article we will 
describe the first clinical results after one year of PESA-ICSI-treatment, 
this means all of the cycles started in 2001.
Patients and methods
After the moratorium had been instituted in 1996, all patients at the 
Radboud University Nijmegen Medical Centre eligible for ICSI-treatment 
with surgically retrieved sperm where registrered on a waiting list. In 2001 
they were informed in writing that ICSI-treatment with surgically retrieved 
sperm was permitted again. The protocol and the subsequent follow-up of 
the children were explained to the couples. After that, "informed consent" 
was obtained. As soon as "obstructive azoospermia" had been diagnosed 
and PESA had been carried out, the couple in question was registered on 
the waiting list for ICSI treatment. A number of couples from the waiting 
list already had their child wish fulfilled either by means of MESA or TESE- 
treatment combined with ICSI abroad, by means of artificial insemination 
with donor sperm, or by means of adoption. On the other hand, after it 
had become known that in Nijmegen treatment was possible again, more 
couples from places outside the district of Nijmegen were referred. In 
the present analysis, only those couples were included who actually had 
started their ICSI treatment in 2001.
Criteria for inclusion and exclusion
The main criterion for inclusion was the existence of a histologically proved 
obstructive azoospermia that could not possibly be cured by means of 
surgery. The exclusion criteria for in-vitro fertilisation (IVF) and ICSI that 
are customary at our hospital were maintained, i.e. woman's age of 42 
years or more, woman's age of 40 or 41 years, combined with a basal (on 
the first three days of the cycle) follicle-stimulating-hormone (FSH) level
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> 10 U/l, or basal FSH-level > 20 U/l for women aged less than 40 years. 
Furthermore, couples were excluded from treatment if the woman was 
either seriously overweight or seriously underweight, if they had serious 
psychosocial problems, or if either the man or the woman was seropositive 
for HIV or for the Hepatitis-B-virus.
Genetic exam ination
Men with a congenital bilateral absence of the ductus deferens (CBAVD) 
were examined as to whether they were carriers of genetic mutations for 
cystic fibrosis.9,10
PESA-procedure
In those cases when cryopreservation of sperm retrieved during PESA had 
been impossible (because after defrosting testing no motile sperm cells 
had been found), but motile sperm cells had been observed during direct 
assessment, the ICSI-procedure was started all the same, and the PESA- 
procedure was repeated on the day of the ovum retrieval (a so-called 
acute PESA).
ICSI-procedure
The woman's treatment did not differ in any way from the regularly 
procedure for IVF or ICSI: suppression of the emission of luteinising 
hormone and FSH by the hypophysis with the aid of gonadotrofine- 
"releasing"-hormone (GnRH) agonists, stimulation of the ovaries with 
recombinant FSH, a last phase of oocyte maturation by means of human 
choriongonadotrofine (hCG), after which a follicle puncture took place in 
order to obtain oocytes. Only mature, morphologically normal oocytes 
were used to inject one motile sperm cell per oocyte with a micropipette 
through the zona pellucida into the cytoplasma of the oocyte (table).11 
Either defrosted sperm cells from a PESA-procedure carried out at an 
earlier stage or fresh sperm cells from an acute PESA-procedure were 
used. If fertilisation had occurred, a maximum of two embryos was inserted 
into the uterus on the third day after the follicle puncture. Whenever 
possible, the remaining embryos were cryopreserved (these embryos 
might possibly be defrosted and inserted into the uterus in a later cycle). 
The luteal phase was supported with progesterone administered through 
the vagina.
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Fifteen days after the embryo transfer a pregnancy test was carried out. 
A pregnancy was defined as being a positive pregnancy test in the urine 
or serum two weeks after the embryo transfer. An ongoing pregnancy 
was defined as an intra uterine pregnancy with a duration of at least 
twelve weeks with heart action determined by means of a ultrasound. The 
primary outcome measure was the number of ongoing pregnancies for 
each cycle that had been started.
Statistical analysis
Differences between percentages of ongoing pregnancies for each cycle 
that had been started were considered to be not statistical significant if 
there was overlapping of the confidence intervals belonging to them.
Results
During the period that was examined, 31 couples had started treatment, 
with a total of 44 ICSI-PESA-cycles in all. Nine couples had two cycles, 
and two couples had three cycles. In one cycle, no follicle puncture was 
carried out because of imminent hyperstimulation. In two cycles, no 
embryo transfer was carried out: in one case no sperm cells had been 
obtained during the PESA-procedure, whereas a follicle puncture had 
been carried out, and in one case only one oocyte was obtained that had 
an abnormal shape and therefore was unsuitable for injection. Altogether, 
511 oocytes were obtained (on average 11.9 oocytes for each follicle 
puncture, extremes: 1-26 oocytes), 417 of which (82% of the oocytes 
obtained) could be injected. Fertilisation occurred 276 times: 54% of the 
oocytes obtained, 66% of the number of oocytes that were injected.
The results of the treatments are presented in Table I. Nineteen pregnancies 
occurred: four times (21%) there was a non-vital pregnancy, and fifteen 
times there was an ongoing pregnancy (34% for each cycle that had been 
started): there were twelve single babies and three twins (20% of the 
fifteen continuous pregnancies). There were no differences between the 
results of the first, the second, and the third cycle. Because of the limited 
period of study, not all eligible couples started a second or a third cycle.
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Table I Result per cycle: number of ongoing pregnancies among 31 couples with a 
child wish and with obstructive azoospermia after intracytoplasmatic sperm 
injection with surgically retrieved sperm, Radboud University Nijmegen Medical 
Centre, 2001
1st cycle 2nd cycle 3rd cycle total
N um ber (% )a
Cycles started 31 11 2 44
Follicle punctures 30 (97) 11 (100) 2 (100) 43 (98)
Embryo transfers 29 (94) 10 (91) 2 (100) 41 (93)
Pregnancies 15 (48) 3 (27) 1 (50) 19 (43)
N um ber (%; 95%  -C I)a 
Ongoing pregnancies 11 (36; 19-55) 3 (27; 6-61) 1 (50) 15 (34; 21-50)
a The percentages are related to the number of cycles started. 
CI = conficence interval
The group could be subdivided according to a number of different causes 
of obstructive azoospermia (Table II): CBAVD (15 couples, 24 cycles); 
vasectomy (six couples; nine cycles); trauma or infection (six couples; 
six cycles); and unexplained cause (four couples; five cycles). There were 
no statistical significant differences between the groups in percentages of 
ongoing pregnancies.
Table II Result per indication: number of ongoing pregnancies with 31 couples with a 
child wish and an obstructive azoospermia after intracytoplasmatic sperm 
injection with surgically retrieved sperm, Radboud University Nijmegen 
Medical Centre, 2001
Cause of obstructive azoospermia
CBAVD Vasectomie Trauma or injury Unknown
N um ber (% )a
Cycles started 24 9 6 5
Follicle punctures 23 (96) 9 (100) 6 (100) 5 (100)
Embryo transfers 23 (96) 9 (100) 5 (83) 4 (80)
Pregnancies 12 (50) 2 (22) 3 (50) 3 (60)
N um ber (%; 95%  -C I)a 
Ongoing pregnancies 10 (42; 22-63) 2 (22; 3-60) 2 (33; 4-78) 2 (40; 5-85)
a The percentages are related to the number of cycles started. 
CI = conficence interval
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An acute PESA was carried out eighteen times in all (one cycle was cancelled 
before the follicle puncture because of imminent hyperstimulation and in 
one case no sperm was retrieved); in the remaining 25 cycles cryopreserved 
sperm was used (table III). The percentages of ongoing pregnancies for 
each cycle that had been started after using fresh sperm or cryopreserved 
sperm were comparable: 36% (7/25) versus 32% (6/19). The four non­
vital pregnancies occurred after using cryopreserved sperm (twice in the 
case of CBAVD, once after an accident or an infection, and once due to an 
unexplained cause).
Table III Number of cycles started and ongoing pregnancies with 31 couples with a 
wish to father children and an obstructive azoospermia after 
intracytoplasmatic sperm injection with surgically retrieved sperm, Radboud 
University Nijmegen Medical Centre, 2001, using cryopreserved sperm or 
fresh sperm
Cause of obstructive azoospermia
CBAVD Vasectomie Trauma or injury Unknown Total
Cryopreserved  sperm
Cycles started 8 8 7 2 25
Ongoing pregnancies 
(%; 95% -CI)a 4 (50) 2 (25) 2 (29) 1 (50) 9 (36; 18-58)
Fresh sperm
Cycles started 15 1 0 3 19
Ongoing pregnancies 
(%; 95% -CI)a 5 (33) 0 (0) 0 (0) 1 (33) 6 (32; 13-57)
a The percentages are related to the number of cycles started. 
CI = conficence interval
From the fifteen pregnancies that occurred, seventeen children were 
born: eleven boys and six girls. No congenital defects were diagnosed 
with any of these children. All of the couples had been offered prenatal 
diagnostics; seven of them did not make any use of it, and seven couples 
had an extensive ultrasound carried out in about the 20th week of the 
pregnancy (no congenital defects were found). One couple with a twin 
pregnancy had an amniocentesis, because of the woman's age. In one 
foetus a partial trisomy 9 (as a result of a small duplication of a piece of 
the long arm of one of the chromosomes 9) was diagnosed. In the 21st 
week of the pregnancy the latter was reduced to a single pregnancy that 
subsequently took an uncomplicated course and resulted in the birth of a 
healthy daughter.
90
Obstructive azoospermia: initial clinical results
Discussion
In this study, ICSI with surgically retrieved epididymal sperm was found 
to be an effective treatment for couples with unvoluntary childlessness 
based on obstructive azoospermia. The fifteen continuous pregnancies that 
resulted from the 44 cycles that had been started yielded a percentage of 
34 (95% - BI: 21-50), which is comparable to the success percentages at 
our hospital for ICSI-cycles with ejaculated sperm (28%; 24-32) (www. 
nvog.nl/files/ivfcijfers2001perkliniek.pdf). The relatively small scale of 
the study produces broad intervals of reliability, so that it is difficult to 
draw any clear conclusions.
During the same period, the average age of the women who had a follicle 
puncture carried out for ICSI-treatment with ejaculated sperm was 32.9 
years, and thus is comparable to the average age of 32.7 years in the 
study group. Moreover, the success percentage is comparable to that in 
foreign studies, in which the percentage of ongoing pregnancies after 
an ICSI-PESA-treatment or an ICSI-MESA treatment with obstructive 
azoospermia varies from 28.6% to 48.5%.12,13,14
Fertilisation of oocytes in our group which is 66% is comparable with 
foreign studies, which includes that the percentages of fertilisation of 
the oocytes obtained vary from 53% to 72.4%.121516 Moreover, these 
percentages were comparable to the percentages of fertilisation in the 
group with whom an ICSI-cycle with ejaculated sperm was started at our 
hospital in 2001. 73% of the oocytes thus obtained were fertilised.
There were no differences between the percentages of onoing pregnancies 
after ICSI-treatment in combination with an acute PESA, compared to the 
percentages in the case when cryopreserved sperm was used. This also 
turned out to be the case in some foreign studies.1516 If it is possible to 
use cryopreserved sperm, this has some advantages for the patient (only 
one operation is necessary and one has the certainty to have vital sperm 
at the moment of the follicle puncture) as well as for the logistics of the 
treatment (no acute PESA is necessary). However, if no sperm can be 
cryopreserved, then it is a good alternative to carry out an acute PESA. In 
this context it is essential that there is good cooperation between the IVF 
Department and the urologists.
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In one pregnancy, a partial trisomy 9 was diagnosed by means of an 
amniocentesis; this probably was a chromosomal de-novo anomaly. It is 
not clear whether this diagnosis was based on coincidence, or whether 
it was due to the ICSI-treatment or to the PESA-procedure. Recently, a 
higher percentage of chromosomal de-novo defects with ICSI-children 
was reported, indicating that it remains necessary to pay attention to 
this aspect.17 A good follow-up of the children is necessary, meaning that 
a physical as well as a psychological examination of the children will be 
carried out at the age of 2 and 6 years. By means of these examinations, 
we intend to examine, as is being done in research abroad, whether ICSI- 
PESA-treatment is not only a successful method but also a safe method 
without consequences for posterity. This new opportunity for patients with 
obstructive azoospermia who wish to father children as an alternative 
to adoption, to artificial insemination with donor sperm, or to treatment 
abroad.
Besides the UMC in Nijmegen, and recently the UMC in Utrecht and the 
MC in Rotterdam, various other hospitals will begin to carry out the ICSI- 
PESA-protocol, so more patients may receive treatment in their own part 
of the country.
No conflict of interests reported. No financial support reported.
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Abstract
BACKGROUND: Over the last three decades, technological developments 
facilitating assisted reproductive techniques (ART) have revolutionized 
the treatment of subfertile couples, including men suffering from severe 
oligospermia or azoospermia. In parallel with the advent of these 
technologies, there is a great concern about the biological safety of ART. 
This concern is supported by the clinical observation that the frequency 
of congenital malformations is slightly elevated among ART-conceived 
children.
METHODS: In this explorative study, we have used tiling-resolution BAC 
array-mediated comparative genomic hybridization to investigate the 
incidence of de novo genomic copy number changes in a group of 12 
ICSI children, compared with a control group of 30 naturally conceived 
children.
RESULTS: In 6 of the 12 ICSI children, we found 10 apparently de novo 
'same direction genomic copy number changes' [i.e. simultaneous copy 
number gain (or loss) with respect to both biological parents], notably 
losses. In statistically significant contrast, similar observations were 
encountered only six times in the control group in 5 of the 30 children. 
However, our study group was small, so a larger group is needed to 
confirm these findings.
CONCLUSIONS: Loci at which we found de novo alterations are known 
from the human genome database to be prone to large DNA segment copy 
number changes. As discussed, various molecular mechanisms, including 
the consequences of delayed male meiotic synapsis and replication fork 
stalling at early embryonic cell cycles, might trigger these copy number 
changes.
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Introduction
In Europe, in 2002, the clinical pregnancy rate for ICSI was 29.4% per 
transfer, and it has been estimated that 1-3% of the overall number of 
live births are the result of ICSI.1 These figures clearly demonstrate that 
ICSI is currently being successfully applied on a large scale. Even men 
with azoospermia often have the possibility to father their own genetic 
progeny, through ICSI with surgically retrieved sperm at the level of the 
epididymis or testis.
In parallel with the advantage of these technological developments, there 
is an observation that ICSI seems to be associated with slightly elevated 
incidences of certain birth defects. Large follow-up studies by several 
independent research groups have revealed a small though statistically 
significant increase in the incidence of certain birth defects in IVF and 
ICSI children compared with naturally conceived infants.2 3 4 In theory, 
this increased risk may be caused by several factors which may either act 
alone or in conjunction.56 In the first place, male gamete-associated risks: 
sperm carrying DNA anomalies, i.e. breaks, aneuploidy, Y chromosome 
deletions or structural changes, may be transferred.7 8 9 Second, there are 
risks contributed by the female gamete: the injection of the oocyte itself 
may cause damage to the ooplasm or meiotic spindle apparatus, and its 
DNA repair status may determine the mutagenic outcome of sperm DNA 
lesions.8,10,11,12 Suboptimal female gametes, which otherwise would have 
been bypassed by natural selection, may be fertilized due to ovulation 
induction.13 Indeed, it is beyond any doubt that a significantly higher rate 
of de novo chromosomal anomalies such as sex chromosome aneuploidies 
and structural chromosome anomalies, notably reciprocal translocations, 
has been observed in ICSI-mediated offspring.14
This has led to a situation in which we do not know to what extent assisted 
reproductive techniques (ART) increase the genetic load, how epigenetic 
aspects my be involved as well and how this could be reflected in the 
expressed congenital malformations. Lack of knowledge regarding the 
primary molecular mechanism(s) underlying the observed ICSI-associated 
increased rate of birth defects has thus far prevented further technical 
innovation for optimalization of the procedure.
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Earlier results from array-based whole genome profiling in the fertile 
population have already firmly established that genomic duplications 
and deletions in the size range of a few kilobases to several megabases 
are relatively common.151617 These duplications and deletions are not 
necessarily translated into readily recognizable phenotypic changes, 
although a role in human evolution has repeatedly been suggested.1819 At 
the same time, de novo regional duplications, deletions and inversions, 
triggered by genomically unstable sequences, involving ectopic homologous 
recombination are well-established causes for a still growing number of 
genetic diseases.20
In the present explorative study, we used bacterial artificial chromosome 
(BAC)-array mediated comparative genomic hybridization (array-CGH) 
analysis in order to identify constitutional de novo DNA copy number 
changes, including those that are phenotypically silent. With DNA copy 
number variation (CNV), two or multiple copies are arranged in tandem 
and/or there may be more elaborate patterns such as those caused by 
segmental duplications, where the numbers of copies are highly variable.17 
In contrast to most of the other whole genome profiling platforms that were 
available at the time the study was performed, the tiling-resolution BAC 
arrays used provide unbiased genomic coverage, including polymorphic 
genomic intervals (comprehensively listed at the 'Database of Genomic 
Variants', http://projects.tcag.ca/variation/), at a practical resolution of 
around 100 kb.21
Through the use of BAC arrays, it is possible to detect DNA changes (i.e. 
large-scale copy number changes) more efficiently than by using the 
single nucleotide polymorphism (SNP)-arrays which were also available 
at the time this study was performed, because with the latter the CNV 
intervals were systematically underrepresented.22 23 This is of considerable 
importance since our data strongly suggest that copy number changes of 
large polymorphic intervals are frequently targeted in ICSI-children.
Materials and Methods
Study design
This explorative study was performed with prior written informed consent 
of both parents and with approval of the Institutional Review Board of 
the Radboud University Nijmegen Medical Centre. Blood samples were 
obtained from both parents and from the umbilical cord of the child
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immediately after delivery. Six children (four boys and two girls) were 
born after ICSI with ejaculated sperm from fathers suffering extreme 
oligoasthenoteratozoospermia (OAT) in which no Y chromosome 
microdeletions or chromosomal abnormalities were found. Six additional 
children (two boys and four girls) born after ICSI with sperm from a 
percutaneous epididymal sperm aspiration (PESA) procedure had fathers 
with obstructive azoospermia [two times congenital bilateral absence of 
vas deferens (CBAVD) and four times failed vasovasostomy].
Relative genomic copy number profiles of all children were determined by 
separate comparison with both parents.
As a reference, we used genomic copy number profiles from 30 trios (child 
and biological parents), which were produced in the context of a previous 
departmental research program,24 all without any apparent link to reduced 
fertility. In this study, the proband and both parents were individually 
compared with a control DNA reference pool containing equal amounts 
of peripheral blood-derived DNA from 10 random individuals, enabling a 
subsequent mathematical establishment of relative copy number changes.
T iling-resolution array-based CGH
In this study, we have used a tiling-resolution genomic microarray consisting 
of 32 447 overlapping BAC clones selected to cover the entire human 
reference genome,2125 which was prepared as previously described.24 26 
In short, genomic target DNAs were isolated from bacterial cultures 
using an AutogenPrep 960 (Autogen, Holliston, MA, USA) according to 
the manufacturer's instructions. Subsequently, ~50 ng DNA from each of 
the clones was amplified using degenerate oligonucleotide-primed PCR 
(DOP-PCR), then dissolved at an average concentration of 1 |jg/Ml in 30% 
DMSO-containing spotting buffer, and spotted onto CMT-ultragaps coated 
glass slides (Corning) using an Omnigrid 100 arrayer (Genomic Solutions).
Labeling and hybridization
DNA was extracted from umbilical cord derived (newborn) or peripheral 
blood (parents and individuals from control group) using the QIAamp 
DNA Mini Kit (Qiagen) according to the manufacturer's procedure with 
minor modifications. In brief, DNA was isolated after Proteinase K and 
RNase treatment. Two washing procedures were performed with washing 
buffer AW2. DNA was eluted in AE buffer. Subsequent hybridizations were 
performed basically as described previously.27 In brief, 500 ng of genomic
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DNA from the umbilical cord blood sample and that of one of the parents 
was labeled by random-primed labeling with Cy3-dUTP or Cy5-dUTP 
(Amersham Biosciences), respectively. Labeled DNAs were mixed with 
120 g^ human Cot-1-DNA (Roche), co-precipitated and re-suspended in 
hybridization solution (50% formamide; 10% dextran sulfate; 2 x sodium 
saline citrate (SSC); 4% SDS; 10 g^/ l^ tRNA (Invitrogen). Slides were 
hybridized for 18 h at 37°C with active re-circulation of hybridization fluid, 
followed by five wash cycles in 50% formamide, 2 x SSC at 45°C and 
five wash cycles in phosphate buffer at 20°C. Subsequently, slides were 
dried by centrifugation and scanned on a GenePix Autoloader 4200AL 
laser scanner (Axon Instruments, Union City, CA, USA). Analysis of the 
microarray image files was performed with the GenePix Pro 5.0 software 
package (Axon Instruments), and all data were uploaded into a local 
database expert system for automated data-normalization and further 
analysis.
Data processing and statistical analysis
Genomic intervals showing altered test/reference (T/R) fluorescent 
intensity values, and as such qualifying as candidate regions for putative 
de novo copy number alterations, were detected by expert eye, with the 
standard aid of hidden Markov modeling (HMM) as described previously.24 
Initial statistical analysis was performed using Fisher's exact test. A 
statistical significant difference was defined as P < 0.05. All identified 
genomic copy number alterations were compared with both public and 
private databases of known disease-unrelated large-scale CNVs (http:// 
projects.tcag.ca/variation/). Gene organization of the regions involved 
was obtained from public databases (mainly: http://genome.ucsc.edu 
NCBI genome build 36.1, March 2006).
Pyrosequencing
In order to further evaluate the array-CGH findings, and in an attempt to 
determine absolute genomic copy numbers for selected genomic intervals 
in both children as well as their biological parents, pyrosequencing 
(PSQ) reactions were performed for multiple SNPs residing within these 
genomic regions. PSQ was selected as the most appropriate technological 
approach as its dynamic detection-range extends well beyond that 
offered by other approaches, for instance, MLPA (L.E.L.M. Vissers, 
personal communication). Interphase fluorescence in situ hybridization 
(FISH) analysis was considered not to be appropriate as the previously 
established limited genomic distance of some of the repeat-intervals under
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investigation was assumed to impair reliable copy number counts due 
to fluorescent signal-merging. PSQ (for an explanation of the technique, 
see http://www.pyrosequencing.com) was performed according to the 
protocol of the manufacturer, with minor modifications.28 Briefly, ratios of 
SNP genotypes were determined using a Pyrosequencer PSQ96MA platform 
(Biotage AB, Uppsala, Sweden). SNP-specific PSQ primer combinations 
were developed in-house, using dedicated 'PSQ Assay Design' software 
(Isogen Life Science). Primers were ordered from Biolegio BV, Nijmegen, 
The Netherlands, or Isogen Life Science, IJsselstein, The Netherlands. 
SNP-specific PSQ primer sequences are available from the authors upon 
request. PSQ reactions were performed in triplicate.
Copy number estim ations
Genomic copy number estimations were mainly based on observed SNP 
genotype ratios. In addition, the number of copies apparently present 
within the human reference genome was estimated through BLAT 
searches at the UCSC Genome Bioinformatics site (http://genome.ucsc. 
edu/cgi-bin/hgBlat), using sequences (typically a few hundred bases) 
encompassing the SNP under investigation (for an example see lower 
panel of Fig. 1, which reveals that SNP RS16875985 appears to be present 
in seven copies per haploid reference genome). Arbitrary 'reference copy 
numbers' obtained in this way were used as initial offsets to establish 
'best-fit copy numbers' in ICSI children and their parents. In addition, 
also average, region-specific T/R values (Fig.1 upper panel) were taken 
into consideration.
Results
One year after birth, all parents of the study group were sent detailed 
questionnaires in order to establish the medical condition of their children. 
In addition, children born after ICSI with sperm from a PESA procedure 
went through an extensive medical examination at the age of 2 years in 
the context of standard national ICSI-PESA guidelines. The mean duration 
of pregnancy of the study group was 39+3 weeks (range: 36-42+1). Their 
mean birthweight was 3578 g (range: 2610-4320). One child was part 
of a twin pregnancy with duration of 36 weeks and a birthweight of 2610 
g (the other part twin was not included in the study group, but was also 
healthy). None of the children had a minor or major malformation, and 
none was admitted at the hospital in the first year of life.
Constitutional DNA copy number changes in ICSI children
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Array-CGH
Using a HMM algorithm with standard settings, as explained in more detail 
in the Materials and Methods section, genomic copy number differences 
with respect to a single parent could easily be identified. The large majority 
of these changes, however, seemed to represent common variations in 
copy number (http://projects.tcag.ca/variation/), which are known to 
be fully compatible with normal Mendelian inheritance. It is therefore 
reasonable to assume that the large majority of these are unlikely to 
represent de novo genomic copy number changes.
In a number of instances, 'same direction copy number changes' [i.e. 
simultaneous copy number gain (or loss) with respect to both parents] 
were identified. There were 10 such genomic intervals in six children 
detected among the ICSI children (n =12). All these intervals belonged 
to a previously defined set of 13 most frequently encountered regions of 
genomic polymorphism.17 29 Scanning of the control group of 30 child- 
parent trios for similar 'same direction copy number changes' in these 
intervals revealed six similar events in five children (Table I).
A representative example of one such interval (targeting chromosome 
5q12, family K) is shown in Figure 1. For this case, the BAC array (upper 
panel) shows a clear copy number gain of the newborn compared with 
both the father (plotted in green) and the mother (plotted in red).
Pyrosequencing
On the basis of available HapMap data (http://www.hapmap.org/) SNP- 
linked PSQ primers were designed and optimized for a total of 14 loci, 
representing five of the seven genomic intervals listed in Table I. No 
informative SNPs could be identified for the 0.5 Mb interval on chromosome 
22q11. Primer-combinations and optimized PCR-/PSQ-conditions are 
readily available upon request from the authors. Primary data-processing 
using standard PSQ96MA software (Biotage AB), yielded reproducible 
SNP genotype ratio calls for all the SNPs typed (primary experimental 
data are available upon request). Figure 2 shows a composite figure 
containing representative examples of the graphical output produced by 
the PSQ96MA software package (family K).
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Table I Same direction copy number changes (target regions)
Chr. 5 q l3 .2  (68 ,75- 
70,75 Mb)
Chr. 8q21.2 (86 ,63- 
86,92 Mb)
Chr. 1 0 q ll .2  
(47 ,08-48 ,13  Mb)
Chr. 1 4 q l l . l  
(18 ,43-19 ,39  Mb)
Chr. 1 5 q ll .2  
(19 ,08-19 ,99  Mb)
Chr. 1 9p l3 .2  (8 ,65- 
8 ,70 Mb)
Chr. 2 2 q l l . l  
(14 ,30-14 ,81  Mb)
SNPs used 
1 for PSQa
RS16875985 RS7388011
RS987390
RS6981582
■ RS915672
RS543617
RS7153371
RS1112179
RS925313
RS2672358
RS4804079
RS301420
RS301424
nothing found
Family ID ICSI children
1 Ab loss loss
1  Bb loss loss
1 Cb loss
1  Db
Eb
I F loss loss loss
G
H loss
1 Kb gain
M
N
0
Controls0
96 loss
58 gain gain
350 loss
117 loss
17 gain
a PSQ: pyrosequencing
b child born after IC S I with sperm from a PESA
c only control fam ilies (n= 30) in which 'sam e direction copy number changes' were observed are listed
C
onstitutional 
DNA 
copy 
num
ber 
changes 
in 
ICSI 
children
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Statistical analysis
There were 10 'same direction copy number changes' detected among six 
ICSI children (total number tested: 12), whereas only six similar genomic 
regions in five children could be detected within our much larger (n = 30) 
control group (Table I). The two tailed P-value by Fisher's exact test for 
these values equals 0.049, so 'same direction copy number changes' are 
significantly more frequent within our panel of ICSI children than among 
children from our control group. Although the numbers are small, in the 
ART group (n = 10), all but one were losses, whereas for the control group 
(n = 6) there was a balance between losses and gains (Table I). Hence, 
when testing for losses only, a higher level of significance is obtained 
(P = 0.031).
There were six copy number changes found in four children (out of six) 
born after ICSI with sperm from a PESA, and four changes in two children 
(out of six) born after ICSI with ejaculated sperm from fathers suffering 
extreme OAT. The two-tailed P-value by Fisher's exact test equals 0.567, 
indicating that there is no significant chance difference for having 'same 
direction copy number changes' between children born after ICSI with 
sperm from a PESA and children born after ICSI with ejaculated sperm 
from fathers suffering extreme OAT.
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Figure 1 Same direction copy number change in family "K" (at 5q13.2).
Upper panel: representative example of a "same direction copy number change" in 
family K (Table 1). 2log(T/R) values of child versus father (in green) and child versus 
mother (in red) are plotted in a superimposed manner. A region with significant T/R value 
differences, as detected by the HMM algorithm (green line) is clearly visible around the 
70 Mb position on chromosome 5q13.2. Middle panels: mapping positions of nucleotide 
sequence surrounding a representative SNP (RS16875985) as identified through a 
standard BLAT search at the Human Genome Browser website are projected, together 
with the mapping position of well established protein encoding genes residing in this 
genomic interval. Lower panel: duplicated intervals identified in the reference human 
genome sequence, and exceeding 1 kb in size reveal the complex genomic architecture 
of this particular genomic interval.
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Figure 2 Haplotype ratios for SNP RS16875985 (family K)
Single Nucleotide Polymorphism (SNP) RS16875985 (residing at 5q13.2 [Figure 1 middle 
panel]) haplotype ratios for family K [Figure 1], as determined by pyrosequencing. 
Standard output format as produced by the PSQ96MA software package is shown. The 
father, mother and child show ratios compatible with minimal "best fit genomic copy 
numbers" of 9, 7, and 5 (as shown "ratio-percentages" (shaded boxes) appear to be 
multiples of 11.1% [one ninth], 14.3% [one seventh] and 20% [one fifth]), respectively. 
As the haploid human reference genome contains 7 copies (i.e. 14 copies in total), we 
assume the parents to have 18 and 14 copies respectively. As the child appears to have 
a T/R value of roughly 1,3 (to 1,5) compared to both parents (Figure 1), the child is 
supposed to actually have something in the order of 4 (or 5) times the minimal genomic 
copy number of 5 (i.e. 20-25) copies.
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Discussion
As mentioned in the Introduction, large follow-up studies by several 
independent research groups have revealed a small though statistically 
significant increase in the incidence of certain birth defects in ICSI 
children compared with naturally conceived infants.2 3 4 Also a significantly 
higher rate of de novo chromosomal anomalies has been observed in 
ICSI-mediated offspring.14 These data suggest that ART procedures 
increase the genetic load. Such an increase, if present, could, besides 
gross chromosomal changes including CNV of large kilobyte range 
sequences, also apply to other mutation types such as simple sequence 
repeat instability, small deletions, duplications, inversions and base pair 
changes. At the moment, we would not know to what extent an increased 
genetic load might manifest itself in congenital malformations. The lack 
of knowledge regarding the primary molecular mechanism(s) underlying 
the observed ICSI-associated increased rate of birth defects, prompted 
us to initiate the study described here. We used BAC array mediated CGH 
(array-CGH) analysis in order to identify possible constitutional de novo 
DNA copy number changes in ICSI children, which can be detected with 
the 32k array with a resolving power of around 100 kb. Up to now, the 
considerable CNV detected with this type of technology at first observation 
appears to be phenotypically silent, although selective pressures must 
have been operative.18,19
There were 10 'same direction copy number changes' [i.e. simultaneous 
copy number gain (or loss) with respect to both parents] found in 6 out 
of the 12 ICSI children, 9 of which were losses. In an attempt to obtain 
a more accurate basis for our copy number estimates, we subsequently 
used PSQ as an independent technology platform to validate our array- 
CGH findings. PSQ data were obtained for all child-parents trios with copy 
number changes (except for an apparent de novo copy number change at 
chromosome 22q11.1, for which no suitable SNPs could be selected) and 
were fully compatible with our BAC array-based observations. As could be 
expected, PSQ does not provide the investigator with exact copy number 
counts. The haplotype ratios obtained through this technique, however, 
can be very helpful nevertheless, as they provide a kind of mathematical 
framework (i.e. 'multiples of ...', as explained in the legend to Figure 2) 
for copy number estimates. It should be realized, however, that the 
ratios obtained by this technique can be explained either by a minimal 
ratio-compatible number of copies or a multiple of this number, thereby
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always providing the mathematical opportunity for a standard Mendelian 
segregation fit (assuming that copy numbers are not limited). Moreover, 
this technique is unsuitable for determining the distribution of these 
copies over the chromosome pair (which would require more extensive 
segregation analysis or combined sperm- and oocyte-typing).
Since no information can be obtained regarding the distribution of individual 
copies over the two autosomes, we decided to use statistics to investigate 
whether the frequency at which 'same direction copy number changes' 
were encountered in our patient population was significantly different 
from that found in our reference population. The two-tailed P-value by 
Fisher's exact test indicated that 'same direction copy number changes' 
appear to be significantly more frequent within our panel of ICSI children 
than among children from our control group (P = 0.049). This result is 
more striking when only repeat losses are considered (P = 0.031). No 
significant difference was found for 'same direction copy number changes' 
in children born after ICSI with sperm from a PESA compared with children 
born after ICSI with ejaculated sperm from fathers suffering extreme OAT 
(P = 0.567). Our study group was small, so a larger group is needed to 
confirm these findings.
A Mendelian explanation of our results would assume appreciable size 
differences between the two 'alleles' from both parents. The reason 
for ART in these couples was a male infertility problem. Moreover, 
the association between allele size difference and infertility is at least 
questionable because of the absence of a theoretical/genetic explanation 
in the literature. So the de novo occurrence of a CNV, notably losses, in 
the male germline is the most plausible explanation.
In PESA patients, spermatogenesis is assumed to be normal. However, de 
Boer et al.30 found indications for altered kinetics of meiotic prophase in this 
class with leptotene and late zygote spermatocytes being overrepresented. 
This is suggestive for difficulties in initiating and finalizing meiotic synapsis 
and hence crossing-over.31 Recently, a decreased efficiency at meiotic 
synaptic initiation and finalization has also been found in cases of human 
azoospermia.32
This observation suggests a link between the increased occurrence of 
CNV and a disturbed kinetics of first meiotic prophase, likely involving the 
organization of the axial lateral elements of the synaptonemal complex,
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as this organization determines which homologous sequences are brought 
together in early and late recombination nodules.33 34
Impaired progression at the end of zygotene is most prominent at the 
large heterochromatic blocks that are often different in size between 
homologues, adjacent to the centromeres of chromosomes 9 and 1.35 
Recently, it has been found that delayed synapsis in these regions also 
can show as a recombination effect in trans on chromosome 5,32 where we 
found CNV at 5q13.2 most frequently.
Alternatively, the origin could be at the elongated spermatid and sperm 
stages as these, due to contracted chromatin are regarded as devoid of 
DNA repair, that is subsequently triggered in the zygote. Double strand DNA 
repair by non homologous end joining and homologous recombination is 
active in the zygote,1112 and a male-female interaction at this level for the 
generation of paternal Retinoblastoma mutations has been proposed.10 
In this scenario, stalled replication forks in the paternal pronucleus by 
compromised homologous recombination repair12 would lead to the mainly 
deletions in large scale repeat areas.
An extension of the explanation of our results has recently been offered 
by CNV analysis of phenotypically concordant and discordant monozygotic 
twins.36 Somatic mosaicism was shown to be common in peripheral blood- 
derived DNA, both by a tiling 32K BAC array and by an Illumina system 
SNP analysis. Hence, the origin of the mutation event, likewise connected 
with repeat replication stalling, could also be later than the first cleavage 
division, with later origins expected to contribute less of a CGH effect, if 
not outweighted by the size of the event.
As far as can be judged by medical examination of the young children of 
concern here, the genomic changes observed do not have a phenotypic 
consequence. Because of the small sample size, phenotypic effects were 
not expected. However, as repeat areas are not by definition genetic 
deserts (see for instance Figure 1) and genes in these and comparable 
areas have been linked to phenotypic effects, dosage effects could be at 
the basis of congenital malformation. For instance, genomic alterations 
affecting SMN1 (see Figure 1) are linked to the development of spinal 
muscular atrophy (http://www.genecards.org/).
113
Chapter 7
Although executed at a small scale, our search revealed a relative 
abundance of 'same direction copy number changes' in an ART setting, 
increased by a factor of 5 relative to the control population. Our estimate 
likely is an underestimate as the two alleles are pooled per individual. 
Hence, meiotic segregation from one parent can obscure a de novo 
event from the other parent (for a de novo deletion this would mean the 
inheritance of a longer repeat array from the other parent).
In conclusion, the recently discovered genome mobility by CNV in the 
human likely is enhanced in an ART setting, a result that should warrant 
more detailed investigation into especially the mechanisms and germ cell 
stages involved.
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Abstract
BACKGROUND: For men with azoospermia, it is possible to father their 
own progeny by intracytoplasmic sperm injection (ICSI) with epididymal 
or testicular sperm. Some studies show that children born after assisted 
reproductive technology (ART) are at increased risk of birth defects, other 
studies suggest that there is no extra concern about ICSI children con­
ceived with epididymal or testicular sperm.
METHODS: Studies about the karyotypes of fetuses, congenital anoma­
lies and the follow-up of the children born after ICSI with non-ejaculated 
sperm were identified by means of a systematic literature search.
RESULTS: Eight relevant studies were identified; two studies reported 
karyotype, five reported malformations and one reported follow-up of 
children after ICSI. In total, there were 55 out of 1973 (2.8%) abnormal 
karyotypes in the ICSI with ejaculated sperm group, 0 out of 31 in the 
ICSI with epididymal sperm group and 5 out of 191 (2.6%) in the ICSI 
with testicular sperm group. Major malformations were found in 543 out 
of 12 377 (4.4%) in the ICSI with ejaculated sperm group, 17 out of 
533 (3.2%) in the ICSI with epididymal sperm group and 31 out of 670 
(4.6%) in the ICSI with testicular sperm group.
CONCLUSIONS: Although there were no statistical differences, the study 
groups were small and heterogenic, with a number of potential biases. 
We therefore recommend a standardized methodology of follow-up stud­
ies after ART, with well-defined groups of ICSI with ejaculated sperm, 
ICSI with epididymal sperm and ICSI with testicular sperm, and a control 
group of naturally conceived children.
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Introduction
Assisted reproductive technology (ART) is nowadays available worldwide 
and has been practiced successfully on a large scale. About 1-4% of 
all live births in Europe are the result of IVF or intracytoplasmic sperm 
injection (ICSI).1 Hansen et al.2 showed in a systematic review that 
children born after ART are at increased risk of birth defects compared 
with spontaneous conceptions. The increase of birth defects in singletons 
born after ART might be related with the hormonal treatment for infertility 
or the procedure itself, but the underlying cause of infertility or its 
determinants might also play a role.3
Azoospermia is present in ~5% of all investigated infertile couples4 and is 
found in 10% of male infertility cases.5 Azoospermia can be divided into 
two groups: obstructive azoospermia (OA) with a normal spermatogenesis 
and nonobstructive azoospermia (NOA) as the result of a testicular failure. 
Since the introduction of ICSI, it is possible for these couples to father 
their own progeny by using sperm retrieved by percutaneous epididymal 
sperm aspiration (PESA), microsurgical epididymal sperm aspiration 
(MESA) or testicular sperm extraction (TESE). PESA and MESA are eligible 
in cases of OA, TESE in cases of NOA or in cases of an azoospermia with 
a PESA or MESA.
Concerns about the health of the children born after these techniques have 
been raised, especially in The Netherlands.67 This led to a moratorium in 
this country for the application of ICSI in azoospermic men using non­
ejaculated sperm from 1996 until 2001. From January 2001, ICSI with 
sperm retrieved by PESA or MESA in the case of an OA was allowed on 
the condition that there was a follow-up programme of the children, which 
was approved by the Central Committee on Human Research (CCMO). 
From June 2007, ICSI with sperm retrieved by TESE followed, on the 
same condition.
The goal of this study was to investigate the karyotypes of fetuses, 
congenital anomalies and the follow-up of the children born after ICSI 
with epididymal or testicular sperm.
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Methods
For this systematic review, we collected from PubMed, EMBASE, Web of 
Science and The Cochrane Central Register of Controlled Trials all papers 
published on the health of children born after ICSI with non-ejaculated 
sperm from 1992 (the year of the publication of the first ICSI child) to 
June 2008 using the keywords: 'epididymal', 'surgical retrieved sperm', 
'surgically retrieved sperm', testicular, 'pesa', 'mesa', 'percutaneous sperm 
aspiration', 'percutaneous epididymal sperm aspiration', 'microsurgical 
epididymal sperm aspiration', 'm icrosurgical sperm aspiration', 'tese', 'tesa', 
'testicular sperm aspiration', 'testicular sperm extraction', in combination 
with 'infertility treatment', 'in vitro fertilization', 'IVF', 'fertilization in vitro', 
'fertilisation in vitro', 'intracytoplasmic sperm injections', 'sperm injections, 
intracytoplasmic', 'ICSI', 'assisted reproductive technique' combined with 
'development', 'child', 'child*', 'hospital', 'abnormalities', 'birth defect', 
'birth defects', 'follow-up', 'congenital malformation', 'congenital anomaly', 
'offspring', 'pregnancy outcome', 'obstetric outcome', 'infant outcome'.
English was used as a limit.
The first and second author selected papers with categorical data of 
karyotyping of the fetuses and/or congenital anomalies and/or follow- 
up of the children conceived by ICSI with epididymal or testicular sperm 
versus ICSI with ejaculated sperm or IVF or naturally conceived children. 
By reading the titles and subsequently the abstracts, the first selection 
was made. Case reports, reports describing less than five children and 
reviews were excluded, but the references of all these articles were 
checked. If in more than one paper essentially the same group of infants 
were discussed, we selected the paper with the larger group or with a 
control group. If it was not possible to discover the origin of the sperm 
(ejaculated, epididymal or testicular), the article was excluded. For 
instance, the paper of Wennerholm et al.8 with a long-term follow-up was 
not included, because there was a combined group of epididymal and 
testicular sperm. The first and second author (G.H.W. and D.E.B.) read 
and selected the studies and extracted data separately. Disagreements 
were solved in discussion with or without the last author (J.A.M.K.).
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Results
The search strategy identified 1662 potentially relevant studies. A flow 
chart summarizing search results is provided in Figure 1. In the first 
selection, 1273 articles were excluded, because they did not fulfill the 
selection criteria, leaving 389 articles. Following further exclusions, nine 
papers with no data overlap were identified for review, and one was 
eventually excluded from the final analysis.
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Two studies discussed karyotyping of fetuses.910 There were six studies 
dealing with congenital anomalies.11-16 These studies discussed children 
born after transfer of embryos fertilized with epididymal sperm or 
testicular sperm. All studies except the study of Fedder et al.16 discussed 
children born after ejaculated sperm as well. Four studies had a control 
group that consisted of IVF children or naturally conceived children, two 
studies1216 had no control groups. Because of the differences between the 
control groups, we analysed the studies, which described children born 
after epididymal sperm and after testicular sperm and children born after 
ejaculated sperm. We used the group with children born after ICSI with 
ejaculated sperm as the control group. The study of Fedder et a l.16 was 
excluded from the final analysis, because there was no group of children 
born after ICSI with ejaculated sperm as a control (comparator) group. 
They found a relatively high incidence of hypospadias, but no further 
increased major malformation rate of ICSI with epididymal or testicular 
sperm compared with IVF children and naturally conceived children as 
reported in the literature.
Only one study was found with follow-up of the children until 2 years of
age.17
Finally, there were eight articles included in the systematic review. Of 
these eight studies reviewed, seven originated from Europe and one 
from the USA. The earliest study was published in 1998, all the others 
between 2000 and 2005. The size of the study groups ranged between 
504 and 4248 children conceived with ejaculated sperm, between 26 
and 198 children conceived with epididymal sperm and between 31 and 
229 children conceived with testicular sperm. The characteristics of the 
remaining studies utilized in this systematic review are described in 
Table I.
K a ryo typ ing
Two studies discussed the karyotyping of fetuses.910 Table II shows the 
number of fetuses tested and the percentage of abnormal karyotypes per 
subgroup. Also the relative risks (RRs) and the 95% confidence interval 
(CI) are given for abnormal karyotypes per study group compared with 
ICSI with ejaculated sperm. In the study of Jozwiak et al.,10 there were 
different groups of ICSI with ejaculated sperm: cases of male factor, 
female factor or unexplained factor. In our analysis, we compared only 
with the group of ICSI in cases of male factor.
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In the study of Bonduelle,9 prenatal diagnosis was performed in 47% 
of the ICSI pregnancies. In 37% of the mothers tested, there was an 
age-related risk (maternal age >35 years), the others underwent a 
prenatal test because of a parental chromosomal anomaly or the possible 
higher risk related to the ICSI procedure, as explained during the 
genetic counselling sessions. A total of 1586 ICSI fetuses were tested, 
of which 47 were abnormal: 25 anomalies were de novo (of these, 10 
were sex chromosomal anomalies and 15 were autosomal anomalies) and 
22 abnormal karyotypes were inherited (17 of these were transmitted 
through the father). None of the prenatal chromosomal anomalies was 
found in fetuses after ICSI with epididymal sperm and three anomalies 
were found in the fetuses after ICSI with testicular sperm. Two of these 
anomalies were de novo (3.2%) and one anomaly (1.6%) was inherited. 
Although the values for de novo anomalies were high, the patient numbers 
were too small to draw valid conclusions. The chromosomal anomalies 
such as de novo structural anomalies or sex chromosomal anomalies had 
a relatively benign character. Abnormal karyotypes were also found in 
338 karyotyped children at birth, but none of these was after the use of 
epididymal or testicular sperm.
In the study of Jozwiak et al.,10 prenatal karyotyping by amniocentesis 
was recommended universally at 16-20 weeks of gestation for all patients 
who conceived by ICSI. Only 735 patients of the 1762 (41.7%) underwent 
amniocentesis, 73% of the mothers were younger than 34 years. They 
found two (1.5%) abnormal karyotypes (both de novo sex chromosomal) 
in fetuses after ICSI with testicular sperm. There was no subgroup of 
fetuses after ICSI with epididymal sperm. No significant difference was 
found for the frequency of abnormal karyotype between the groups in 
which ejaculated spermatozoa and testicular spermatozoa were used. 
Post-natal karyotyping was not described.
Congen ita l an om a lie s
Three studies111314 defined major malformations as structural defects of 
the body and/or organs, which affect viability and quality of life requiring 
medical intervention. Kallen et a l.15 excluded congenital malformations 
that are relatively common, variable in registration, and sometimes 
associated with preterm birth and low birthweight. The following of such 
conditions were excluded: preauricular appendix, patent ductus arteriosus 
at preterm birth (37 weeks), single umbilical artery, undescended testicle, 
congenital hip (sub)luxation and minor skin malformations (mainly nevus).
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Table I Study characteristics by stud ies of karyotyping, congenita l anom alies and follow -up
Authors and 
publication 
year
Location Study design Study
centres
Study
groups
Kind of assessment Age of 
assessment
Birth
years
Maternal age 
(years) mean 
± SD
Total
sample
size
Percentage
multiples®
Lost for 
follow- 
up
Karyotyping 1
Bonduelle et 
al, 2002b
Belgium Prospective 
cohort study
Single
centre
ICSI in 
subgroups
Prenatal karyotyping by 
chorionic villus sampling or 
amniocentesis or postnatal 
karyotyping
Between 12 
and 20 weeks 
of gestation 
or at birth
1990-
2001
33.5 1563 43.1 53%
Jozwiak et 
al, 2004
Turkey Retrospective 
case control 
analysis
Single
centre
ICSI in 
subgroups
Amniocentesis Between 16 
and 20 weeks 
of gestation
1992-
2002
31.8±4.4 632 53,9 58.3%
Congenital anomalies
Bonduelle et 
al, 2002a
Belgium Prospective 
cohort study
Single
centre
IVF and 
ICSI
Questionnaires and physical 
examination
At birth and 
at 2 months
1990-
1999
IVF: 32.7±4.3 
ICSI: 32.2±4.1
5743 48.3 1.5%
Kàllén et al, 
2005
Sweden Retrospective 
population 
based study
Multi­
centre
IVF and 
ICSI
Diagnostic codes in Swedish 
Registry of Congenital 
Malformations and Swedish 
Hospital Discharge Register
At birth 1987-
2001
NA 14 646 NA NA
Ludwig and 
Katalinic, 
2002
Germany Prospective 
control cohort 
study
Multi­
centre
ICSI and 
natural 
conceived
Physical examination and 
ultrasound examination of 
the kidneys and the hips
Before 8 
weeks o f age
1998-
2000
NA 34 139 39.0b 5.4%
Palermo et 
al, 2000
USA Prospective 
cohort study
Single
centre
IVF and 
ICSI
Physical examination At birth 1993-
1999
Ejac.: 36.1±5 
Non-ejac.: 34.4±5
3855 41.8 NA
Wennerholm 
et al, 2000
Sweden Retrospective 
cohort study
Multi­
centre
CSI in 
subgroups
Physical examination 
obtained from medical 
records
At birth 1993-
1998
Epid.: 32.2±4.3 
Test.: 32.7±3.7
1034 35.2 NA
Follow up 1
Bonduelle et 
al, 1998
Belgium Prospective 
follow up 
study
Single
centre
ICSI in 
subgroups
Neurological and 
psychomotor assessment 
by a geneticist or 
paediatrician; a Bayley test
At 2 months, 
12 months 
and 2 years; 
at ~ 2 years
1991-
1995
Epid.: 32.2±4.2 
Test.: 32.1 ±4.3
163 37.4 77% 
(at 1
year)
a percentage multiple children of total study groups 
b percentage only o f ICSI study group 
NA= not available
Chapter 
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Table II Abnorm al fetal karyotypes per study group (%) with RR (95% C l) com pared to ICSI with ejaculated sperm
Authors Abnorm al fetal karyotypes Outcom e3
ICSI with ejacul. sperm ICSI with epidid. sperm ICSI with testic. sperm
Bonduelle et al 45/1469 (3.1) 0/31 
RR: 0
3/63 (4.8)
RR: 1.53 (0 .49-4 .79)
Values for de-novo anom alies 
were high after ICSI with 
testicu lar sperm , but the 
patient num bers were 
too sm all to draw valid 
conclusions
Jozw iak et al 10/504 (1 .9 )b NA
2/128 (1.5)
RR: 0.79 (0 .18-3 .57)
No sign ificant difference 
between the groups in which 
ejaculated sperm atozoa and 
testicu lar sperm atozoa were 
used
a outcom e o f the study as mentioned in article 
b in cases o f male factor
ejac.= ejacu lated; epid.= ep id idym al; testic.=  testicu lar; NA=not available
0 0
ICSI 
w
ith 
non
-ejacu
lated 
sp
erm
: 
system
atic 
review
Table III S tudy characteristics by stud ies of karyotyping, congenita l anom alies and follow -up
Authors Major m alform ations Outcom e3
IC S I  with ejac. 
sperm
IC S I  with 
epid. sperm
IC S I  with 
testic. sperm IV F
Natural conceived  
children
Bonduelle et al 84/2477 (3.4) 4/105 (3.8) 6/206 (2.9) 112/2955 (3.8) NA
No statistica l d ifference 
(ejaculated sperm  vs 
non-ejacu lated sperm ; 
testicu la r sperm  vs 
ep id idym al sperm ; ICSI vs 
IVF)
Kâllén et al 139/4248 (3.3) 5/135 (3.7) 3/147 (2.0) 284/10116 (2.8) NA
No sign ificant difference 
(between different 
m ethods of ICSI; between 
standard IVF and ICS I)b
Ludwig and 
Katalin ic
248/2944 (8.4) 1/26 (3.8) 21/229 (9.2) NA 2140/30940 (6.9)
No influence of sperm  
orig in; increased risk  after 
ICSI com pared with natural 
conceived ch ild ren0
Palermo et al 33/1774 (1.9) 4/198 (2.0) 1/87 (1.1) 30/1796 (1.7) NA
No d ifference in frequency 
(between IVF and ICSI;
between ejaculated, 
ep id idym al and testicu lar 
sperm )
W ennerholm  
et al 39/934 (4.2) 3/69 (4.3) 0/31(0.0) NA NA
S im ila r rate in d ifferent 
subgroups
a outcom e o f the study as mentioned in article
b adjusted for potential confounders: year o f birth, m aternal age and parity, years of invo luntary ch ild lessness and m aternal 
sm oking in early pregnancy 
c included still b irths
ejac.= ejacu lated; epid.= ep id idym al; testic.=  testicu lar; NA=not available
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The remaining malformations were classified as 'weeded'. Wennerholm 
et a l.12 applied the following definition of malformation: any congenital 
malformation defined in the International Classification of Diseases.1819 In 
the article of Palermo et al.,11 it was not clear if the major malformations of 
the study groups were with or without minor malformations. One article13 
described the malformations of live born and stillborn children, as well as 
of fetuses from spontaneous miscarriages or terminated pregnancies, after 
the 16th week of gestation. Discrimination for malformations between 
these groups was not described. In the study, there were 35 (1.0%) 
spontaneous miscarriages, 18 (0.5%) terminations of pregnancy and 12 
(1.4%) stillborns. Three articles111214 stated the number of stillbirths, but 
they described only the malformations of the live born children. Palermo 
et a l.11 report 18 (0.84%) fetal deaths after 20 weeks of gestation and 
16 (0.75%) neonatal mortalities. In the study of Wennerholm et al.,12 
there was no perinatal death reported in the epididymal retrieved sperm 
group (n = 69), and 1 out of 31 in the testicular retrieved sperm group. 
Bonduelle et al.14 presented data on stillbirths in the ICSI group of 49 of 
2889 (1.7%) births, and in the IVF group, 40 of 2995 births (1.3%). In 
the ICSI group, there were abnormal findings at physical examination or 
autopsy in 8 of the 49 children, but the origin of the sperm was not stated. 
In the IVF group, 2 of 40 stillborn children had congenital abnormalities.
A differentiation for malformations between singletons and multiples was 
not made in any of the studies. Only one study15 made an adjustment for 
year of birth, maternal age and number of infants in birth for comparison 
of malformations between IVF and ICSI (with differentiation in source of 
sperm).
Table IV Relative risks (RR) with 95% CI for m ajor m alform ations of ICSI children 
with ep id idym al or testicu lar sperm  com pared with m ajor m alform ations of 
ICSI ch ildren with ejaculated sperm
Authors RR (95% CI)
epid/ejac test/ejac
Bonduelle et al 1,12 (0 .42-2 .98) 0,86 (0 .38-1 .94)
Kallén et al 1,13 (0 .47-2 .72) 0,62 (0 .20-1 .93)
Ludwig and Katalin ic 0,46 (0 .07-3 .13) 1,09 (0 .71-1 .66)
Palermo et al 1,09 (0.39-3 .03) 0,62 (0 .09-4 .47)
W ennerholm  et al 1,04 (0.33-3 .28) 0
epid=epid idym al, e jac=ejacu lated; test= testicu la r
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No studies reported statistically significant differences in the rate of 
major malformations when they compared ICSI children conceived with 
ejaculated, epididymal or testicular sperm (Table III). In all five studies 
analysed together, major malformations were found in 543 out of 12 377 
(4.4%) in the ICSI with ejaculated sperm group, 17 out of 533 (3.2%) in 
the ICSI with epididymal sperm group and 31 out of 670 (4.6%) in the 
ICSI with testicular sperm group. Table IV shows the RR and the 95% 
CIs of major malformations in children from ICSI with epididymal sperm 
compared with ICSI with ejaculated sperm and in ICSI with testicular sperm 
compared with ICSI with ejaculated sperm. In conclusion, the differences 
in rate of malformations between the children conceived with ejaculated, 
epididymal or testicular sperm were sim ilar in all the studies regarding 
their 95% CI. Note that the study of Ludwig and Katalinic13 deviates in the 
direction of the estimates compared with the other studies. They found a 
lower RR for major malformations between ICSI with epididymal sperm 
(based on only 26 infants) and ejaculated sperm and a higher RR between 
ICSI with testicular sperm and ejaculated sperm than the other studies. 
They also found an increased risk of major malformations of ICSI children 
in comparison with naturally conceived children (data were taken from 
a prospective population-based birth registry in Germany). It was not 
clear if this increased risk was related to ICSI with ejaculated sperm or to 
ICSI with non-ejaculated sperm as well. Furthermore, malformations in 
stillbirths were included in the major malformations, and finally, although 
the relative size of the ICSI subgroups are quite different between the 
five studies, the study of Ludwig and Katalinic13 deviates most at this 
point with the smallest group of ICSI with epididymal sperm (n = 26) and 
a more than eight times larger group of ICSI with testicular sperm. This 
again may illustrate the diversity in protocols used in the studies.
Minor malformations were mentioned in two of the studies.1112 In one 
study11, it was not possible to discover the origin of the sperm and in the 
other study,12 the minor malformations were distributed evenly in the 
subgroups with the same incidence as in the general population.
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Fo llow -up
Only one article described the follow-up of children born from ICSI with 
epididymal or testicular sperm.17 In the group of children born from ICSI 
with epididymal sperm, 14 out of 55 children were seen at the age of 1 
year for a physical, neurological and psychomotor assessment. There was 
a large group (77%) lost for follow-up at 1 year and most of the children 
were still <2 years of age. Two children had a minor developmental 
problem, one child had an axial hypotonia at 2 months, but was normal 
at 2 years and one child had a language delay at 2 years. Ten out of 50 
children born from ICSI with testicular sperm were seen at 1 year. No 
problems were described.
Discussion
The goal of this study was to review the literature about abnormal 
karyotypes, congenital anomalies and the follow-up of the children born 
after ICSI with non-ejaculated sperm. In doing this, we were aware 
of the differences in study design and study groups. All studies were 
cohort or case-control studies, none of them was matched. Some were 
retrospective, by identifying health registers,15 and some were prospective, 
by physical examination111213 or by physical examination as well as by 
sending questionnaires.14 Only one study15 made adjustment for some 
variables, which could act as confounders: year of birth, maternal age and 
parity, years of involuntary childlessness and maternal smoking in early 
pregnancy.
Identifying the studies, none of them was more methodologically superior 
or reliable regarding inclusion and exclusion criteria, sample size, 
statistical adjustment and kind of assessment. The study of Ludwig and 
Katalinic13 was superior with inclusion of stillbirths and the study of Kallen 
et a l.15 was superior with statistical adjustment. Most reliable for kind of 
assessment was the study of Bonduelle et al.,14 by sending questionnaires 
and physical examination. The studies suggest that the risk ratios may be 
sim ilar in the subgroups of the ICSI procedures. Points of concern are the 
possible heterogeneity and the low number of children in some subgroups 
resulting in large CIs. Possible heterogeneity between the study groups 
in the articles is related to the age of the mother, indication for PESA or 
TESE, difference in OA and NOA, the use of fresh or frozen-thawed sperm 
or embryos and difference in percentage of singletons and multiples.
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There is a maternal age-related risk (>35 years) for aneuploidy;20 
therefore, it is important to eliminate this possible bias in studies for 
karyotyping. In the study of Bonduelle et al.,9 they found 2.2% de novo 
anomalies in the age-related group (>34 years) and 1.2% in the group 
of the fetuses with mothers aged <35 years. The study of Jozwiak et 
a l.10 did not found a significantly correlation between the maternal age 
and the frequency of abnormal karyotypes: 1.4% abnormal karyotypes 
in the group mothers <34 years and 1.6% in the group mothers >35 
years. Furthermore, there is still a risk for miscarriage after chorionic 
villus sampling or amniocentesis.21 Because of this risk not all women do 
the test, especially considering the long time they waited to get pregnant. 
Therefore, a small number of children were karyotyped post-natally.9 The 
percentage of patients who underwent prenatal diagnosis by chorionic 
villus sampling or amniocentesis was <50%, although all the patients 
were recommended to do these tests. In the case of a higher percentage 
of patients undergoing prenatal karyotyping, especially of the patients 
with an age of <34 years, the real figures of abnormal karyotypes will 
possibly be lower.
In all studies, there was a classification in epididymal sperm and testicular 
sperm, but testicular sperm was used in cases of OA and NOA. The study 
of Ludwig and Katalinic13 had an apparently larger group of children 
conceived by ICSI using testicular sperm than children conceived by 
ICSI using epididymal sperm. It was not possible to discover in what 
cases testicular sperm was used and why there were more children after 
ICSI with testicular sperm. In the case of NOA (severe testicular failure), 
the spermatozoa are known to show a higher chromosomal aneuploidy 
rate.22-25 The aneuploidy frequency in embryos obtained from NOA is also 
very high, but sim ilar to embryos from OA.26 Furthermore, it is assumed 
that genomic imprinting may be less complete when immature gametes 
are used.27 However, all these concerns are theoretical, and the only study 
that compared the prevalence of congenital malformations in live born 
children obtained with testicular sperm of NOA men (n = 54) and children 
obtained with testicular sperm of OA men (n = 188) has not shown a 
difference.28
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None of the studies made a difference in using fresh or frozen-thawed sperm 
or embryos. There was no difference between using fresh or frozen-thawed 
epididymal or testicular sperm on the outcome of ICSI, in spontaneous 
miscarriage rate, pregnancy and delivery rate.29 30 31 No congenital anomalies 
were found; however, group sizes were too small to draw any valid conclusions. 
A recent study found a significantly higher major malformation rate in the 
ICSI cryo embryo live born group than in the fresh ICSI embryo live born 
group.32 Other data suggest that malformation rates after cryopreservation 
seem to be comparable with those of fresh ICSI and fresh IVF.33 34 35 More 
de novo karyotype anomalies were found prenatally in the cryo ICSI group 
compared with the fresh ICSI group, but this difference was not statistically 
significant.32
The total malformation rate (major + minor) has been shown to be higher 
in IVF/ICSI twins than in IVF/ICSI singletons, which is strongly associated 
with preterm birth of the twins.36 Furthermore, the physical health of 
twins is poorer compared with singletons, because of prematurity and low 
birthweight;37 38 therefore, especially in follow-up studies, it is important to 
know whether the children are singleton or a part of a multiple.
There are a number of limitations and sources of potential bias in this review; 
the studies described here, with the exception of Ludwig and Katalinic,13 did 
not mention the stillborn and neonatal deaths and their cause of death and 
malformations, although this is important to know to draw valid conclusions. 
Thus, there might be an underestimation of the number of malformations. 
This is one of the possible biases in the studies. Secondly, the children born 
after IVF/ICSI are possibly more carefully investigated and malformations 
are more carefully recorded than in non-IVF/ICSI children; however, in none 
of the studies, blinding was applied, this will give another bias.
Not all major malformations are found at birth, but will be identified up to 12 
months of age; two-thirds of major malformations were detected within the 
first 7 days of life and about 90% within the first 6 months.39 Only in three 
of the studies, there was an investigation of the children at birth and at an 
older age; Bonduelle et al.14 and Ludwig et al.13 up to 2 months and Fedder 
et al.16 up to 3 months-7 years (mean 20 months). It is therefore possible 
that in the other studies not all the malformations were identified within the 
study timeframe. Further, a proportion of children were lost to follow-up 
(Table I), because not all of them will come for examination or response the 
questionnaire, introducing further bias.
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Although in the studies analysed a large number of ICSI children were 
included, most subgroups were small, even to detect a 2-fold increase (or 
decrease) in malformations. For example, if epididymal sperm retrievals 
account for only 5% of the ICSI children and if the prevalence of birth 
defects in the ejaculated ICSI group was 6%, you would need 168 
children in the epididymal ICSI group in order to detect an RR of 2.0 and 
431 to detect an RR of 0.5, with 80% power at 5% level of significance. 
On the basis of this example, only one-fifth epididymal sperm subgroups 
and two-fifths testicular sperm subgroups were large enough (n>168) 
to detect a 2-fold increase in birth defect risk, if such a large increase 
should exist. None of the subgroups was large enough (n >431) to detect 
a decreased risk of 0.5. In the Netherlands, 500 ICSI children were born 
between January 2002 and June 2009 after ICSI with epididymal sperm; 
only 35 children were born between March 2008 and June 2009 after ICSI 
with testicular sperm, because of a moratorium on this treatment until 
2007 (unpublished data). This indicates that the subgroup of epididymal 
sperm is large enough to detect an RR of 0.5, but it will take over 5 years 
to reach such a large subgroup of testicular sperm.
Unfortunately, there was only one study about the physical, neurological 
and psychomotor development of children with a large lost for follow-up 
rate. So it is not possible to draw conclusions about this item.
Conclusions
Although there are no statistical differences in abnormal karyotypes, 
major malformations and follow-up of the children found in the studies 
we analysed, it should be considered that the study groups are small 
and heterogenic with numerous potential biases. We therefore call for 
standardized methodology for follow-up studies after ART, with a physical 
examination at birth and psychomotor assessment in childhood. Well- 
defined groups are necessary, such as ICSI with ejaculated sperm, ICSI 
with epididymal sperm and ICSI with testicular sperm and a control group 
of naturally conceived children. Maybe ESHRE could play a role in this 
process, by making standards for the methodology of follow-up of children 
after reproductive technologies.
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Abstract
BACKGROUND: To evaluate the safety of ICSI with epididymal sperm, 
this study compared children born after ICSI treatment with epididymal 
sperm and children conceived after IVF and ICSI with ejaculated sperm. 
Additionally, the results of a multidisciplinary, multicentre follow-up of the 
children conceived with epididymal sperm at 2 years of age are described.
METHODS: This follow-up study included 378 children conceived after 
ICSI with epididymal sperm (percutaneous epididymal sperm aspiration: 
PESA group) and a control group of 1192 IVF and 1126 ICSI (with 
ejaculated sperm) children, all with a gestational age of 20 weeks or 
more. Questionnaires were sent at birth, 1 year and 4 years of age, 
collecting data on parental, pregnancy and child factors. A total of 148 
PESA children were assessed at 2 years of age for motor performance, 
mental- and language development and compared with the Dutch norms.
RESULTS: PESA children showed no increased risks for stillbirths, total 
deaths and malformations. They also did not differ from IVF and ICSI 
children in gender rate, birthweight and gestational age. The mental Bayley 
score was higher (P < 0.05) for PESA singletons and parents reported 
fewer (P < 0.05) behavioural problems in the PESA group than the Dutch 
reference group. The scores for syntactic and lexical development for the 
PESA singletons were better (P < 0.05) than the Dutch standards.
CONCLUSIONS: ICSI with epididymal sperm does not lead to more 
stillbirths or congenital malformations in comparison to IVF and ICSI with 
ejaculated sperm and does not lead to poor development in comparison 
with the Dutch reference group.
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Introduction
Azoospermia is present in ~5% of all infertile couples and is found in 
10% of male infertility cases.12 Since the introduction of ICSI in 1991, 
it is possible for these couples to father their own progeny by using 
sperm retrieved by percutaneous sperm aspiration (PESA), microsurgical 
epididymal sperm aspiration (MESA) or testicular sperm extraction (TESE). 
PESA and MESA are applied in cases of obstructive azoospermia (OA) 
with an assumed normal spermatogenesis. In cases of non-obstructive 
azoospermia (NOA), as the result of a testicular failure or in cases of 
unsuccessful PESA or MESA, TESE is indicated.
Introduction of ICSI with non-ejaculated sperm in the Netherlands has a 
special history. From 1994, ICSI in the Netherlands was carried out either 
with ejaculated semen or with non-ejaculated semen. However, a few years 
later concerns arose in the Dutch society about the health of the children 
born after ICSI with non-ejaculated sperm, referring to unknown risks of 
using aged (epidydimal) or immature (testicular) sperm cells. This led to a 
national moratorium for the application of ICSI with non-ejaculated sperm 
in 1996. With support from the Dutch government, studies were set up to 
obtain more information about these risks. Preclinical studies showed that 
motile epididymal sperm cells did not show increased DNA abnormalities, 
as measured by terminal deoxynucleotidyltransferase-mediated dUTP 
nick-end labelling and chromomycin A3 assays.34 Furthermore, studies in 
other countries showed no increase in the number of congenital defects 
in children born after ICSI in combination with MESA, PESA and TESE 
compared with ICSI with ejaculated sperm.5 6 7 Therefore, the Dutch 
government agreed in 2001, with the start of a new prospective and 
multicentre clinical study, to confirm whether sperm retrieved by PESA 
or MESA in case of an OA can be used safely for ICSI. There was still a 
moratorium for the application of ICSI with TESE.
On the other hand, as recently published in a systematic review about 
karyotyping, congenital anomalies and follow-up of children after ICSI 
with non-ejaculated sperm, it was concluded that the study groups in 
these studies were small, heterogenic and with a lot of (possible) biases.8 
Therefore, well developed, large studies are necessary.
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In this article, we will describe the children born during 7 years of ICSI 
treatment with epididymal sperm in the Netherlands. These results 
were compared with the results of children conceived after IVF and 
ICSI with ejaculated sperm. Additionally, we will describe the results of 
a multidisciplinary, multicentre follow-up of the children conceived with 
epididymal sperm at 2 years of age.
Materials and Methods
Se tting
The protocol for this multicentre study was approved by the Dutch 
Central Committee on Research involving Human Subjects (CCMO, The 
Hague, The Netherlands). Patients from six IVF centres (the only ones 
in the Netherlands which may be performing PESA or MESA treatment 
before October 2007) were included: University Medical Centre St 
Radboud Nijmegen, University Medical Centre Utrecht, University Hospital 
Maastricht, University Medical Centre Rotterdam, VU University Medical 
Centre Amsterdam and Medical Centre for Childwish Leiderdorp.
Pa tie n ts
All patients signed an informed consent for treatment and follow-up 
before participating in this study. Men with an azoospermia were seen 
by the urologist to diagnose whether there was an OA or NOA. In cases 
of an OA (anamnesis for obstruction, normal volume of testis, FSH 
<10 IU/l) a diagnostic PESA or MESA was planned to check if semen 
could be harvested. If possible this semen was cryopreserved for later 
treatment, otherwise an acute PESA/MESA was necessary at the time of 
ovum retrieval. Female patients were seen on the fertility department for 
a routine intake for an ICSI treatment; exclusion and inclusion criteria 
were according to the local clinical protocol. Included patients underwent 
ovarian hyperstimulation according to the local protocol. Only mature, 
morphologically normal oocytes were used for ICSI, either with frozen- 
thawed or fresh sperm cells. Intrauterine embryo replacement of one or 
two embryos was performed at 2 -5  (dependent to the clinic) days after 
ovum retrieval.
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Fo llow -up  by q ues tionna ire s
The study group was called the 'PESA group', although in ~15% of the 
cases sperm was retrieved by MESA. The follow-up of these children was 
co-ordinated from Radboud University Nijmegen Medical Centre by asking 
the patients to return questionnaires after birth, after 1 year and 4 years of 
age. These questionnaires collected data on parental, pregnancy and child 
factors, including gestational age, mode of delivery, birthweight, presence 
or absence of malformations and neonatal problems. The study included all 
children with a gestational age of 20 weeks or more born between January 
2002 and May 2008.
The control group consisted of IVF and ICSI (with ejaculated sperm) children 
with a gestational age of 20 weeks or more, who were born between June 
1995 and May 2007 after treatment in the Radboud University Nijmegen 
Medical Centre. Information on fertility treatment and pregnancy outcome 
(birthweight, gender, alive or not at time of birth) of all children was 
retrieved from medical records (there is no national register for children 
born using IVF and ICSI). In addition, questionnaires were sent to the 
parents of all children near the first and fourth birthday to obtain data on 
parental, pregnancy and child factors. The questionnaire at 1 year of the 
control group obtained the same information as the combination of the 
questionnaires at birth and at 1 year of the PESA group.
If the parents (of the study group and control group) did not respond to 
the questionnaire, they received a reminder 3 months later. When they did 
not respond again at 1 year, the data asked in the 1-year questionnaire 
were included in the 4-years questionnaire. In both groups, only children 
born after replacement of fresh embryos were included. Only singletons 
and twins were included, because there were no triplets in the study group.
Fo llow -up  by a ssessm en t
Additional to the questionnaires, the PESA group was assessed for motor 
performance, mental- and language development and compared with the 
Dutch norms according to the individual tests (explained below for the 
different tests). The PESA group was seen at chronological age of at least 2 
years and 4 months at the department of Neonatology, Radboud University 
Nijmegen Medical Centre by a medical doctor, paediatric physical therapist, 
speech and language therapist and child psychologist during a single clinic 
visit. All observations were performed by one single person per area. 
Parents were present throughout the test procedures.
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Physical examination was performed by a medical doctor, especially for 
validation of the questionnaires on major and minor malformations.
Motor performance and mental development was assessed using the 
Bayley Scales of Infant Development, 2nd edition, Dutch version (BSID- 
II-NL).910 Based on content, construct and concurrent validity the BSID-II 
has been shown to be a comprehensive and appropriate instrument for 
assessing motor performance.1112 The results were compared with the 
Dutch standards as described by van der Meulen et al.,10 which differ 
from the US norms at 2 years of age.13 The BSID-II-NL motor scale 
assesses gross and fine motor skills. The mental scale consists of items 
that measure visual and auditive information processing, eye-hand 
coordination, imitation, language skills, memory and problem-solving. 
Raw scores are recalculated into a psychomotor developmental index 
(PDI) and a mental developmental index (MDI), with a mean value of 
100 and a SD of 15 using norm-referenced tables. Scores of 115 or more 
are indicative of accelerated performance; scores between 114 and 85 
reflect a normal performance. Scores between 84 and 70 reflect a mildly 
delayed performance and scores of 69 and less reflect a significantly 
delayed performance. Here, the classification 'accelerated' and 'normal' 
performances were combined into 'normal' performance.
Behavioural outcome was assessed using the Dutch version of the Child 
Behavior Checklist (CBCL) for children aged 1.5-5 years.14 The CBCL is a 
validated parental questionnaire and rates 113 problem behaviour items 
on a 3-point scale ranging (0 = not true, 1 = somewhat true, 2 = very 
true). A total problem score is obtained by summing the scores of all items 
with a normative value of 50 and a SD of 10. Raw scores are recalculated 
into T scores. A T-score <60 is classified as normal, 60-63 is borderline 
and >63 is in the clinical range.
The speech therapist used the Dutch Reynell test, a standardized test that 
examines the receptive language development of Dutch-speaking children 
between 1.02 and 6.03 years of age.15 In this test expressive language is 
not required since the children can point out their answers. To examine 
the language expression of the children, the tests for syntactic and lexical 
development of the Schlichting test were applied.16 The Schlichting test is 
a standardized test for Dutch-speaking children of the same age group. 
The test for syntactic development elicited grammar structures and the 
test for lexical development measured the active vocabulary by instructing
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the children to name objects and pictures. The numbers of correct 
answers resulting from both the Reynell and the Schlichting tests were 
transformed into aged-independent standard quotient scores: RLDQ = 
receptive language development quotient; SDQ = syntactic development 
quotient; LDQ = lexical development quotient. These scores had a mean 
of 100 and a SD of 15, with extreme values at - 3  and + 3 SD.
D e fin it io n s
Except for late neonatal death (death of a child from day 7 until day 
28 inclusive) and infant death (death of a child later than day 28),7 
all the definitions used conform with the glossary mentioned in 'The 
International Committee for Monitoring Assisted Reproductive Technology 
and the World Health Organization revised glossary on ART terminology, 
2009'.17 A widely accepted definition of major malformation was used,
i.e. malformations that generally cause functional impairment or require 
surgical correction. The remaining malformations were considered minor. 
Ductus arteriosus was considered major if still patient at 3 months for 
a child born at term, or at 6 months for a preterm child born before 
37 completed weeks. Inguinal hernia was considered minor in a preterm 
child born before 37 completed weeks and major for a child born after 37 
weeks. Pyloric stenosis was counted as major.
S ta t is t ic s
Descriptive statistics are given with mean and percentage with 95% 
confidence interval (CI). We used the independent samples t-test for 
comparing the means in birthweight between the PESA group and control 
groups. Descriptive statistics were used for the BSID-II-NL, classification 
and for the prevalence of language delay. The PDI, MDI, RLDQ, SDQ 
and LDQ were tested for normality according to the Dutch standards. 
One-sample t-tests were carried out to compare whether the children 
differed from the reference group. Independent sample t-tests were 
used to compare singletons and twins. P values <0.05 were considered 
statistically significant.
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Results
Fo llow -u p  by q u e s tio n n a ire s
The flow chart (Figure 1) shows all included pregnancies with a gestational 
age of 20 weeks or more of the PESA, IVF and ICSI groups.
Table I shows details on stillbirths, live births and neonatal deaths of 
the fetuses at the age of 20 weeks or more, without the fetuses lost for 
follow-up. Of the stillbirths, six terminations (two PESA, three IVF and 
one ICSI) were performed after prenatal karyotyping. These terminations 
took place between 20 and 24 weeks of gestational age. Total stillbirths 
did not differ between groups. Also the causes for these deaths were 
comparable over the three groups, however only the IVF group showed 
perinatal loss resulting from solution placentae (n = 3). In general, most 
live born children who died before 1 year of age were related to twin 
pregnancies (40 out of 56). In total, 48 out of 56 children (85.7%) died 
after preterm birth (8 PESA, 26 IVF and 14 ICSI children) and of these 
44 (78.6%) died after very preterm birth (7 PESA, 24 IVF and 13 ICSI 
children). For one IVF child who died the gestational age was not known. 
Major malformations as cause of death were present in one PESA child, 
seven IVF- and three ICSI children.
The first part of the follow-up of the children consisted of questionnaires. 
For the PESA group these were sent at birth, with a response of 99%. The 
response on the questionnaire at 1 year of age was 96% for the PESA 
group, 83% for the IVF group and 90% for the ICSI group. At 4 years of 
age the response was 89% for the PESA group, 73% for the IVF group and 
75% for the ICSI group.
Table II shows the parental characteristics of the live born deliveries. 
In general the groups showed no differences. Exceptions are the lower 
proportion of primiparae in the IVF group and the relatively high age of 
fathers of the PESA children. Table III shows the paediatric characteristics 
of live born children. There was no difference in mean birthweight between 
the study group and the control groups, although there was a higher 
percentage of twins with a very low birthweight (<1500 g) in the PESA 
group than in the ICSI group. There were no differences between the 
groups in gender rate and gestational age.
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Figure 1 Flow chart of all pregnancies > 20 weeks with de livery between January 2002 
and May 2008 for the PESA children and between June 1995 and May 2007 for 
the IVF and ICSI children
Pregnancies > 20 weeks
PESA
313
IVF
971
ix:
ICSI
905
Foetuses > 20 weeks
PESA
378
IVF
1192
ICSI
1126
Live births
PESA IVF ICSI
370 1168 1105
Lost for follow -up
PESA
1
IVF
6
ICSI
7
Still b irths
PESA IVF ICSI
7 18 14
Neonatal death (<28 days)
PESA IVF ICSI
7 25 15
Infant death (>28 days)
PESA
1
IVF
5
ICSI
3
1 year* Responders
PESA IVF ICSI ------------- ► PESA IVF ICSI
271 1138 1086 260 943 973
4 year* Responders
PESA IVF ICSI ------------- ► PESA IVF ICSI
87 817 736 77 594 71
^reached the age of 1 year respective ly 4 years before May 2008
9
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Table I Live and stillb irths, neonatal and infant deaths (fetuses > 20 weeks) follow ing ICSI with ep id idym al sperm  (PESA group) or 
IVF and ICSI using ejaculated sperm
PESA IVF ICSI
Singletons Multiples Total Singletons Multiples Total Singletons Multiples Total
Total live b irths 
and stillb irth s3
247 130 377 744 442 1186 679 440 1119
S tillb irths 4 (1.6% ) 3 (2.3%) 7 (1.9%) 11 (1.5% ) 7 (1.6%) 18 (1.5% ) 10 (1.5%) 4 (0.9%) 14 (1.3% )
Live births 243 127 370 733 435 1168 669 436 1105
Early neonatal 
death 
( 0 - 7  days)
2 2 4 5 17 22 4 9 13
Late neonatal 
death 
(7 - 28 days)
0 3 3 2 1 3 1 1 2
Infant death 
(28 days -  1 year)
0 1 1 1 4 5 1 2 3
Perinatal deathb 6 (2.4% ) 5 (3.8%) 11 (2.9% ) 16 (2.2% ) 24 (5.4% ) 40 (3.4%) 14 (2.1%) 13 (3.0% ) 27 (2.4%)
95% CIC 0.5 -4 .4 0.5-7 .2 1.2-4.7 1.1-3.2 3 .3-7.6 2.3-4 .4 1.0-3.2 1.3-4.6 1.5-3.3
Total deaths 6 (2.4% ) 9 (6.9% ) 15 (4.0% ) 19 (2.6% ) 29 (6.6% ) 48 (4.0% ) 16 (2.4% ) 16 (3.6% ) 32 (2.9%)
95% CIC 0 .5 -4 .4  2 .5 -11.4  2.0-6 .0  1.4-3.7 4 .2 -8 .9  2.9-5 .2  1 .2-3.5 1.9-5 .4  1.9-3.9
a W ithout fetuses lost for follow up 
b S tillb irths and early  neonatal death together 
c 95% confidence interval (C l) of percentage
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The numbers of major and minor malformations of live born children are 
given in Table IV. There were no differences in major malformation rates 
between all groups. Minor malformations were seen less frequently in the 
PESA children than in the IVF and ICSI groups. There were no differences 
between singletons and twins in major or minor malformations.
Fo llow -u p  by a sse ssm en t
The characteristics of the parents of the assessed group (i.e. who did 
follow-up) were comparable with the total PESA group (Table V). Table VI 
shows the results of the follow-up scores of the PESA children at the age 
of at least 2 years and 4 months. Of 167 invited children, 4 children moved 
with unknown address and 14 children (6 singletons and 4 twins) did 
not appear for different reasons such as follow-up programme elsewhere, 
operation or illness, forgotten or did not want to come. In total, there 
were 149 children assessed. Reliable assessment was not possible in 
all the children, because some refused items or did not understand the 
instructions owing to language barriers (9 children had another language, 
although one or both parents understood Dutch).
No additional malformations were found by physical examination than 
already found and reported at 1 year of age.
The BSID-II-NL showed no differences for the mean PDI (motor 
performance) between the study group and the Dutch reference group.
The mean MDI (mental development) of the PESA group was within the 
normal range but was higher (P < 0.05) than the Dutch reference group. 
This positive effect was only present in the singleton subgroup; the twin 
subgroup did not differ from the norm group. There were more than the 
expected numbers of PESA children with normal mental development and 
fewer PESA children at risk or abnormal.
Concerning the CBCL, parents reported fewer behavioural problems than 
the norm. In the overall group the behavioural scores were lower (P < 0.05) 
than the normative mean value of 50 +SD (10). No differences were 
found when comparing the singletons and twins.
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Table II Parental characteristics of those with a live birth(s)
PESA IVF ICSI
n/mean % ; 95% CI/range (SD ) n/mean % ; 95% CI/range (SD ) n/mean % ; 95% CI/range (SD )
Total de liveries 308 952 888
S ing letons 243 78.9; 74 .2 -83 .5 733 77.0; 74 .3-79.7 669 75 .3 ;72 .4 -78.2
Twins 65 21.1; 16.5-25.8 219 23.0; 20.3-25.7 219 24 .7 ;21 .8 -27.6
Maternal age (years)3
Total 33.4 23.1-41.9  (3.7) 34.3 21.5-43.5  (4.0) 33.4 20.7-42.7  (3.8)
S ing letons 33.5 23.1-41.9  (3.7) 34.6 21.5-43.5  (4.0) 33.6 21.3-42.7  (3.8)
Twins 33.1 23.6-40.8  (3.6) 33.5 21.5-41.0  (3.8) 32.9 20.7 -41 .2  (3.7)
Paternal age (years)3
Total 41.1 26.8-67.2  (7.9) 36.7 21.4 -61 .4  (4.9) 36.5 22.7-56.8  (5.2)
S ing letons 41.4 26.8-64.2  (8.1) 36.9 21.5 -61 .4  (4.9) 36.6 22.7-56.8  (5.3)
Twins 40.0 29.8-67.2  (7.2) 36.1 21.4-58.9  (5.1) 36.1 25.6 -55 .0  (4.9)
Maternal sm ok ingb
No smoking 284 93.4; 90 .6 -96 .3 714 90.2; 88 .0 -92 .2 720 91.5; 89 .5-93.5
Sm oking 20 6.6; 3 .7-9 .4 78 9.8; 7 .7 -12.0 67 8.5; 6 .5-10.5
Unknown 4 160 101
Education mother
Lowc 46 15.2; 11.1-19.3 125 15.8; 13 .2-18.4 123 15.6; 13.0-18.2
Highd 257 84.8; 80 .7 -88 .9 667 84.2; 81 .6 -86 .8 665 84.4; 81 .8-87.0
Unknown 5 160 100
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Table II Continued
PESA IVF ICSI
n/mean % ; 95% CI/range (SD ) n/mean % ; 95% CI/range (SD ) n/mean % ; 95% CI/range (SD )
Education father
Lowc 48 15.9; 11.7-20.1 172 21.8; 18.9-24.8 159 20.2; 17.3-23.1
Highd 254 84.1; 79 .9 -88 .3 616 78.2; 75.2-81.1 628 79.8; 76.9-82.7
Unknown 6 164 101
Parity
First 243 79.9; 75 .3 -84 .5 546 69.2; 65 .9 -72 .5 599 75.7; 72 .7-78.8
> Second 61 20.1; 15.5-24.7 243 30.8; 27.5-34.1 192 24.3; 21.2-27.3
Unknown 4 163 97
a at tim e of de livery 
b during pregnancy
c low: (no) prim ary school or lower level of secondary school and vocational tra in ing
d high: m edium  and h igher level of secondary school or m edium  and higher level o f vocational tra in ing or un iversity
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Table III Paediatric characteristics of live births
PESA IVF ICSI
n/mean % ; 95% CI/range (SD ) n/mean % ; 95% CI/range (SD ) n/mean % ; 95% CI/range (SD )
Total 370 1168 1105
S ing letons 243 65.7; 60.7-70.6 733 62.8; 59.5-65.6 669 60.5; 57 .6-63.5
Twins 127 34.3; 29.4-39.3 435 37.2; 34.4-40.1 436 39.5; 36.5 -42 .4
Gender
Boys 181 49.6; 44 .4 -54 .8 565 51.9; 48 .9 -54 .9 504 48.0; 44 .9 -51 .0
G irls 184 50.4; 45 .2 -55 .6 524 48.1; 45.1-51.1 547 52.0; 49.0-55.1
Unknown 5 79 54
Birthweight (gram)
Total 2983.2 500-4840 (624.9) 2932.5 375-4885 (776.6) 2967.6 350-5180 (748.5)
S ing letons 3315.6 500-4840 (655.6) 3271.5 375-4885 (613.7) 3318.2 720-5180 (580.2)
Twins 2337.1 765-4010 (733.4) 2359.3 385-4055 (665.0) 2434.5 350-4288 (616.1)
Unknown 2 19 6
Birthweight < 1500 g
Total 23 6.3; 3 .7-8.8 42 3.7; 2 .5-4.8 28 2.5; 1.6-3.5
S ing letons 3 1.2; 0 .0-2.7 8 1.1; 0 .3-1 .9 3 0.5; 0 .0-1 .0
Twins 20 16.0; 9 .4-22.6 34 8.0; 5 .3-10.6 25 5.7; 3 .5-8.0
Birthweight < 2500 g
Total 91 24.7; 20.2-29.2 222 19.3; 17.0-21.7 225 20.5; 18.0-22.9
S ing letons 23 9.5; 5 .7-13.2 43 6.0; 4 .2-7 .7 41 6.2; 4 .3-8.1
Twins 68 54.4; 45 .5 -63 .2 179 41.9; 37.1-46.7 184 42.2; 37 .5-46.9
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Table III Continued
PESA IVF ICSI
n/mean % ; 95% CI/range (SD ) n/mean % ; 95% CI/range (SD ) n/mean % ; 95% CI/range (SD )
Gestational age 
(weeks)
Total 38.0 23 .3 -42 .4  (3.3) 38.0 21.9-43.1 (3.3) 38.2 20.4-43.3  (3.0)
S ing letons 39.3 23 .3 -42 .4  (2.4) 39.3 24.6-43.1 (2.4) 39.4 20.9-43.3  (2.2)
Twins 35.6 27.1-42.1 (3.4) 35.7 21.9-40.0  (3.6) 36.3 20.4-40.6  (3.1)
Unknown 6 133 71
Prem aturity < 37 
weeks
Total 84 23.1; 18.7-27.5 262 25.3; 22.6-28.0 227 22.0; 19.4-24.5
S ing letons 22 9.1; 5 .4-12.8 70 10.6; 8 .2-12.9 46 7.3; 5 .2-9 .4
Twins 62 50.4; 41 .4 -59 .4 192 51.6; 46 .4 -56 .8 180 44.3; 39.4-49.3
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Table IV Major and m inor m alform ations of live born children
PESA IVF ICSI
n % ;9 5 % C I n % ;9 5 % C I n % ;9 5 % C I
Total 370 1168 1105
Major m alform ation3 13 3.6; 1 .6-5.5 46 4.8; 3 .4-6.2 33 3.4; 2 .2-4.6
M inor m alform ation1 27 7.4; 4 .7-10.1 142 14.9; 12.6-17.2 147 15.2; 12.9-17.5
No m alform ations 325 89.0; 85 .8-92.3 766 80.3; 77.7 -82 .9 788 81.4; 78 .9-83.9
Unknown 5 214 137
S ing letons 243 733 669
Major m alform ation3 8 3.3; 1 .0-5.6 28 4.5; 2.8-6.1 18 3.0; 1 .6-4.4
M inor m alform ation1 17 7.0; 3 .7-10.3 92 14.6; 11 .8-17.4 100 16.7; 13.6-19.7
No m alform ations 217 89.7; 85 .8-93.6 509 80.9; 77.7-84.1 481 80.3; 77 .1-83.6
Unknown 1 104 70
Twins 127 435 436
Major m alform ation3 5 4.1; 0 .5-7 .6 18 5.5; 3.0-8.1 15 4.1; 2.0-6.1
M inor m alform ation1 10 8.1; 3.2-13.1 50 15.4; 11 .4-19.4 47 12.7; 9 .3-16.2
No m alform ations 108 87.8; 81.9-93.7 257 79.1; 74.6 -83 .6 307 83.2; 79.3-87.1
Unknown 4 110 67
A  w idely accepted defin ition o f m ajor m alform ation was used i.e. m alform ations that genera lly  cause functional im pairm ent or require 
surgical correction. The rem ain ing m alform ations were considered minor. Ductus arteriosus was considered m ajor if still patent at 3 
months for a child born at term , or at 6 m onths for a preterm  child born before 37 com pleted weeks. Inguinal hernia was considered 
m inor in a preterm  child born before 37 com pleted weeks and m ajor for a child born after 37 weeks. Pyloric stenosis was counted as 
major.
3 num ber of ch ildren with one or more m ajor m alform ations or m ajor and m inor m alform ations 
b num ber of children with one or more m inor m alform ations and no m ajor m alform ations
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Discussion
In this prospective multicentre study, it was found that children born 
after an ICSI treatment with epididymal sperm of men with an OA 
showed no increased risks for stillbirths, total deaths, malformations and 
psycho-motor problems. They also did not differ from IVF and ICSI (with 
ejaculated sperm) children in gender rate, birthweight and gestational 
age. On some aspects the PESA group scored even better than the IVF and 
ICSI control groups. The minor malformations rate in the PESA group was 
lower than in the control groups. Furthermore, the mental Bayley score 
was significantly higher for PESA singletons, and parents reported fewer 
behavioural problems in the PESA group than the Dutch reference group. 
Finally, the scores for syntactic development and lexical development for 
the PESA singletons were significantly better than the Dutch standards.
The percentage of stillbirths was in accordance with other studies for IVF 
and ICSI children, although these percentages are higher than for children 
conceived naturally.7181920 It is thought that infertility, irrespective of 
treatment, increases the risk of perinatal death and other problems in 
the offspring.21-25 A higher incidence of low birthweight, preterm birth and 
perinatal death is not only a complication of multiple pregnancies but is 
also more prevalent in IVF and ICSI singletons.19 The actual infertility 
is a possible explanation for this phenomenon but more obvious is the 
fact that the women who conceive after IVF or ICSI are often older and 
primiparous. Also vanishing twins are seen more often in women who 
conceive after IVF or ICSI and may cause lower birthweight, preterm birth 
and perinatal death.26,27,28
In our study, there were no differences in gender rate between groups. 
However, there were slightly more girls in the PESA group and ICSI group 
(with ejaculated sperm) in contrast to slightly more boys in the IVF group. 
In other studies they also found more boys after an IVF treatment, but 
different results for sex ratios after ICSI with ejaculated or epididymal 
sperm. Bonduelle et al.7 found more boys after ICSI with epididymal 
sperm and Fedder et al.29 found more girls, although both results were 
not significant and were based on small numbers in groups only.
In agreement with the present results, previous studies showed no 
increased risks related to the use of epididymal sperm.7 30 In different 
meta-analyses, a higher rate of malformations has been reported for
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Table V  Parental and Paediatric characteristics of the assessed PESA children at 2 years of age and total PESA group
Total PESA group Group of assessed PESA children
n/mean % ; 95% CI/range n/mean % ; 95% CI/range
Total 370 149
S ing letons 243 65.7; 60 .7-70.6 92 61.7; 53.8-69.7
Twins 127 34.3; 29.4-39.3 57 38.3; 30.3-46.2
Maternal age (years)3
Total 33.4 23.1-41.9 33.2 23.1-40.8
Paternal age (years)3
Total 41.1 26.8-67.2 40.6 26.8-61.3
Education mother
Lowb 46 15.2; 11.1-19.3 17 14.0; 7 .7 -20.4
Highc 257 84.8; 80 .7-88.9 104 86.0; 79.6-92.3
Unknown 5 1
Education father
Lowb 48 15.9; 11.7-20.1 20 16.5; 9 .7-23.3
Highc 254 84.1; 79 .9-88.3 101 83.5; 76.7-90.2
Unknown 6 1
Gender
Boys 181 49.6; 44 .4 -54 .8 70 47.0; 38.8-55.1
G irls 184 50.4; 45 .2 -55 .6 79 53.0; 44 .8 -61 .2
Unknown 5
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Table V  Continued
Total PESA group Group of assessed PESA children
n/mean % ; 95% CI/range n/mean % ; 95% CI/range
Birth weight (gram)
Total 2983.2 500-4840 2966 1080-4440
S ing letons 3315.6 500-4840 3358 1625-4440
Twins 2337.1 765-4010 2334 1080-3400
Unknown 2
Gestational age (weeks)
Total 38.0 23.3-42.4 38.2 29 .6 -42 .4
S ing letons 39.3 23.3-42.4 39.6 33 .3 -42 .4
Twins 35.6 27.1-42.1 36.0 29.6-42.1
Unknown 6
Prem aturity < 37 weeks
Total 84 23.1; 18.7-27.5 39 26.2; 19.0-33.4
S ing letons 22 9.1; 5 .4-12.8 7 7.6; 2.1-13.1
Twins 62 50.4; 41 .4 -59 .4 32 56.1; 43 .0 -69 .3
a at tim e of de livery
b low: (no) prim ary school or lower level of secondary school and vocational tra in ing
c high: medium  and h igher level of secondary school or m edium  and h igher level o f vocational tra in ing or un iversity
KD
ICSI 
w
ith 
n
on
-ejacu
lated 
sp
erm
: 
follow
-up 
stu
d
y
Chapter 9
Table VI Follow-up outcome of the PESA children at 2 years o f age
Total
n (% )/m ea n (SD ) I
Bayley score: motor
Normal (> -1 SD) 105 (75.0)
At R isk (-2 < x < -1 SD) 20 (14.3)
Abnorm al (< -2 SD) 15 (10.7)
M issing 9
PDI: mean (SD) 97.6 (21.2)
S tudent-t test -1.37, p = 0.173
Bayley score: mental
Normal (> -1 SD) 132 (95.7)
At R isk (-2 < x < -1 SD) 4 (2.9)
Abnorm al (< -2 SD) 2 (1.4)
M issing 11
MDI: mean (SD) 103.8 (11.6)
S tudent-t test 3.811, p < 0.05
CBCL: total problem score
Normal range (< 60) 123 (93.9)
Borderline (60-63) 2 (1.5)
C lin ical range (>63) 6 (4.6)
M issing 18
CBCL: mean (SD) 46.9 (9.5)
S tudent t-test -3 .642, p < 0.05
Receptive language developm ent 
(Reynell test)
Normal (> -1 SD) 132 (94.3)
At R isk (-2 < x < -1 SD) 8 (5.7)
Abnorm al (< -2 SD) -
M issing 9
RLDQ: mean (SD) 100.3 (SD 9.27)
S tudent t-test 0.364, p = 0.717
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S ing letons Twins
n (% )/m ea n (SD ) n (% )/m ea n (SD )
70 (77.8) 35 (70.0)
14 (15.5) 6 (12.0)
6 (6.7) 9 (18.0)
2 7
99.2 (20.8) 94.7 (21.7)
-0 .385, p = 0.701 -1 ,742, p =0.088
82 (96.5) 50 (94.3)
3 (3.5) 1 (1.9)
0 2 (3.8)
7 4
105.1 (11.1) 101.6 (12.1)
4.271, p < 0.05 0.930, p = 0.356
73 (93.6) 50 (94.3)
1 (1.3) 1 (1.9)
4 (5.1) 2 (3.8)
14 4
47.69 (9.3) 45 .94  (9.7)
-2 .196, p < 0.05 -3 .030, p < 0.05
81 (93.1) 51 (96.2)
6 (6.9) 2 (3.8)
- -
5 4
101.2 (SD 9.91) 98.7 (SD 8.04)
1.158, p = 0.250 -1 .145, p = 0.258
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Table VI Continued
Total I
n (% )/m ea n (SD )
Syntactic developm ent 
(Schlichting test)
Normal (> -1 SD) 128 (94.2)
At R isk (-2 < x < -1 SD) 8 (5.8)
Abnorm al (< -2 SD) -
M issing 13
SDQ: mean (SD) 101.7 (SD 10.22)
S tudent t-test 1.970, p = 0.051
Lexical developm ent 
(Schlichting test)
Normal (> -1 SD) 118 (92.9)
At R isk (-2 < x < -1 SD) 9 (7.1)
Abnorm al (< -2 SD) -
M issing 22
LDQ: mean (SD) 100.9 (SD 11.09)
S tudent t-test 0.888, p = 0.376
Bayley, Reynell and Schliching tests: the normal group has a mean ± SD of 100 ± 15.
CBCL (=Child Behaviour Checklist ): the normal group has a normal mean ± SD of 50 ± 10. 
Student's t-test was performed over the means, SD's and numbers of the study group vs the Dutch 
reference group.
PDI = Psychomotor Developmental Index; MDI = Mental Developmental Index; RLDQ = Receptive 
language development quotient; SDQ = Syntactic development quotient; LDQ = Lexical development 
quotient
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S ing letons Twins
n (% )/m ea n (SD ) n (% )/m ea n (SD )
82 (96.5) 46 (90.2)
3 (3.5) 5 (9.8)
- -
7 6
103.7 (SD 9.44) 98.1 (SD 10.68)
3.654, p < 0.05 -1 .259, p = 0 .214
72 (93.5) 46 (92.0)
5 (6.5) 4 (8.0)
- -
15 7
103.0 (SD 11.65) 97.6 (SD 9.47)
2.247, p <0.05 -1 .762, p = 0 .084
9
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For speech and language development (Reynell test and Schlichting 
tests), the PESA singleton group showed a better (P < 0.05) mean score 
for syntactic and lexical development (SDQ and LDQ) as compared with 
the Dutch reference values. The receptive language development (Reynell 
test) showed no differences for the mean RDLQ between the study group 
and the Dutch reference group.
IVF and ICSI children than children conceived naturally but these rates 
did not differ between IVF and ICSI.31-34 Moreover, the risk of major 
malformations did not seem to be related to the source of sperm.8 In 
general, various methodological pitfalls were mentioned in studies about 
malformations, such as failure to take into account potential confounding 
variables, the way in which malformations are determined and registered, 
and inconsistent criteria with respect to classifying malformations 
(inclusion or exclusion of minor malformations and malformations present 
in terminated pregnancies and stillb irths).35 36 Because of these pitfalls 
and because of studies with only small groups of children conceived after 
ICSI with epididymal sperm, it was difficult to compare the finding of 
fewer minor malformations in our PESA group. Not all malformations are 
diagnosed at birth but will be identified up to 12 months of age; two- 
thirds of major malformations were detected within the first 7 days of life 
and about 90% within the first 6 months.37 The data on malformations of 
the IVF and ICSI children were all from the questionnaires for 1 year old. 
As only 260 out of 357 (72.8%) live born PESA children reached the age 
of 1 year before May 2008, this could partly explain the lower prevalence 
of minor malformations in this group.
In one of the first studies about development of the ICSI children, a 
lower mental development with Bayleys at 1 year of age was found, 
especially for boys.38 These findings were not confirmed by later studies, 
which showed no significant difference in development between the ICSI 
children and their naturally conceived peers.38 39 40 Studies about children 
conceived after ICSI with epididymal sperm with a follow-up of at least 
2 years are rare.841 Our findings of a significantly higher mental Bayley 
score for PESA singletons and fewer reported behavioural problems in 
the PESA group than the Dutch reference group could be explained by a 
higher educational level of the parents of the PESA children than of the 
Dutch reference group [high education of mother in 77.0% and of father 
in 73.1%10]. The same explanation could be given for the significantly 
better scores for syntactic development and lexical development for the
162
ICSI with non-ejacu lated sperm : fo llow -up study
PESA singletons than the Dutch standards.
The strengths of our study were the large numbers in the study and control 
groups, the sim ilar way of collecting information for all groups using the 
same questionnaires with a good response, the availability of information 
about the parents and children, and the long period of follow-up of the 
children up to 4 years of age. Possible weaknesses of our study were the 
composition of the control group (no natural conceived children but IVF 
and ICSI children), the use of questionnaires, the un-blinded design and 
the lack of matched controls for the follow-up at 2  years of age.
The reassuring outcomes of the present study are important not only 
for clinicians and future patients but also for policy-makers who have 
to decide about ethics and costs of new techniques. At time of writing, 
the questionnaires (at birth, 1 year and 4 years of age) have been sent 
to the parents of the PESA children conceived in Nijmegen. We stopped 
the assessment at 2 years of age. The first 90 PESA children seen at 
2  years of age by assessment were already seen at 5  years of age for 
another assessment by a medical doctor, a psychologist and a physical 
therapist, and unfortunately our project has been stopped for reasons of 
cost effectiveness, therefore no additional data at 5 years will be collected. 
Our study focused on ICSI with epididymal sperm and not on ICSI with 
testicular sperm. More research is necessary to confirm whether testicular 
sperm retrieved by TESE in case of an NOA can be used safely for ICSI.
In conclusion, ICSI with epididymal sperm does not lead to more stillbirths 
and congenital malformations in comparison with IVF and ICSI with 
ejaculated sperm and does not lead to poor development in comparison 
with the Dutch reference group.
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General d iscussion
The main aim of this thesis was to evaluate the health, growth and 
development of children conceived after ICSI with ejaculated and 
especially with non-ejaculated sperm.
Firstly, the theoretical risks and complications for women, men and 
children were described in this thesis after a literature search. Secondly, 
a systematic review was carried out to investigate the karyotypes of 
foetuses, congenital anomalies and the follow-up of the children born 
after ICSI with epididymal or testicular sperm. Thirdly, an explorative 
study was described in order to identify constitutional de novo DNA copy 
number changes, including those that are phenotypically silent. Fourth, a 
questionnaire was sent to parents of IVF and ICSI children at one and four 
years of age. This provided us with data about the parents, pregnancy 
(e.g. pre-eclampsia) and child (e.g. growth). Finally, a clinical study 
was carried out with the follow-up of children conceived after ICSI with 
epididymal sperm.
In this chapter the answers to the main questions are mentioned and 
discussed. The most relevant methodological issues are reviewed and at the 
end the implications for the different stakeholders and recommendations 
for future research are given.
Answ ers to the main questions
1. Theoretical risks of ICSI (especially with non-ejaculated sperm) 
may result in fertilisation failure, miscarriages, birth defects, genetic 
abnormalities, developmental abnormalities and infertility in the 
offspring. (C hap te r 2)
2. Diminished responsiveness of the ovaries to FSH stimulation in an 
IVF cycle, reflecting decreased ovarian reserve, is associated with an 
increased risk of developing pre-eclampsia in a subsequent pregnancy. 
(C hap te r 3)
3. Although IVF and ICSI singletons had a statistically significantly lower 
birth weight than naturally conceived singletons, the average individual 
weight curves showed that this difference disappeared before the age 
of 4 years. (C hap te r 4)
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4. ICSI with epididymal sperm was successfully used as a treatment 
of infertility caused by obstructive azoospermia in the first year 
after restarting this treatment under conditions in the Netherlands. 
(C hap te r 5 and 6)
5. ICSI children had more de novo 'same direction genomic copy number 
changes' than the control group of naturally conceived children. 
(C hap te r 7)
6. A systematic review of studies on the health of children born after ICSI 
with ejaculated, epididymal or testicular sperm showed no statistical 
differences between the study groups in karyotypes (two studies), 
malformations (five studies) and follow-up (one study). (C hap te r 8)
7. ICSI with epididymal sperm does not lead to more stillbirths or 
congenital malformations in comparison with IVF and ICSI with 
ejaculated sperm and does not lead to poor development at two years 
of age in comparison with the Dutch reference group. (C hap te r 9)
In te rp re ta t io n  o f the  a n sw e rs
There are theoretical risks of ICSI that may result in fertilisation failure, 
abortion, birth defects, genetic abnormalities, developmental abnormalities 
and infertility in the offspring. Surgical retrieved sperm from the epididymis 
or from the testis are of special concern, because of additional risks such 
as aging due to a prolonged stay in the epididymis (in case of obstruction) 
and incomplete maturation (in cases of non-obstructive azoospermia).1 
This is important to know for counselling the future parents, especially 
if these risks will result in genetic abnormalities and birth defects. The 
cause of infertility is also of concern, because these risks may be due to 
the infertility itself, rather than the ICSI technique.2 Moreover, a causal 
relationship between ICSI and adverse effects on the offspring is difficult 
to make, because in most studies maternal characteristics (such as age 
and parity), co morbidity, life-style (smoking, drinking, drugs) and the 
fact that ICSI children are more often born prematurely (singletons and 
especially multiples), with a low birth weight are confounding factors.3
Beside possible effects of ICSI treatment for the children, there are 
possible short-term complications for women after assisted reproductive 
technology such as pre-eclampsia.45 Pre-eclampsia affects 2 -10% of 
all pregnancies and relates to substantial maternal and fetal morbidity
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and mortality.67 In our study we explored a possible association between 
ovarian reserve, as measured by basal ovarian function and response 
capacity to FSH stimulation on one hand and the development of pre­
eclampsia as pregnancy-related vascular complication on the other. The 
administered FSH per follicle and FSH per obtained oocyte was the most 
powerful predictor of all variables studied. In accordance to other studies 
we observed a shorter pregnancy duration in the pre-eclampsia subgroup, 
which was expected considering the tendency to induce delivery in case 
of preeclampsia. Although these children had a lower birth weight, after 
adjustment for gestational age, parity and sex, the outcome of the 
children born after pre-eclampsia and the children in the control group 
were comparable. This is in contrast with findings of several other studies 
that state that birth weight even after adjustment for gestational age is 
lower in children born to mothers with pre-eclampsia.8 Possibly we did not 
observe this in our study because of the limited number of cases.
Although the indication for ICSI treatment is based on the male subfertility, 
it is important to have a partner with a sufficient ovarian reserve because 
of the lower pregnancy rate, the higher risk on pre-eclampsia and possible 
effects on birth weight and fetal morbidity in women with a low ovarian 
reserve. This knowledge is important, because it is already known from 
other studies, that IVF and ICSI singletons had a significantly lower 
birth weight than reference singletons.9 In our study we confirmed that 
term IVF and ICSI singletons had a significantly lower birth weight than 
children from a national reference group. The mechanism behind this 
difference in birth weight is unknown, but several explanations have been 
given, such as a late effect of the hormonal ovary stimulation, the IVF/ 
ICSI procedure itself (oocyte retrieval, culture medium, embryo transfer), 
the pre-existing condition of the mother, factors related to subfertility or 
double-embryo transfer.101112 It was not possible in our study to verify all 
these explanations. There were no differences in birth weight between the 
IVF and ICSI group, so it is not likely that the factors related to subfertility 
or the ICSI procedure itself are of a great influence. In most cases the 
indication for ICSI was only male related, most women did not have a 
fertility problem.
In this thesis we were interested in the health of the ICSI children, 
and growth is an important aspect of health in children. Especially 
because reduced birth weight and delayed growth are not without health 
consequences, like cardiovascular disease in later life.1314 Some studies
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reported already on postnatal growth of IVF children15-20 and other studies 
about ICSI children as well.21-23 They have some limitations such as having 
not differentiated for gestational age or performed only one single weight 
measurement at five years of age. Our study differentiated for gestational 
age, had at least four measurements and included both IVF and ICSI 
children. It showed that the longitudinal growth of IVF and ICSI children 
is comparable with the growth of natural conceived children and that the 
difference in birth weight disappeared before the age of four years.
In this thesis we were especially interested in children conceived after ICSI 
with non-ejaculated sperm. In the Netherlands, in 2001 a prospective and 
multicentre clinical study was started to confirm whether sperm retrieved 
by PESA or MESA in cases of an obstructive azoospermia, can be used safely 
for ICSI. Evaluation after one year showed that ICSI with sperm retrieved 
by PESA was an effective treatment for couples with childlessness due to 
an obstructive azoospermia. Beside this, no congenital defects were found 
in any of the seventeen children, born in this first year.
In one pregnancy, a chromosomal anomaly was diagnosed by 
amniocentesis, probably a de novo anomaly. It is not clear whether this 
diagnosis was based on coincidence, or whether it was due to the ICSI- 
treatment or to the PESA-procedure. However, a significantly higher 
percentage of de novo chromosomal anomalies has been observed in 
ICSI-mediated offspring,24 indicating that it remains necessary to pay 
attention to this aspect.
This significantly higher rate of de novo chromosomal anomalies suggests 
that ART procedures increase the genetic load. Such an increase, if present, 
could besides gross chromosomal changes including copy number variation 
of large kilobase (kb) range sequences, also apply to other mutation types 
such as simple sequence repeat instability, small deletions, duplications, 
inversions and base pair changes. It is not known to what extent an 
increased genetic load might manifest itself in congenital malformations, 
so we initiate an explorative study in order to identify constitutional de 
novo DNA copy number changes. Significantly more 'same direction copy 
number changes' (i.e. simultaneous copy number gain [or loss] with 
respect to both parents) were found in ICSI children compared to children 
from the control group. No significant correlation was found for 'same 
direction copy number changes' in children born after ICSI with sperm 
from a PESA and in children born after ICSI with ejaculated sperm from
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fathers suffering extreme OAT. None of the children had major or minor 
malformations, so the genomic changes do not seem to have phenotypic 
consequences.
Beside our own first observations about the health of children born after 
ICSI with epididymal sperm, we were interested in the literature about 
abnormal karyotypes, congenital anomalies and the follow-up of the 
children born after ICSI with non-ejaculated sperm. The studies found in 
the systematic review suggest that the risk ratios may be sim ilar in the 
subgroups of the ICSI procedures (with epididymal sperm, testicular sperm 
or ejaculated sperm). Points of attention are the possible heterogeneity 
and the low number of children in some subgroups resulting in large 
confidence intervals (CI's). Possible heterogeneity between the study 
groups in the articles, are related to the age of the mother, indication 
for PESA or TESE, difference in OA and NOA, the use of fresh or frozen 
thawed sperm or embryos and difference in percentage of singletons and 
multiples.
In the Netherlands there was a national moratorium for the application of 
ICSI with non-ejaculated sperm from 1996 until 2001. Studies in other 
countries showed no increase in the number of congenital defects in 
children born after ICSI in combination with MESA or PESA compared 
to ICSI with ejaculated sperm,25,26,27 so the Dutch government agreed 
in 2001 to start a prospective and multicentre clinical study to confirm 
these findings. In this study it was found that children born after an ICSI 
treatment with epididymal sperm of men with an obstructive azoospermia 
showed no increased risks for stillbirths, total deaths, malformations 
and psycho motor problems. In different meta-analysis a higher rate of 
malformations has been reported for IVF and ICSI children compared to 
natural conceived children, but these rates did not differ between IVF and 
ICSI.28-31 In our study group (ICSI with epididymal sperm) we found the 
same rate of major malformations and a lower rate of minor malformations 
than in the IVF and ICSI (with ejaculated sperm) groups. Furthermore, 
the mental Bayley score, the scores for syntactic development and lexical 
development were significantly higher in singletons of the study group 
and parents reported less behavioural problems in this group than the 
Dutch reference group.
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The two reviews (chapter 2 and chapter 7) mentioned some methodological 
issues of the reviewed studies, like differences in study design and study 
groups. Most studies were cohort or case control studies, none of them 
were matched, some were retrospective, by identifying health registers 
and some were prospective, by physical examination or by physical 
examination as well as by sending questionnaires. Rarely a study made 
adjustment for some variables, which could act as confounders: year of 
birth, maternal age and parity, years of involuntary childlessness and 
maternal smoking in early pregnancy. Possible heterogeneity between 
the study groups in the articles, are related to the age of the mother, 
in- or exclusion of stillbirths, indication for PESA or TESE, difference in 
OA and NOA, the use of fresh or frozen thawed sperm or embryos and 
difference in percentage of singletons and multiples. Beside this possible 
heterogeneity there were low numbers of children in some subgroups 
resulting in large CI's.
The selection of cases in the case-control study about risk of developing 
pre-eclampsia, was based on self report of the women in the 
questionnaires. Although all data were verified in both cases and controls, 
the reported incidence of preeclampsia was low compared to that of the 
general population, especially since preeclampsia is stated to occur more 
frequently in pregnancies resulting from ART.5 These figures could also 
be biased by our local selection protocol prior to IVF, which excluded 
women having a BMI above 32 kg/m2. Overweight increases the chance of 
pregnancy induced hypertension.32 Beside this, the low number of women 
reporting preeclampsia resulted in a small case group that led to a modest 
power, although the strength of the study was the design as case-control 
study.
In the explorative study to identify constitutional de novo DNA copy 
number changes, we used Bacterial Artificial Chromosome (BAC)-array 
mediated comparative genomic hybridization (array CGH) analysis. The 
tiling-resolution BAC arrays used provide unbiased genomic coverage, 
including polymorphic genomic intervals at a practical resolution of around 
100 kb. Although executed at a small scale, our search revealed a relative 
abundance of 'same direction copy number changes', but a larger group 
is needed to confirm these findings.
Methodological issues
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The study about weight and growth of the IVF and ICSI children had a 
large sample size (especially the reference group), high response rate 
on the questionnaires and relatively long follow-up with at least four 
measurements up to four years of age. A disadvantage was the comparison 
between longitudinal data of IVF and ICSI children with cross-sectional 
data of a reference group, although it gave us the opportunity to have a 
large population based control group of natural conceived children.
The last clinical study about the follow up of the children born after ICSI 
with epididymal sperm had well defined groups of children conceived after 
IVF, ICSI with ejaculated sperm or ICSI with epididymal sperm. Other 
strengths of the study were the large numbers in the study and control 
groups, the sim ilar way of collecting information of all groups by the 
same questionnaires with a good response, the availability of information 
about the parents and children and the long period of follow-up of the 
children up to four years of age. Possible weaknesses of this study were 
the composition of the control group (no natural conceived children but 
IVF and ICSI children), the use of questionnaires, the un-blinded design 
and the lack of matched controls for the follow-up at two years of age.
Im p lic a t io n s  fo r  s ta keh o ld e rs
The reassuring outcomes of these studies are important for clinicians and 
future patients, but also for policymakers who have to decide about ethics 
and costs of new techniques.
Although some concerns about the findings of lower birth weight of IVF 
and ICSI children compared to naturally conceived singletons remain, 
these differences disappeared before the age of 4 years. There were 
statistical significant more 'same direction copy number changes' of DNA 
in ICSI children (with ejaculated and epididymal sperm) compared to in 
the control group, but there were not more congenital malformations 
found in ICSI children conceived with ejaculated or epididymal sperm 
compared to IVF children. In the literature and in our clinical follow up 
study, there were not more concerns about children born after ICSI with 
epididymal sperm compared to ICSI with ejaculated sperm or after IVF. 
There are still concerns about the mortality and morbidity of multiples, 
which are seen more often after IVF and all ICSI treatment.
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The future patients have to be counselled that the ICSI procedure is safe 
even with epididymal sperm, but that we do not know the future outcomes 
like fertility and chances of diseases at later age.
For clinicians it is important to counsel their patients and inform them 
about these findings. Since we found that the risk of multiple pregnancies 
exceed the potential risks of ICSI with epididymal sperm, it stresses the 
importance of advocating single embryo transfer.
For policymakers in the Netherlands it is necessary to withdraw the 
moratorium and to see ICSI with epididymal sperm as a regular treatment 
in cases of obstructive azoospermia.
R ecom m enda tio n s  fo r  fu tu re  resea rch
Firstly, we will recommend to do research on larger groups and a longer 
follow up of the children born after IVF, ICSI with ejaculated or epididymal 
sperm, although the first results are reassuring. Special interests are late 
effects on health and fertility of these children. A sim ilar follow up is 
recommended for the follow up of children born after ICSI with testicular 
sperm.
Secondly, we recommend concentration of new techniques in ART (like 
in vitro maturation, vitrification of oocytes, pre-implantation genetic 
screening), in specialized clinics with a good scientific evaluation of the 
treatment, outcome and follow up of the children.
Finally, we recommend a model for follow up of children born after new 
techniques in ART. This model must include: detection of DNA changes; 
questionnaires to collect data about the parents, pregnancy and children, 
developmental tests; a matched control group of natural conceived 
children; large study- and control groups; a blinded design and a long time 
of follow up. A model like this should be developed by the national and 
international professional organizations (Dutch Society of Reproductive 
Medicine (DSRM) and European Society of Human Reproduction and 
Embryology (ESHRE)). The latter might use its influence to call upon society 
to take its responsibility also with regard to proper health registries, with
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concern of privacy.33 
Conc lu s ion
In conclusion, we showed in this thesis that ICSI with epididymal sperm 
is a safe treatment. Although there may be some theoretical and scientific 
indications for potential health risks for the children, we did not found 
increased numbers of congenital anomalies, stillbirth and developmental 
problems in a large clinical follow-up study.
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Summary
The birth of the first IVF-baby Louise Brown on July 25, 1978 was the 
start of a revolution for infertile couples worldwide. However, IVF could 
not help the infertile couples with severe male factor, which account for 
approximately half of the cases. The introduction of ICSI in 1992 enabled 
the management of severe male factor infertility with high success rates, 
even for men with azoospermia, ICSI with sperm retrieved at the level of 
the epididymis or testis is a possibility to father their own genetic progeny.
The use of IVF and ICSI with ejaculated and non-ejaculated sperm as 
well, has increased and its effectiveness has grown over time. Along 
with the success story, less attention is paid to safety and the potential 
risks and complications of this treatment. In the Netherlands, there 
were concerns about the health of the children born after ICSI with non­
ejaculated sperm, referring to unknown risks of using aged (epididymal) 
or immature (testicular) sperm cells. This led to a national moratorium 
for the application of ICSI with non-ejaculated sperm in 1996. In 2001 
the Dutch government agreed to start a new prospective and multicentre 
clinical study to confirm whether ICSI with epididymal sperm in case of an 
obstructive azoospermia can be used as a safe treatment.
This chapter describes the background (theoretical risks and complications 
of ICSI), the aim (follow-up of the children conceived after ICSI with 
ejaculated and especially with non-ejaculated sperm) and outline 
(literature searches, analyses of the results of the questionnaires and 
clinical studies of ICSI children) of this thesis and mentions the main 
questions.
Chapter 1
11
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Chapter 2
In this chapter we reviewed the literature about risks and complications of 
ICSI. There are theoretical risks of the female gamete, the male gamete 
and the process of genomic imprinting. These theoretical risks may result 
in fertilisation failure, abortion, birth defects, genetic abnormalities, 
developmental abnormalities and infertility in the offspring. The incidence 
of chromosomal abnormalities, including de novo abnormalities, is higher 
after ICSI than in the general population. This might be a result of the 
infertility per se rather than the ICSI technique. The incidence of congenital 
malformations might be slightly higher after ICSI, with special attention 
for children born after ICSI using epididymal or testicular sperm obtained 
from men with obstructive or non-obstructive azoospermia. The increased 
risk of congenital malformations seems also to be related to preterm and 
multiple births, so a twin pregnancy is regarded as a complication.
Risks for women by inducing ovulation or retrieving oocytes for ICSI are 
rare. Risks for men, after surgical sperm retrieval by epididymal sperm 
aspiration, or testicular sperm extraction in case of obstructive or non­
obstructive azoospermia, are also rare.
Chapter 3
Pre-eclampsia affects 2-10% of all pregnancies and is a major cause of 
maternal and fetal morbidity and mortality. As compared with the general 
population, IVF pregnancies are associated with a 2.7-fold risk of pre­
eclampsia.
In this chapter, we hypothesize that decreased ovarian reserve in women 
is associated with pre-eclampsia as a vascular complication in pregnancy. 
We conducted a retrospective case-control study and compared 41 
cases with a history of pre-eclampsia to 82 matched controls without 
hypertension or (pre)eclampsia. All pregnancies were established after IVF 
or ICSI treatment. The 82 controls were matched according to the type of 
fertility treatment and several characteristics known to influence the risk 
of pre-eclampsia in pregnancy: the number of fetuses, parity, maternal 
age at the time of delivery, pre-pregnant BMI (kg/m2), race and smoking.
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The administered FSH units per follicle and per obtained oocyte were 
calculated, defined as the total amount of administered FSH divided by 
the number of follicles and the number of obtained oocytes, respectively. 
The condition of the neonates was evaluated as well.
We found that a higher amount of total administered FSH and FSH per day, 
together with a lower number of obtained oocytes during IVF treatment, 
were associated with an increased risk to pre-eclampsia in a subsequent 
pregnancy. The administered FSH per follicle and per obtained oocyte 
showed even stronger relationship, the latter having the best predictive 
value. The neonatal outcome was comparable between the groups.
We concluded that diminished responsiveness of the ovaries to FSH 
stimulation in an IVF cycle, reflecting decreased ovarian reserve, is 
associated with an increased risk of developing pre-eclampsia in a 
subsequent pregnancy. We speculated that reduced ovarian responsiveness 
also reflects diminished vascular reserve capacity, the latter giving rise to 
pregnancy associated vascular complications.
Chapter 4
Singletons conceived through IVF and ICSI have a lower birth weight than 
children conceived spontaneously. Whether the effect is limited to birth 
weight or reflects a general delay in growth is not yet known.
In this chapter we compared birth weight and longitudinal growth in the 
first 4 years of life of 347 IVF and 330 ICSI (with ejaculated sperm) 
term singletons (gestational age of >37 weeks) with those of 5059 term 
singletons of a national reference group.
The mean birth weights were calculated from the observed data, and the 
weights from 1 month to 4 years were calculated by using a linear mixed 
model. A linear regression model was developed to estimate the average 
weight curves in the two sex categories of the reference group, separately.
Our study showed that term IVF and ICSI singletons had a significantly 
lower birth weight than children from the national reference group. We 
also showed that the longitudinal growth of the IVF and ICSI children is 
comparable with the growth of natural conceived children and that the 
difference of birth weight was lost before the age of 4 years. The differences 
between the IVF and ICSI group were never statistically significant.
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In 2001 the Dutch government agreed to start a new prospective clinical 
study to confirm whether ICSI with epididymal sperm in case of an 
obstructive azoospermia can be used as a safe treatment. In chapter 5 
and 6 we described the first clinical results of this study: firstly the results 
of PESA and testis biopsies (chapter 5) and secondly the clinical results of 
PESA-ICSI-treatment (chapter 6).
In our hospital PESA was carried out in 93 men with supposed obstructive 
azoospermia. From all men a testis biopsy was taken at the same 
time for the determination of the Johnsen score as a measurement of 
spermatogenesis. Epididymal motile sperm was retrieved from 76 patients 
(82%). In 73 of these patients the Johnsen score was higher than or 
equal to 8 and three had a score of 7.4. The average Johnsen score was 
statistically significant higher in cases when sperm was retrieved by PESA 
than in those cases when no sperm could be retrieved (P < 0,001).
In cases of an unexplained cause of azoospermia, there was a lower 
probability of retrieval of epididymal sperm than in those cases when the 
cause was known, but the difference between the two groups was not 
statistically significant.
In chapter 6 we described the first clinical results of the PESA-ICSI- 
treatment. In the first year, 31 couples started in total 44 cycles of ICSI with 
epididymal sperm retrieved by a PESA. There were 15 ongoing pregnancies 
(34% per started cycle). In one pregnancy, a chromosomal anomaly was 
diagnosed by amniocentesis, probably a de novo anomaly. This pregnancy 
was terminated. There were 17 children born, no congenital defects were 
found in any of them. There were no differences in percentage of ongoing 
pregnancies between the subgroups of cause of obstructive azoospermia 
or between the use of cryopreserved sperm and fresh sperm.
Chapter 5 and 6
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In parallel with the advent of technological developments facilitating ART, 
especially of ICSI in cases of men suffering from severe oligozoospermia 
or azoospermia, there is a great concern about the biological safety. 
This concern is supported by the clinical observation that the frequency 
of congenital malformations is slightly elevated among ART-conceived 
children and a significantly higher rate of de novo chromosomal anomalies 
has been observed in ICSI-mediated offspring.
In this chapter we describe an explorative study, using tiling-resolution 
BAC array-mediated comparative genomic hybridization to investigate the 
incidence of de novo genomic copy number changes in a group of 12 ICSI 
children, compared with a control group of 30 naturally conceived children. 
In 6 of the 12 ICSI children, we found 10 apparently de novo 'same 
direction genomic copy number changes' (i.e. simultaneous copy number 
gain (or loss) with respect to both biological parents), notably losses. In 
statistically significant contrast, similar observations were encountered 
only six times in the control group in 5 of the 30 children. No significant 
correlation was found for 'same direction copy number changes' in children 
born after ICSI with sperm from a PESA and in children born after ICSI 
with ejaculated sperm from fathers suffering extreme OAT. None of the 
children had major or minor malformations, so the genomic changes do 
not seem to have phenotypic consequences.
Chapter 8
In this chapter a systematic review was carried out to investigate the 
karyotypes of fetuses, congenital anomalies and the follow-up of the 
children born after ICSI with epididymal or testicular sperm.
Because of the differences between the control groups, we analysed the 
studies, which described children born after epididymal sperm and after 
testicular sperm and children born after ejaculated sperm. We used the 
group with children born after ICSI with ejaculated sperm as the control 
group. The search strategy identified 1662 potentially relevant studies, 
but after exclusion, only eight articles were included in the systematic 
review. Two studies discussed karyotyping of fetuses, five studies were 
dealing with congenital anomalies and only one study was found with 
follow-up of the children.
Chapter 7
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There were no statistical differences in abnormal karyotypes, major 
malformations and follow-up of the children found in the studies we 
analysed, but it should be considered that the study groups were small 
and heterogenic with numerous potential biases.
Chapter 9
In this chapter we evaluate the safety of ICSI with epididymal sperm, by 
comparing children born after ICSI-treatment with epididymal sperm and 
children conceived after IVF and ICSI with ejaculated sperm. Additionally, 
the results of a multidisciplinary, multicentre follow-up of the children 
conceived with epididymal sperm at two years of age are described.
This follow-up study included 378 children after ICSI with epididymal 
sperm (PESA group) and a control group of 1192 IVF and 1126 ICSI 
(with ejaculated sperm) children, all with a gestational age of 20 weeks 
or more. Questionnaires were sent at birth, at one year and at four years 
of age, collecting data on parental, pregnancy and child factors, including 
gestational age, mode of delivery, birth weight, presence or absence 
of malformations and neonatal problems. 148 children born after ICSI 
with epididymal sperm were assessed at two years of age for motor 
performance, mental- and language development and compared with the 
Dutch norms.
Children born after ICSI with epididymal sperm showed no increased risks 
for stillbirths, total deaths and malformations. They also did not differ from 
IVF and ICSI (with ejaculated sperm) children in gender rate, birth weight 
and gestational age. The minor malformations rate in the PESA group was 
significantly lower than in the control groups. The mental Bayley score 
was significantly higher for PESA singletons and parents reported less 
behavioural problems in the PESA group than the Dutch reference group. 
The scores for syntactic development and lexical development for the 
PESA singletons were significantly better than the Dutch standards.
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In this chapter the answers on the main questions are mentioned and 
discussed. The most relevant methodological issues are reviewed and 
the implications for the different stakeholders and recommendations for 
future research are given.
Theoretical risks of ICSI (especially with non-ejaculated sperm) for men, 
women and children are mentioned and discussed. Although there remain 
some concerns about the findings of lower birth weight of IVF and ICSI 
children compared to naturally conceived singletons, these differences 
disappeared before the age of 4 years. There were statistical significant 
more 'same direction copy number changes' of DNA in ICSI children (with 
ejaculated and epididymal sperm) compared to the control group, but 
there were not more congenital malformations found in ICSI children con­
ceived with ejaculated or epididymal sperm compared to IVF children. 
In the literature and in our clinical follow up study, there were not more 
concerns about children born after ICSI with epididymal sperm compared 
to ICSI with ejaculated sperm or after IVF. There are still concerns about 
the mortality and morbidity of multiples, which are seen more often after 
IVF and ICSI treatment.
Chapter 10
11
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Samenvatting 
Hoofdstuk 1
De geboorte van de eerste IVF-baby Louise Brown op 25 juli 1978, was 
het begin van een wereldwijde revolutie voor infertiele paren. Helaas was 
IVF niet de oplossing voor paren met een ernstige mannelijke factor, wat 
ongeveer de helft van de indicaties betreft. Voor deze paren maakte de 
introductie van ICSI in 1992 het mogelijk om genetisch eigen kinderen 
te krijgen, zelfs voor mannen met een azoöspermie, waarbij ICSI wordt 
verricht met zaadcellen verkregen uit de epididymis of testis.
In de afgelopen jaren zijn het aantal IVF en ICSI behandelingen, zowel 
met geëjaculeerd als met niet-geëjaculeerd zaad, toegenomen en is de 
effectiviteit verbeterd. Naast deze goede resultaten is er minder aandacht 
besteed aan de veiligheid en potentiële risico's en complicaties van deze 
behandelingen. In Nederland was men vooral bezorgd over de gezondheid 
van de kinderen, die ontstaan waren na ICSI met niet-geëjaculeerd 
zaad, vooral door de onbekende risico's van het gebruik van oudere 
(epididymale) of niet rijpe (testiculaire) zaadcellen. Dit heeft geleid tot 
een nationaal moratorium in 1996, waarbij het verboden was om ICSI te 
verrichten met niet-geëjaculeerd zaad. Na geruststellende onderzoeken 
uit het buitenland, stemde de Nederlandse regering in 2001 toe met het 
gedeeltelijk opheffen van het moratorium onder voorwaarde dat alleen 
ICSI verricht zou worden met epididymaal zaad in gevallen van een 
obstructieve azoöspermie. Tevens zou er een goede follow-up moeten 
plaats vinden van de kinderen die uit deze behandeling geboren zouden 
worden om te bewijzen dat het een veilige methode is.
Dit hoofdstuk beschrijft de achtergrond (theoretische risico's en 
complicaties van ICSI), het doel (follow-up van de kinderen ontstaan na 
ICSI met geëjaculeerd en met name ook na niet-geëjaculeerd zaad) en de 
opzet (literatuur studies, analyses van de resultaten van de vragenlijsten 
en klinische onderzoeken van de ICSI kinderen) van dit proefschrift en 
benoemt de hoofdvragen.
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Hoofdstuk 2
In dit hoofdstuk wordt besproken wat er in de literatuur is beschreven 
over de risico's en complicaties van ICSI. Zo zijn er theoretische risico's 
van de vrouwelijke gameet (eicel), de mannelijke gameet (zaadcel) en het 
proces van inprenting van het genoom. Deze theoretische risico's kunnen 
resulteren in het ontbreken van bevruchting, miskramen, aangeboren 
afwijkingen, genetische afwijkingen, ontwikkelingsstoornissen en 
infertiliteit bij het nageslacht. De incidentie van chromosomale afwijkingen, 
inclusief nieuwe afwijkingen, is hoger na ICSI dan in de algemene populatie. 
Dit kan een resultaat zijn van de oorzaak van de infertiliteit of van de ICSI 
procedure zelf. Het vóórkomen van aangeboren afwijkingen zou mogelijk 
wat hoger zijn bij kinderen geboren na ICSI, waarbij vooral aandacht is 
voor de kinderen ontstaan na ICSI met epididymaal of testiculair zaad. 
Dit verhoogde risico op aangeboren afwijkingen zou ook kunnen komen 
door het hogere aantal vroeggeboortes bij meerlingen, zodat ook een 
tweelingzwangerschap als complicatie gezien moet worden.
Risico's voor de vrouw door de hormoonstimulatie en het verkrijgen van 
de eicellen, zijn zeldzaam. Ook voor de man zijn er weinig risico's na een 
chirurgische ingreep, waarbij zaad wordt verkregen uit de epididymis of 
testis in het geval van respectievelijk een obstructieve of niet-obstructieve 
azoöspermie.
Hoofdstuk 3
In 2-10% van alle zwangerschappen treedt pre-eclampsie op als 
complicatie en het is tevens één van de hoofdoorzaken van ziekte en 
sterfte bij moeder en kind. Vergeleken bij de algehele populatie komt pre­
eclampsie 2,7 maal zoveel voor bij IVF-zwangerschappen.
In dit hoofdstuk hebben we de aanname gedaan dat verminderde 
ovariële reserve bij de vrouw geassocieerd is met pre-eclampsie als 
een vasculaire complicatie tijdens de zwangerschap. We hebben een 
retrospectieve case-control studie uitgevoerd waarbij we 41 zwangere 
vrouwen met pre-eclampsie in de voorgeschiedenis vergeleken met 82 
vergelijkbare controles zonder hypertensie of (pre)eclampsie. Al deze 
zwangerschappen waren ontstaan na een IVF of ICSI behandeling. De 
82 controles waren gematched op soort fertiliteitsbehandeling en op 
verschillende karakteristieken die invloed kunnen hebben op het risico 
van pre-eclampsie in de zwangerschap: het aantal foetussen, pariteit, 
leeftijd moeder op dag van bevalling, BMI (kg/m2), ras en rookgedrag.
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Het aantal toegediende eenheden FSH per follikel en per verkregen oöcyt 
werd berekend, gedefinieerd als de totale hoeveelheid van toegediende 
eenheden FSH gedeeld door het aantal follikels respectievelijk het aantal 
verkregen oöcyten. De gezondheid van de pasgeborene werd eveneens 
geëvalueerd.
We vonden dat een hogere hoeveelheid van totaal toegediend FSH en 
FSH per dag samen met een lager aantal verkregen oöcyten bij een IVF 
behandeling, waren geassocieerd met een hogere kans op pre-eclampsie 
in een daaropvolgende zwangerschap. Het aantal toegediende eenheden 
FSH per follikel en per verkregen oöcyt gaf zelfs een betere relatie, waarbij 
de laatst genoemde een betere voorspellende waarde had. De gezondheid 
van de pasgeborenen was vergelijkbaar tussen de groepen.
We concludeerden dat verminderde respons van de ovaria op FSH tijdens 
een IVF behandeling een weergave is van verminderde ovariële reserve 
en geassocieerd is met een verhoogd risico op het ontwikkelen van pre­
eclampsie in een daaropvolgende zwangerschap. We speculeerden dat 
verminderde ovariële respons een weergave is van verminderde vasculaire 
reserve capaciteit, welke laatste een verhoging kan geven op vasculaire 
complicaties die geassocieerd zijn met een zwangerschap.
Hoofdstuk 4
Eenlingen die ontstaan zijn na een IVF of ICSI behandeling hebben een 
lager geboortegewicht dan kinderen die spontaan zijn ontstaan. Of dit 
effect beperkt is tot het geboortegewicht of ook invloed heeft op een 
algehele vertraging in groei, is niet bekend.
In dit hoofdstuk vergelijken we het geboortegewicht en de longitudinale 
groei in de eerste vier levensjaren van 347 IVF en 330 ICSI (met 
geëjaculeerd zaad) aterm geboren eenlingen (zwangerschapsduur > 37 
weken) met die van 5059 aterm geboren eenlingen uit een nationale 
referentiegroep.
Het gemiddelde geboortegewicht werd berekend uit de geobserveerde 
data en de gewichten van 1 maand tot 4 jaar werden berekend met behulp 
van een lineair mixed model. Een lineair regressie model was ontwikkeld 
om de gemiddelde groeilijnen te schatten voor de twee afzonderlijke 
geslachten van de referentiegroep.
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Onze studie liet zien dat aterm geboren IVF en ICSI eenlingen een 
significant lager geboortegewicht hadden dan de kinderen uit de nationale 
referentiegroep. Tevens toonden we aan dat de longitudinale groei van 
IVF en ICSI kinderen vergelijkbaar is met die van natuurlijk verwekte 
kinderen en dat het verschil van geboortegewicht reeds verdwenen was 
voor de leeftijd van 4 jaar. De verschillen tussen de IVF en ICSI groep 
waren nergens significant.
Hoofdstuk 5 en 6
In 2001 stemde de Nederlandse regering in met het starten van een 
nieuwe prospectieve klinische studie om aan te tonen dat ICSI met 
epididymaal zaad, in het geval van een obstructieve azoöspermie, een 
veilige behandeling is. In hoofdstuk 5 en 6 beschrijven we de eerste 
klinische resultaten van deze studie: ten eerste de resultaten van de PESA 
en de testis biopsie (hoofdstuk 5) en ten tweede de klinische resultaten 
van de PESA/ICSI-behandeling (hoofdstuk 6).
In ons ziekenhuis werd een PESA verricht bij 93 mannen met een 
vermeende obstructieve azoöspermie. Tegelijkertijd werd bij al deze 
mannen een testis biopt afgenomen om een Johnsen score te bepalen 
als maat voor de spermatogenese. Epididymaal beweeglijke zaadcellen 
werden verkregen bij 76 patiënten (82%). Bij 73 van deze patiënten was 
de Johnsen score hoger of gelijk aan 8 en drie hadden een score van 
7,4. De gemiddelde Johnsen score was statistisch significant hoger in 
de gevallen waarbij zaadcellen was verkregen bij de PESA, dan bij de 
gevallen waarbij geen zaadcellen werden gevonden (P < 0,001).
Bij de mannen zonder duidelijke oorzaak van de azoöspermie was een 
lagere kans op het verkrijgen van epididymaal zaad, dan bij de mannen 
waarvan de oorzaak wel bekend was. Echter, het verschil tussen de 
groepen was niet statistisch significant.
In hoofdstuk 6 worden de eerste klinische resultaten van de PESA/ICSI- 
behandeling beschreven. In het eerste jaar werden bij 31 paren in totaal 44 
cycli opgestart voor een ICSI behandeling met epididymaal zaad, verkregen 
bij een PESA. Er traden 15 doorgaande zwangerschappen op (34% per 
gestarte cyclus). Bij één zwangerschap werd bij vruchtwaterpunctie een 
chromosomale afwijking gediagnosticeerd, waarschijnlijk een nieuw 
ontstane afwijking. Deze zwangerschap werd voortijdig afgebroken. Er 
werden 17 kinderen geboren, bij geen van hen werd een aangeboren
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afwijking gevonden. Er waren geen verschillen in percentage van 
doorgaande zwangerschappen tussen de subgroepen naar oorzaak van 
de azoöspermie en ook niet tussen het gebruik van ingevroren zaad of 
vers zaad.
Hoofdstuk 7
Gelijktijdig met de voortschrijding van technologische ontwikkelingen rond 
ART, speciaal bij ICSI in het geval van mannen met ernstige oligospermie 
of azoöspermie, zijn er grote zorgen rond de biologische veiligheid. Deze 
zorgen worden gesteund door de klinische observatie dat de frequentie 
van aangeboren afwijkingen licht verhoogd is bij kinderen geboren na ART 
en dat er een statistisch verhoogd aantal nieuw ontstane chromosomale 
afwijkingen zijn geconstateerd bij ICSI kinderen.
In dit hoofdstuk beschrijven we een verkennende studie waarin we 
met een hoge resolutie Bacteriële Artificiële Chromosomen array de 
incidentie van nieuw ontstane genomische kopie aantal veranderingen 
in 12 ICSI kinderen hebben onderzocht en deze hebben vergeleken met 
een controlegroep van 30 natuurlijk verwekte kinderen. In 6 van de 12 
ICSI kinderen vonden we in totaal 10 nieuwe genomische kopie aantal 
veranderingen, waarbij het kind een toename (of juist afname) in kopie 
aantal liet zien ten opzichte zowel de biologische vader als de moeder. 
Het betroffen hier vooral afnames in kopie aantal. Er was een statistisch 
significant verschil met de controle groep, waarbij slechts 6 vergelijkbare 
observaties waren bij 5 van de 30 kinderen. Er waren geen significante 
verschillen gevonden voor genomische kopie aantal veranderingen tussen 
kinderen geboren na ICSI met zaad van een PESA en kinderen geboren 
na ICSI met geëjaculeerd zaad van vaders met een extreme OAT. Geen 
van de kinderen had grote of kleine afwijkingen, dus de genomische 
veranderingen lijken geen fenotypische consequenties te hebben.
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Hoofdstuk 8
In dit hoofdstuk wordt een systematische literatuurstudie beschreven naar 
de karyotypering van foetussen, aangeboren afwijkingen en de follow-up 
van kinderen geboren na ICSI met epididymaal of testiculair zaad.
Vanwege de verschillen tussen de controle groepen, analyseerden we alleen 
de studies die kinderen beschreven die ontstaan waren na gebruik van 
epididymaal zaad en na testiculair zaad en kinderen geboren na gebruik van 
geëjaculeerd zaad. De groep kinderen geboren na ICSI met geëjaculeerd zaad 
gebruikten we als controle groep. De zoekstrategie leverde 1662 potentieel 
relevante studies op, maar na exclusie waren slechts acht artikelen bruikbaar 
voor deze systematische literatuurstudie. Twee studies beschreven de 
karyotypering van foetussen, vijf studies gingen over aangeboren afwijkingen 
en slechts één was gevonden over de follow-up van de kinderen.
Er waren geen statistische verschillen gevonden in de studies die we 
analyseerden betreffende abnormale karyotypes, grote aangeboren 
afwijkingen en follow-up van de kinderen, hierbij echter wel in aanmerking 
genomen dat de studiegroepen klein en heterogeen waren met talrijke 
potentiële bias.
Hoofdstuk 9
In dit hoofdstuk evalueren wij de veiligheid van ICSI met epididymaal zaad, 
door het vergelijken van kinderen geboren na een ICSI behandeling met 
epididymaal zaad en kinderen ontstaan na IVF en ICSI met geëjaculeerd 
zaad. Aanvullend worden de resultaten beschreven van een multidisciplinaire, 
multicentrum follow-up op tweejarige leeftijd van de kinderen ontstaan na 
epididymaal zaad.
Deze follow-up studie bestaat uit 378 kinderen geboren na ICSI met 
epididymaal zaad (PESA groep) en een controle groep van 1192 IVF 
en 1126 ICSI (met geëjaculeerd zaad) kinderen, allen geboren na een 
zwangerschapsduur van 20 weken of meer. Er werden vragenlijsten 
gestuurd bij de geboorte, bij één jaar en op 4 jarige leeftijd. Hierbij werden 
gegevens gevraagd betreffende de ouders, zwangerschap en het kind, 
inclusief zwangerschapsduur, bevallingsmechanisme, geboortegewicht, 
aan- of afwezigheid van aangeboren afwijkingen en neonatale problemen. 
Op 2-jarige leeftijd werden 148 kinderen, die ontstaan waren na ICSI 
met epididymaal zaad, getest op motorische-, mentale- en spraak/taal­
ontwikkeling en vergeleken met de Nederlandse norm.
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Kinderen geboren na ICSI met epididymaal zaad lieten geen verhoogd 
risico zien voor het aantal doodgeborenen, het totaal aantal overleden 
kinderen en aangeboren afwijkingen. Ook was er geen verschil met de 
IVF en ICSI (met geëjaculeerd zaad) kinderen betreffende ratio jongens/ 
meisjes, geboortegewicht en zwangerschapsduur. Het percentage kleine 
aangeboren afwijkingen was bij de PESA groep significant lager dan in de 
controle groepen. De mentale Bayley score was significant hoger voor de 
PESA eenlingen en de ouders meldden minder gedragsproblemen bij de 
PESA groep dan de Nederlandse referentiegroep. De scores voor de taal- 
en spraak ontwikkeling van de PESA eenlingen was significant beter dan 
de Nederlandse standaard.
Hoofdstuk 10
In dit hoofdstuk worden de antwoorden op de hoofdvragen gegeven en 
bediscussieerd. De meest relevante methodologische problemen worden 
besproken en de consequenties voor de verschillende belanghebbenden 
en aanbevelingen voor de toekomst worden gegeven.
Theoretische risico's van ICSI (vooral met niet-geëjaculeerd zaad) voor 
mannen, vrouwen en kinderen worden benoemd en bediscussieerd. Ook 
al blijven er zorgen over de bevinding van het lagere geboortegewicht 
van IVF en ICSI kinderen vergeleken met natuurlijk verwekte eenlingen, 
deze verschillen zijn verdwenen voor de 4-jarige leeftijd. Er waren 
significant meer genomische kopie aantal veranderingen van het DNA 
bij ICSI kinderen (zowel met geëjaculeerd als met epididymaal zaad) 
vergeleken met de controle groep, maar er waren niet meer aangeboren 
afwijkingen gevonden bij ICSI kinderen ontstaan met geëjaculeerd of 
epididymaal zaad vergeleken met IVF kinderen. In zowel de literatuur 
als in onze klinische follow-up studie waren er niet meer zorgen voor de 
kinderen geboren na ICSI met epididymaal zaad vergeleken met ICSI met 
geëjaculeerd zaad of na IVF. Wel zijn er nog steeds zorgen over de ziekte 
en sterfte van meerlingen, welke nog steeds vaak gezien worden na een 
IVF of ICSI behandeling.
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Aan het "lied zonder eind" is dan toch eindelijk een eind gekomen, ook 
al is het "lied" in deze uitdrukking een proefschrift. Dit eind, maar ook 
het begin en middenstuk was natuurlijk nooit gelukt zonder hulp van 
anderen, aan wie ik veel dank verschuldigd ben. Daar is het dankwoord 
voor verzonnen, iets wat meestal als eerste wordt gelezen, maar toch 
aan het eind staat. Hier zal ik maar in meegaan. Ook is er meestal een 
vaste volgorde in personen die in het dankwoord genoemd worden, maar 
zoals velen weten, zal ik het toch net weer anders doen dan anders, ook 
al doet dat niets af aan het feit dat iedereen die genoemd wordt een even 
wezenlijke bijdrage heeft geleverd aan het uiteindelijk tot stand komen 
van dit proefschrift.
Als eerste noem ik hier mijn gezin: lieve Joep en lieve meiden: Pippa, 
Mytte, Dedde en Birre. Ik heb altijd geprobeerd om het schrijven van dit 
proefschrift zo min mogelijk thuis te doen, maar soms was er niet aan te 
ontkomen. Ik voelde me dan schuldig omdat ik dan minder leuke dingen 
met jullie samen kon doen en toch deden jullie daar zelden moeilijk over. 
Ik hou van jullie lieve schatten, heel erg bedankt voor jullie jarenlange (!) 
steun en support!
Gelijk noem ik hier ook mijn vader en moeder, die me hebben opgevoed 
en gestimuleerd in mijn studie, waardoor ik voor een groot deel ben zoals 
ik ben. Dank jullie wel hiervoor! Lieve pap, wat zou je trots zijn geweest, 
ik draag mijn proefschrift dan ook op aan jou, in de hoop dat je daar 
boven een beetje mee geniet. Lieve mama, fantastisch dat je dit ook mee 
mag maken en ik weet dat je nu trots bent voor twee!
Beste Jan, uiteraard hoor jij als een van de eersten genoemd te worden, 
want zonder jou was het idee al niet eens ontstaan, laat staan de rest van 
dit proefschrift. Ik heb het je vaak gezegd, maar nu dan ook zwart-op-wit: 
iedereen zou je zo'n promotor gunnen zoals jij! Zo snel als jij een stuk 
beoordeelde en op jouw bekende positieve manier terug zond, voorzien 
van zeer bruikbare correcties, was fantastisch. Soms zelfs zo snel dat 
ik er bijna van baalde, want dacht ik het even uit mijn gezichtsveld te 
hebben, lag het al weer in mijn mailbox... Verder was het altijd weer apart 
om te merken dat het je elke keer lukte om me vol energie en optimisme 
je kamer uit te laten wandelen. Jan, heel erg bedankt voor je geduld, 
vertrouwen en ondersteuning in al die jaren!
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Aangezien er verder geen andere promotor of co-promotoren bij dit 
proefschrift waren betrokken, noem ik hier mijn para-nimfen Pippa en 
Bea. Lieve Pippa, heel bijzonder dat je naast me staat! Niet alleen als 
mijn oudste dochter, maar ook als degene die veel invoerwerk voor me 
heeft verricht. Een enorme bulk van data heb je verwerkt, waardoor ik 
aan ander werk toe kwam. Heel erg bedankt hiervoor, maar ook voor je 
interesse en luisterend oor! Je wordt vast een hele goeie dokter!
Beste Bea, vanaf dag één dat ik bij het IVF-team kwam werken, was er 
een klik en volgens mij is het sindsdien zelden stil geweest als wij samen 
waren. Vaak hadden we het dan over onze frustraties en lichtpuntjes van 
onze promotietrajecten. Ruim een jaar geleden mocht ik naast jou staan 
en jij nu naast mij, wie had dat op die eerste dag kunnen vermoeden? 
Dank voor je stimulans, hulp en vriendschap!
Degene die mij indertijd betrokken hebben bij het PESA-traject, wil ik 
apart noemen, want als zij mij hier niet voor gevraagd hadden, was dit 
proefschrift er nooit geweest! Beste Alex, bedankt voor alles wat je 
hebt gedaan om de PESA-ICSI behandeling weer mogelijk te maken in 
Nederland. Ook al was je blij dat je het aan mij over kon dragen, je 
bleef er toch altijd bij betrokken en geïnteresseerd, tot en met het laatste 
artikel.
Beste Liliana, bedankt voor de prettige samenwerking om van het begin 
af aan gegevens te verkrijgen over de "PESA-mannen". Je was me ver 
voor met het afronden van je proefschrift, maar tevens een voorbeeld 
voor me en een stimulans, vooral ook door jouw paranimf te mogen zijn. 
Beste Eric, lang geleden nog uroloog in het UMCN. Samen startten we de 
gezamenlijke "uro-gyn-spreekuren" om te bekijken of paren in aanmerking 
kwamen voor een PESA-ICSI behandeling. De eerste resultaten van deze 
behandelingen beschreven we in twee artikelen in het NTvG. Daarna kwam 
je met een eerste aanzet voor een review op een presenteerblaadje, iets 
wat ik alleen maar verder hoefde uit te werken. Dank hiervoor! Jammer 
dat je de Nijmeegse setting hebt verlaten!
Beste Didi, dank voor je vertrouwen en de mogelijkheid om de follow-up 
van de PESA kinderen te mogen doen.
Dan al mijn mede-auteurs, zonder wie ik nooit een artikel gepubliceerd 
had gekregen.
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Beste Deric, Eric, Liliana, A lex en Didi. Jullie waren allen betrokken 
bij mijn eerste twee artikelen voor het NTvG. Dat deze artikelen het 
begin zouden vormen voor het idee om een promotietraject in te gaan, 
konden we toen nog niet vermoeden. Mogelijk was jullie enthousiasme al 
een eerste drijfveer hiervoor. Dank voor jullie begeleiding in mijn eerste 
stappen op schrijversgebied!
Beste Marjolein en Marc. Wat een geluk had ik met jullie, dat jullie met 
een mooie, uitgewerkte onderzoeksvraag kwamen en waarbij ik met mijn 
data aan kon schuiven. In een recordtempo werd het onderzoek verricht 
en het artikel over pre-eclampsie geschreven en gepubliceerd. Veel dank 
hiervoor!
Beste Jan H, Judith, Gerhard, Stef en Louis. Het groei-artikel leek 
echt een lied zonder eind te worden, maar we hebben het toch voor 
elkaar gekregen! Ik zal niet alle tegenslagen noemen, die er van het 
begin af aan waren en maar op bleven stapelen. Echter dankzij het 
doorzettingsvermogen van jullie allen, maar met name het geduld van 
Jan H, is het gelukt om er een mooi artikel met een duidelijke boodschap 
van te publiceren. Dank jullie wel!
Beste Wim, ook jou wil ik bij dit stukje betrekken en bedanken voor al je 
statistische berekeningen!
Beste Eric, Peter, Irene, Jane en Christa. DNA-arrays: een erg leuk 
en leerzaam uitstapje op een voor mij geheel onbekend terrein. Het was 
voor mij in eerste instantie erg ver van mijn bed allemaal, maar door jullie 
heldere uitleg en geduld, is deze interessante materie toch een beetje 
duidelijk geworden. Heel erg bedankt voor al jullie tijd!
Beste Joris en Hans, ook jullie wil ik hierbij noemen en bedanken, 
aangezien jullie in eerste instantie bij dit project betrokken waren en tot 
het eind toe geïnteresseerd bleven.
Beste Dagmar en Alice, jullie dank ik beide voor jullie expertise op het 
gebied van het schrijven van een systematic review respectievelijk het 
systematisch zoeken van alle relevante literatuur. Het was een hele klus, 
maar dat het zelfs in het Russisch en Chinees is vertaald, geeft wel aan 
dat het een mooi overzicht is geworden. Heel erg dank voor jullie input!
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Beste Maud, Anjo, Jolanda, Sandra, Katerina, Kathleen en Alex. Een grote 
groep, maar ieder met een eigen belangrijke inbreng in het laatste artikel 
betreffende de follow-up. Maud, bedankt voor het verwerken van vele data 
en het maken van de eerste analyses en natuurlijk voor de vele gezellige 
uurtjes met "cappu". Anjo, Jolanda en Sandra, heel erg bedankt voor 
het nakijken van alle PESA kinderen en tevens het analyseren van al de 
verkregen data. Katerina (en natuurlijk ook jouw "voorganger" Louis), 
bedankt dat we gebruik mochten maken van het goedlopende follow-up 
programma op de afdeling neonatologie. Kathleen, hartelijk dank voor 
de vruchtbare samenwerking met de afdeling urologie, want zonder zaad 
"van jullie", waren we nergens. .  Alex, hier nogmaals genoemd, want ook 
hierbij was je bijdrage van grote waarde voor me: bedankt daarvoor!
Jan H en Peter wil ik hier ook nog apart noemen, aangezien jullie beide 
bij meerdere artikelen betrokken waren en beide op jullie geheel eigen 
wijze je bijdrage hebben geleverd aan respectievelijk vele statistische en 
biologische vraagstukken. Heel erg bedankt voor de vele uren die jullie 
hieraan besteed hebben!
Beste Michaela, bedankt voor het vertalen van de twee artikelen van het 
NTvG, uit het Nederlands naar het Engels.
Beste Rianne, Marlies en Lisette, bedankt voor het consequent opsturen 
van vele vragenlijsten aan alle ouders van IVF-, ICSI- en PESA kinderen. 
Rianne en Lisette, tevens bedankt voor het oproepen van de PESA kinderen 
voor de follow-up en het netjes bijhouden van de database.
Beste Heidy en Marjolein, bedankt voor het elke keer aan mij denken en 
doorgeven als er een plekje vrij kwam voor de follow-up. Ook dank voor 
alle administratieve rompslomp die hierbij kwam kijken.
Beste Mark en Elly, bedankt voor het elk jaar weer compleet maken van de 
lijsten met data van doorgaande zwangerschappen en voor het aanleveren 
van mooie bestanden als ik andere leuke opdrachtjes voor jullie had.
Vele IVF artsen hebben ons team versterkt en helaas weer verlaten. 
Allen mochten mee "genieten" van mijn beslommeringen rondom mijn 
promotietraject. Bea, Marieke, Ilse, Marijke, Anika, Selma, Esther, Joyce, 
Corien en Lobke, bedankt voor jullie invallen als ik weer eens PESA kinderen 
moest onderzoeken en bedankt voor jullie luisterend oor, maar vooral ook 
voor jullie gezelligheid!
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Beste verpleegkundigen, doktersassistentes, analisten, embryologen, 
gynaecologen en secretaresses van het IVF team. Jullie zijn met teveel 
om allemaal bij naam te noemen, vooral als ik ook aan de mensen moet 
denken die ooit deel uitmaakten van ons team. Ik ben bang dat ik dan 
mensen ga vergeten en dat wil ik niet, want jullie allen wil ik bedanken 
voor het fijne samenwerken in de kliniek, wat een geweldige afwisseling 
bood met mijn onderzoek en het schrijven van artikelen.
Beste onderzoekers uit de kantoortuin. Heel erg bedankt voor jullie 
gezelligheid, interesse, koffie-met-taart momentjes enzovoorts. Ook al 
was ik er niet vaak en onttrok ik me wel eens aan bepaalde activiteiten, 
dat neemt niet weg dat ik hoop dat jullie allen ook snel het doel bereiken 
waar je voor in die tuin zit!
Alle IVF centra die in de loop der tijd mee deden in het PESA protocol en 
hun data aanleverden, bedankt hiervoor.
Alle PESA kinderen moeten natuurlijk ook heel erg bedankt worden voor 
het feit dat ze (geheel nietsvermoedend) zich lieten onderzoeken. Wat 
waren jullie leuk, mooi, lief en ondeugend! Een welkome afwisseling in 
het schrijven om jullie te mogen zien en onderzoeken. Degene die ik met 
vijf jaar ook gezien heb: bedankt voor jullie naam of tekening op de kaft!
Ook dank aan alle ouders van deze PESA kinderen, die vrij namen om 
te kunnen komen voor het follow-up onderzoek. Het was voor mij een 
voorrecht om dit onderzoek te mogen doen en het was geweldig om 
mensen terug te zien die ooit "patiënt" waren en nu trotse ouders.
Verder ben ik ook dank verschuldigd aan alle ouders van de andere PESA 
kinderen, maar ook de ouders van IVF en ICSI kinderen. Zij vulden de 
vragenlijsten in en stuurden deze trouw terug, vaak samen met foto's en 
enthousiaste (en helaas soms ook schrijnende) verhalen.
Beste leden van de manuscriptcommissie, beste Han, Joop en Peter. 
Hartelijk dank dat jullie mijn manuscript hebben gelezen en beoordeeld. 
Ik vond het een eer dat jullie dit wilden doen!
Beste Joppe en Jos, dankzij jullie hulp en urenlange inzet voor de lay-out 
van de buiten- en binnenkant van dit boekje, is het mogelijk nog mooier 
geworden dan ik had gehoopt! Dank hiervoor!
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Beste familie, vrienden, (ex)buurtgenoten en verder iedereen die ik 
(hopelijk niet) vergeten ben: bedankt dat jullie er altijd voor me waren en 
het me nooit kwalijk hebben genomen als ik zat te werken of moe was van 
het werken en dus geen tijd had voor jullie. Hopelijk komen er nu tijden 
waar we dat in kunnen halen!
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Gwendolyn Woldringh werd op 11 augustus 1959 geboren in Alkmaar. Na 
enkele omzwervingen via Italië en Bennekom (waar zij de basisschool 
doorliep), woonde zij in de bossen bij Wageningen. Zij ging naar het 
Heldring College in Zetten: elke dag met de fiets en later op de brommer, 
met het pontje over de Rijn. In 1977 behaalde zij haar VWO diploma.
Na een jaar uitgeloot te zijn (waarin "van alles en nog wat" werd gedaan), 
mocht zij in 1978 in Nijmegen beginnen met de studie waar ze al lang 
naar uit had gekeken: geneeskunde. Van kleins af aan had ze in haar 
hoofd om "kinderdok" te worden, maar tijdens haar co-schappen kwam 
ze er achter dat dit toch niet helemaal was wat ze zocht.
Twee dagen na haar afstuderen in maart 1986, startte zij haar (naar later 
bleek) gevarieerde carrière, als AGNIO op de afdeling kinderchirurgie in 
het St Radboud ziekenhuis in Nijmegen. Dit duurde slechts 2 en een halve 
maand, echter binnen hetzelfde ziekenhuis kon ze gelijk doorstromen 
naar de afdeling algemene heelkunde. Ook hier was ze AGNIO, maar nu 
2 en een half jaar. Dit bleek een vak, waar ze veel voldoening uithaalde, 
zodat ze in 1988 probeerde om in opleiding te komen voor chirurgie. 
Helaas werd ze hier niet voor aangenomen en aangezien in die tijd maar 
één keer meegedaan kon worden aan een opleidingsronde, viel haar 
droom om ooit kinderchirurg te worden in duigen. Tevens werd zij 2 maal 
uitgeloot voor de huisartsenopleiding, zodat de knop om gezet moest 
worden. Dit lukte door gelijk aan de slag te kunnen als docent anatomie 
en fysiologie bij de in-service opleiding van het St Radboud ziekenhuis 
voor A-verpleegkundigen en als docent chirurgie bij de specialisatie voor 
eerste-hulp verpleegkundigen. Gelijktijdig kon ze gaan waarnemen (en 
na enige tijd ook in vast dienstverband) als consultatiebureau-arts in 
Nijmegen en omgeving.
Naast deze werkzaamheden had ze samen met haar man Joep (met 
wie zij in 1985 getrouwd is) het geluk om de trotse ouders te mogen 
worden van vier prachtige dochters: Pippa, Mytte, Dedde en Birre. Op 
het moment dat de jongste ruim een jaar was en ze al 10 jaar werkzaam 
was op het consultatiebureau, begon het te kriebelen en werd er naar 
een nieuwe uitdaging gezocht. Dit werd gevonden in wederom het St 
Radboud ziekenhuis, maar dan als IVF arts. Vanaf het begin (maart 1999) 
was ze bezig met het verzamelen van data over de gezondheid van de
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IVF en ICSI kinderen en later ook van de PESA kinderen. Na de eerste 
publicatie in december 2003 over de eerste resultaten van de ICSI/ 
PESA behandelingen, werd er daadwerkelijk een plan richting promotie 
gesmeed. Dit proefschrift is het uiteindelijke resultaat hiervan!
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